HMOX1 inducers

By developing a novel compound, the hERG inhibition and solubility of HMOX1 inducer in the prior art was solved, and the effective induction and expression of HMOX1 was achieved, and the potential for treating oxidative stress-related diseases was significant.

CN113874074BActive Publication Date: 2024-11-01MITOBRIDGE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080038769.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-08
Filing Date
2020-04-08
Publication Date
2024-11-01
Estimated Expiration
2040-04-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively induce heme oxygenase 1 (HMOX1) to alleviate chronic diseases related to oxidative stress, and existing inducers have problems with hERG inhibition and solubility.

Method used

A novel compound has been developed that has strong HMOX1 inducible activity, good solubility and significant effects on HMOX1 protein expression in vivo and can bind to Bach 1 to induce the production of HMOX1 to treat oxidative stress-related diseases.

Benefits of technology

This compound significantly increases the expression and activity of HMOX1, reduces hERG inhibition, and has potential effects on the treatment of fibrotic diseases, neurodegenerative diseases, cardiovascular diseases, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113874074B_ABST
    Figure CN113874074B_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) #imgabs0# The present invention also relates to a method of controlling the activity or amount or both the activity and amount of heme oxygenase 1 in a mammalian subject. Definitions of the variables are provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 833,031, filed April 12, 2019, and U.S. Provisional Application No. 62 / 932,629, filed November 8, 2019. The entire teachings of the foregoing applications are incorporated herein by reference. Technical Field

[0003] The present application relates to heme oxygenase 1 (HMOX1) inducers and methods of use thereof, such as for controlling the activity or amount or both the activity and amount of heme oxygenase in a mammalian subject. Background Art

[0004] Oxidative stress represents an imbalance between the production of cellular reactive oxygen species (ROS) and the cellular responses to ROS, such as degradation of ROS species and production of endogenous antioxidant molecules.

[0005] ROS provide a critical cell signaling requirement, but if overproduced or allowed to develop, it can have harmful effects. Increased ROS levels in cells can lead to damage to components such as lipids, proteins, polysaccharides, and DNA. Long-term oxidative stress is also associated with chronic diseases that affect almost every major organ system. For example, long-term oxidative stress is involved in the onset or progression of disease conditions such as neurodegenerative diseases, lung disease, cardiovascular disease, kidney disease, diabetes, inflammatory pain, and cancer. Therefore, strategies to reduce oxidative stress are desirable for many therapeutic situations.

[0006] Under normal physiological conditions, the production of ROS is balanced by a set of well-defined and conserved cellular pathways that respond to, limit, and repair the damage caused by ROS. This adaptive gene set is called the phase II system. It encodes enzymes that directly degrade ROS and increase the levels of endogenous antioxidant molecules in the cell, including glutathione and bilirubin.

[0007] In the Phase II enzyme system, HMOX1 (a human gene encoding the enzyme heme oxygenase 1) has been found to be a key component. The role of HMOX1 is to metabolize heme into bilirubin, carbon monoxide, and free iron in a two-step process. The first and rate-limiting step is the production of biliverdin and carbon monoxide from heme by HMOX1. The second step is the production of bilirubin from biliverdin by biliverdin reductase. Both bilirubin and carbon monoxide have been shown to scavenge ROS and have strong antioxidant and anti-inflammatory activities.

[0008] Agents that induce HMOX1 production have shown beneficial activity in models of diabetes, cardiovascular disease, hypertension, and lung function. Heme, heavy metal ions (e.g., arsenite, cadmium, iron, lead, chromium, and mercury), and electrophiles (e.g., natural products such as sulforaphane and curcumin) can all induce HMOX1 production. The induction of HMOX1 and other phase II genes is controlled by a variety of transcription factors that respond to heavy metals, heme, and electrophiles. The transcription factors Nrf2, Bach1, and small Maf proteins are particularly important in this process. For example, a common sequence called the antioxidant responsive element (ARE) is present in the promoters of genes for phase II enzymes, and their expression is induced by the transcription factor Nrf2 (NF-E2-related factor 2).

[0009] HMOX1 is also induced as part of a general stress response to stimuli such as heat shock, oxidative stress, and cytokines such as interleukin-1 (IL-1), tumor necrosis factor, and interleukin-6 (IL-6). This stress response is considered beneficial because it protects vulnerable cells from multiple insults.

[0010] HMOX1 has been reported to be induced by small molecules that bind to the transcription factor Bach1. Heme binding to Bach1 has been shown to reduce Bach1's DNA binding activity and induce gene transcription. See Ogawa K et al., EMBO J (2001) 20:2835-284. In addition, small molecules have been reported to induce HMOX1 by binding to Bach1. See Attucks OC et al., PLOS ONE (2014) 9(7):e101044, WO2011 / 103018, and WO2012 / 094580.

[0011] Therefore, there is a need for new HMOX1 inducers and / or Bach 1 binders / inhibitors for the above-referenced therapeutic indications. Summary of the Invention

[0012] Applicants have discovered novel compounds that are potent HMOX1 inducers (see Examples 1-142). Specifically, certain compounds of the present invention have been shown to effectively induce HMOX1 production (see Example 143). Furthermore, certain compounds of the present invention exhibit a combination of desirable properties, including potent HMOX1 induction activity (Example 143), significantly reduced hERG inhibition compared to certain comparative compounds (see Example 145), good solubility (Example 144), and a potent effect on HMOX1 protein expression in vivo (Example 151). Furthermore, Applicants have discovered that the compounds disclosed herein bind to Bach 1 (see Example 146).

[0013] In one embodiment, provided herein is a compound represented by the following structural formula (I):

[0014]

[0015] or a pharmaceutically acceptable salt thereof, definitions of each variable are provided below.

[0016] Also disclosed herein are pharmaceutical compositions of the compounds of the present invention. Specific embodiments include a pharmaceutically acceptable carrier or diluent and one or more of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

[0017] The compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as agents for inducing the production and / or increasing the activity of HMOX1, and are therefore useful for treating various chronic diseases that are at least partially related to oxidative stress, including but not limited to fibrotic diseases, neurodegenerative diseases, cardiovascular diseases, kidney diseases, inflammatory diseases, liver diseases, eye diseases, thyroid diseases, viral infections, osteoporosis, pregnancy disorders, endometriosis, diabetes, cancer, skin diseases, mitochondrial diseases, blood disorders, and muscle diseases.

[0018] Another embodiment of the present invention includes treating the above-mentioned diseases or conditions in a subject by administering to the subject an effective amount of one or more compounds of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the disclosed compounds.

[0019] Also provided herein is the use of one or more compounds of the invention, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition comprising one or more compounds of the invention, for the preparation of a medicament for treating the above-mentioned diseases or conditions.

[0020] In another embodiment, provided herein are compounds of the invention, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising one or more disclosed compounds, for use in treating the above-mentioned diseases or conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1A and 1B Depicted are graphs showing significant fold changes in gene-specific mRNA in HepG2 cells treated with the compound of Example 17 or the Nrf2 activator DMF. Figure 1A It is depicted that the compound of Example 17 induces HMOX1 expression more strongly than DMF. Figure 1B As depicted, the compound of Example 17 and DMF induced FTH1 expression with comparable fold increases.

[0022] Figure 2 Depicts a graph showing that the compound of Example 17 does responsively inhibit microvascular stasis in Townes-SS sickle cell disease mice. Townes-SS mice were gavaged once daily with vehicle or the compound of Example 17 for 8 days. After the last gavage, a dorsal skinfold chamber was implanted on the mice, and 20 to 22 flowing venules were selected and located in the subcutaneous skin using intravital microscopy. The mice were then infused with panhematin (3.2 μmol heme / kg body weight) via the tail vein. One hour after the infusion, each venule was examined for microvascular stasis (no flow), and the data are expressed as % stasis. Stasis values ​​are mean + SD. One-way ANOVA with Dunnett's multiple comparisons to vehicle, ****P < 0.0001

[0023] Figure 3 Depicts a graph showing the increased percentage of F cells in Townes-SS mice treated with the compound of Example 17. Blood smears were prepared using heparinized whole blood for F cell staining. Stained F cells and total red blood cells were counted in four fields of view on the blood smear; mean = 77 red blood cells / field of view. F cells are expressed as a percentage of total red blood cells. Values ​​are mean + SD. One-way ANOVA with Dunnett's multiple comparisons to vehicle, **p≤0.01, ***p≤0.001, ****p≤0.0001

[0024] Figure 4 Depicts a graph showing glutathione (GSH) levels in primary human endothelial cells. ####p≤0.0001 by two-tailed unpaired t-test compared to DMSO; ****p≤0.0001 by one-way ANOVA with Dunnett's multiple comparisons with hemin (GSH graph).

[0025] Figure 5 Depicts a graph showing fold changes in gene expression in primary human endothelial cells. ####p≤0.0001, one-way ANOVA with Dunnett's multiple comparisons with TNFa (VCAM graph), ****p≤0.0001 DETAILED DESCRIPTION

[0026] In response to higher reactive oxygen species (ROS) levels, cells induce the expression of oxidative stress response genes, such as genes encoding proteins that degrade ROS or increase the level of endogenous antioxidant molecules in the cell. One such gene is HMOX1. The induction of the expression of HMOX1 and other oxidative stress response genes is regulated in part by the transcription factor Nrf2. Under normal circumstances, the adaptor protein Keap1 forms a heterodimer with Nrf2, targeting Nrf2 for proteolysis and inhibiting the transcription regulated by Nrf2. When cells are exposed to chemical electrophiles or agents that increase ROS, the interaction between Keap1 and Nrf2 is weakened and the level of Nrf2 in the cell increases, which in turn increases the level of Nrf2 in the cell nucleus and causes the induction of oxidative stress response genes. Nrf2 activity is also regulated by the transcriptional repressor Bach1, which blocks the binding of Nrf2 to the promoter region of oxidative stress response genes.

[0027] In order to mitigate the effects of oxidative stress in cells, for example in disease situations, it is therefore desirable to identify compounds that promote the induction of expression of oxidative stress response genes, such as compounds that modulate the interaction of Nrf2 with Keap1 or the interaction of Bach1 with Maf recognition elements (MAREs) to increase transcription of cytoprotective genes. However, it is also desirable that such compounds do not act as electrophiles or otherwise stimulate stress responses in cells.

[0028] Compounds of the present invention

[0029] Disclosed herein are examples of compounds having the general structural formula (I).

[0030] In a first embodiment, the present invention provides a compound represented by the following structural formula (I):

[0031]

[0032] or a pharmaceutically acceptable salt thereof, wherein:

[0033] Ring A is a 5-7 membered monocyclic cycloalkyl group, a 5-7 membered monocyclic heterocyclyl group, a 5-6 membered heteroaryl group or a phenyl group;

[0034] X is -S-, -O- or -NR b -;

[0035] When X is -S- and Ring A is phenyl, then R is a 3-7 membered monocyclic heterocyclic group optionally substituted with one or more groups selected from the group consisting of halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy and -NR a R a ;

[0036] When X is -S- and Ring A is a 5-7 membered monocyclic cycloalkyl, a 5-7 membered monocyclic heterocyclyl or a 5-6 membered heteroaryl; or when X is -O- or -NR b -; then R is -H, -(C1-C4)alkyl or -(CH2) i 3-7 membered monocyclic heterocyclic group, wherein the -(C1-C4)alkyl group or the 3-7 membered monocyclic heterocyclic group represented by R is optionally substituted by one or more groups selected from the group consisting of: halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy, -SO2R a and -NR a R a ;

[0037] Each R1 is independently -H, halogen, -(CH2) k COOH, -(CH2) k CO(C1-C4)alkyl, -(CH2) k COO(C1-C4)alkyl, -(CH2) p C(=O)NR a R3, -CH(CF3)NR a R3, -C(=NOH)CF3 or -CH(CF3)OR3, wherein the (C1-C4)alkyl group in the group represented by R1 is optionally substituted by one or more groups selected from the group consisting of: halo, -CN, -OH, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy and -NR a R a ;

[0038] Each R2 is independently -H, halo, CN, -(C1-C4)alkyl, -OH, -(C1-C4)alkoxy, -COOH, -C(=O)(C1-C4)alkyl, -C(=O)O(C1-C4)alkyl, -C(=O)NR a (C1-C4)alkyl, -NR a R a , 3-6 membered monocyclic cycloalkyl, -O(CH2)i a 3-7 membered monocyclic heterocyclic group, a 3-7 membered monocyclic heterocyclic group or a 5-6 membered heteroaryl group, wherein the -(C1-C4)alkyl, -(C1-C4)alkoxy, heterocyclic group or heteroaryl group represented by R2 or in the group represented by R2 is optionally substituted by one or more groups selected from the group consisting of: halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)haloalkoxy and -NR a R a ;

[0039] Each R3 is independently H, (C1-C4) alkyl, (C1-C4) alkoxy, -(CH2) p1 3-7 membered monocyclic heterocyclic group, -(CH2) p1 NH3-7-membered monocyclic heterocyclic group, 5-6-membered heteroaryl, -O(CH2) p2 NR a C(=O)(C1-C4)alkyl, -(CH2) p2 O(CH2) p2 O(C=O)(C1-C4)alkyl or (CH2) p2 NR a C(═O)(C1-C4)alkyl, wherein the alkyl, alkoxy, heteroaryl or heterocyclic group represented by R3 or in the group represented by R3 is optionally substituted by one or more groups selected from the group consisting of halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy, -(C1-C4)carboxyalkoxy, -S(O)2(C1-C4)alkyl, -(C1-C4)hydroxyalkoxy and -NR a R a ;

[0040] Each R a are independently -H or -(C1-C4)alkyl;

[0041] Each R b are independently -H or -(C1-C4)alkyl; wherein R b The -(C1-C4)alkyl represented by is optionally substituted by one or more groups selected from the group consisting of halo, -CN, -OH, -(C3-C6)cycloalkyl, phenyl, 3-7 membered monocyclic heterocyclyl, and 5-6 membered heteroaryl;

[0042] i is 0 or 1;

[0043] k is 0, 1, 2, 3, or 4;

[0044] m is 0, 1, 2, 3, or 4;

[0045] n is 0, 1, 2, 3, or 4;

[0046] p is 0, 1, 2, 3, or 4;

[0047] p1 is 0, 1, 2, 3, or 4; and

[0048] p2 is 2, 3, or 4.

[0049] In a second embodiment, the present disclosure provides a compound according to the preceding embodiment, wherein the compound is represented by the following structural formula (II):

[0050]

[0051] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0052] In a third embodiment, the present disclosure provides a compound according to the first embodiment, wherein the compound is represented by structural formula (II'):

[0053]

[0054] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0055] In a fourth embodiment, the present disclosure provides a compound according to the first or second embodiment, wherein the compound is represented by structural formula (II-A):

[0056]

[0057] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0058] In a fifth embodiment, the present disclosure provides a compound according to the first or second embodiment, wherein the compound is represented by structural formula (II-B):

[0059]

[0060] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0061] In a sixth embodiment, the present disclosure provides a compound according to the first or second embodiment, wherein the compound is represented by structural formula (II-C):

[0062]

[0063] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0064] In a seventh embodiment, the present disclosure provides a compound according to the first or third embodiment, wherein the compound is represented by structural formula (II'-A):

[0065]

[0066] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0067] In an eighth embodiment, the present invention provides a compound according to the sixth embodiment, or a pharmaceutically acceptable salt thereof, wherein R b is -H or -(C1-C4)alkyl, wherein R b The -(C1-C4)alkyl represented by is optionally substituted by one or more groups selected from the group consisting of halo, -CN, and -OH. The remaining variables are as defined in the first embodiment. In a preferred embodiment, R b Yes -H.

[0068] In a ninth embodiment, the present invention provides a compound according to the first, second, third, fifth, sixth, seventh and eighth embodiments, or a pharmaceutically acceptable salt thereof, wherein R is -(C1-C4)alkyl optionally substituted with -(C1-C4)alkoxy; or -(CH2) optionally substituted with one or more groups selected from the group consisting of: i 3-6 membered monocyclic heterocyclic group: halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy and -NR a R a , wherein the remainder of the variables are as defined in the first or eighth embodiment.

[0069] In a tenth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh or eighth embodiment, or a pharmaceutically acceptable salt thereof, wherein R is azetidinyl, azepanyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, tetrahydrofuranyl or tetrahydropyranyl, each of which is optionally substituted with one or more groups selected from the group consisting of halo, -OH, -(C1-C4)alkyl and -NH2, wherein the remainder of the variables are as defined in the first or eighth embodiment.

[0070] In an eleventh embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment, or a pharmaceutically acceptable salt thereof, wherein R1 is -(CH2) k COOH, -(CH2) optionally substituted by halogen k CO(C1-C4)alkyl, -(CH2) p C(=O)NR a R3, -C(=NOH)CF3 or -CH(CF3)NR a R3, wherein the remainder of the variables are as defined in the first, eighth, ninth or tenth embodiment.

[0071] In a twelfth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiment, or a pharmaceutically acceptable salt thereof, wherein R2 is H; halogen; CN; -(C1-C4)alkyl optionally substituted with halo; -(C1-C4)alkoxy optionally substituted with halo, hydroxy, methoxy or ethoxy; -C(═O)(C1-C4)alkyl; 3-4 membered monocyclic cycloalkyl; -O(CH2) i 3-7 membered monocyclic heterocyclyl, 3-7 membered monocyclic heterocyclyl or 5-6 membered heteroaryl, wherein the heterocyclyl or heteroaryl represented by R or in the group represented by R is optionally substituted with halo, hydroxy or -(C1-C4)alkoxy, wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth or eleventh embodiment. In a preferred embodiment, R is H or -OCF3.

[0072] In a thirteenth embodiment, the present invention provides a compound according to the first, second, third, fifth, sixth, seventh, eighth, ninth, eleventh or twelfth embodiment, or a pharmaceutically acceptable salt thereof, wherein R is -(C1-C4)alkyl optionally substituted with methoxy or -SO2CH3; -(CH2)tetrahydrofuranyl; -(CH2)oxetanyl optionally substituted with hydroxy; pyrrolidinyl; piperidinyl; or tetrahydropyranyl; wherein the pyrrolidinyl or piperidinyl is optionally substituted with -(C1-C4)alkyl, wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh or twelfth embodiment. In a preferred embodiment, the pyrrolidinyl or piperidinyl is optionally substituted with -CH3.

[0073] In a fourteenth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth or thirteenth embodiment, or a pharmaceutically acceptable salt thereof, wherein R1 is -COOH, -C(═O)CF3, -CH(CF3)(NH2), -C(═NOH)CF3 or -C(═O)NHR3, wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh, twelfth or thirteenth embodiment.

[0074] In a fifteenth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth or fourteenth embodiment, or a pharmaceutically acceptable salt thereof, wherein R3 is (C1-C4)alkyl, (C1-C4)alkoxy, (CH2) p1 3-6 membered monocyclic heterocyclic group or (CH2) p2 NHC(=O)(C1-C4)alkyl, wherein the alkyl, alkoxy or heterocyclic group represented by R3 or in the group represented by R3 is optionally substituted by one or more groups selected from the group consisting of: halo, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy, -S(O)2(C1-C4)alkyl, -(C1-C4)hydroxyalkoxy and -NR a R a , wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth or fourteenth embodiment.

[0075] In a sixteenth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth or fifteenth embodiment, or a pharmaceutically acceptable salt thereof, wherein R2 is H; halogen; CN; -(C1-C4)alkyl optionally substituted with halo; -(C1-C4)alkoxy optionally substituted with halo, hydroxy, methoxy or ethoxy; -C(═O)(C1-C4)alkyl; cyclopropyl; O-tetrahydropyranyl; N-pyrrolidinyl; or thiazolyl, wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth or fifteenth embodiment.

[0076] In a seventeenth embodiment, the present disclosure provides a compound according to the fifth embodiment, wherein the compound is represented by structural formula (III-B):

[0077]

[0078] or a pharmaceutically acceptable salt thereof, wherein the remainder of the variables are as defined in the first embodiment.

[0079] In an eighteenth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth or seventeenth embodiment, or a pharmaceutically acceptable salt thereof, wherein R1 is -COOH or -C(═O)NHR3; R3 is -(C1-C4)alkyl, -hydroxy(C1-C4)alkyl, -methoxy(C1-C4)alkyl, -amino(C1-C4)alkyl, -(C1-C4)hydroxyalkoxy(C1-C4)alkyl or -(CH2) p2 NHC(═O)(dimethylamino(C 1 -C 4 )alkyl), wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth or seventeenth embodiment.

[0080] In a nineteenth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth or eighteenth embodiment, or a pharmaceutically acceptable salt thereof, wherein R2 is H, halo, -(C1-C4)haloalkyl, -(C1-C4)haloalkoxy, -(C1-C4)alkoxy optionally substituted with methoxy, or -N-pyrrolidinyl, wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth or eighteenth embodiment. In a preferred embodiment, R2 is H, F, CF3, OCHF2, OCF3, OCH2CH2OCH3, or -N-pyrrolidinyl.

[0081] In a twentieth embodiment, the present invention provides a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth or nineteenth embodiment, or a pharmaceutically acceptable salt thereof, wherein

[0082] R2 is H, R1 is -C(=O)NH(C1-C4)alkyl optionally substituted with -OH, NH2, oxetanyl or -(C1-C4)hydroxyalkoxy; or -C(=O)NH(CH2) p2 NHC(=O)(dimethylamino(C1-C4)alkyl); or

[0083] R2 is F, R1 is -C(=O)NH(methoxy(C1-C4)alkyl); or

[0084] R2 is -N-pyrrolidinyl, R1 is -C(=O)NH((C1-C4)hydroxyalkoxy(C1-C4)alkyl),

[0085] R2 is CF3, OCHF2 or OCF3, R1 is -COOH; or

[0086] R2 is OCH2CH2OCH3, R1 is -C(=O)NH((C1-C4)hydroxyalkoxy(C1-C4)alkyl), -C(=O)NH(hydroxy(C1-C4)alkyl), -C(=O)NH(methoxy(C1-C4)alkyl), or -C(=O)NH(hydroxy(C1-C4)alkoxy);

[0087] wherein the remainder of the variables are as defined in the first, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth or nineteenth embodiment.

[0088] In a twenty-first embodiment, the present invention provides a compound according to the seventeenth embodiment, or a pharmaceutically acceptable salt thereof, wherein

[0089] R1 is -C(=O)NH(C1-C4)alkyl optionally substituted with -OH, NH2, -(C1-C4)alkoxy or -(C1-C4)hydroxyalkoxy, and

[0090] R2 is H or OCH2CH2OCH3.

[0091] In a twenty-second embodiment, the present invention provides a compound according to the twenty-first embodiment, or a pharmaceutically acceptable salt thereof, wherein

[0092] R2 is H,

[0093] wherein the remainder of the variables are as defined in the twenty-first embodiment.

[0094] In a twenty-third embodiment, the present invention provides a compound according to the twenty-second embodiment, or a pharmaceutically acceptable salt thereof, wherein

[0095] R1 is -C(=O)NH(C1-C4)alkyl substituted by -(C1-C4)hydroxyalkoxy,

[0096] wherein the remainder of the variables are as defined in the twenty-second embodiment.

[0097] In a twenty-fourth embodiment, the present invention provides a compound according to the twenty-first embodiment, or a pharmaceutically acceptable salt thereof, wherein

[0098] R1 is -C(=O)NH(C1-C4)alkyl substituted by -(C1-C4)alkoxy, and

[0099] R2 is OCH2CH2OCH3.

[0100] In one embodiment, the compound or a pharmaceutically acceptable salt thereof is selected from the compounds disclosed in the Examples and Table 1.

[0101] definition

[0102] The term "pharmaceutically acceptable salt" refers to a pharmaceutical salt that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, and is commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in J. Pharm. Sci., 1977, 66, 1-19.

[0103] The present teachings include pharmaceutically acceptable salts of the compounds disclosed herein. Compounds having a basic group can form pharmaceutically acceptable salts with pharmaceutically acceptable acids. Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include salts of inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid) and organic acids (such as acetic acid, benzenesulfonic acid, benzoic acid, ethanesulfonic acid, methanesulfonic acid and succinic acid). Compounds of the present teachings having an acidic group (such as a carboxylic acid) can form pharmaceutically acceptable salts with a pharmaceutically acceptable base. Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (such as sodium salts and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).

[0104] As used herein, the term "halo" means halogen and includes chlorine, fluorine, bromine, and iodine.

[0105] The term "alkyl," used alone or as part of a larger moiety such as "alkoxy" or "haloalkyl," means a saturated aliphatic straight or branched monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group typically has from 1 to 5 carbon atoms, i.e., (C1-C5)alkyl. As used herein, "(C1-C4)alkyl" means a group having from 1 to 4 carbon atoms in a straight or branched chain arrangement. Examples include methyl, ethyl, n-propyl, isopropyl, and the like.

[0106] The term "alkoxy" refers to an alkyl group connected through an oxygen linking atom, represented as -O-alkyl. For example, "(C1-C4)alkoxy" includes methoxy, ethoxy, propoxy and butoxy.

[0107] The terms "haloalkyl" and "haloalkoxy" refer to an alkyl or alkoxy group, as the case may be, substituted with one or more halogen atoms.

[0108] The term "cycloalkyl" refers to a monocyclic saturated hydrocarbon ring system. Unless otherwise specified, a cycloalkyl group has 3 to 7 carbon atoms. For example, C3-C6 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless otherwise specified, a "cycloalkyl group" has three to six carbon atoms.

[0109] The terms "heteroaryl," "heteroaromatic," "heteroaromatic ring," "heteroaryl," "heteroaromatic ring," or "heteroaromatic group," used alone or as part of a larger moiety as in "heteroaralkyl," "heteroaralkoxy," refer to a monocyclic aromatic ring radical having five or six ring atoms (i.e., "5-6 membered") selected from carbon and at least one (typically 1 to 4, more typically 1 or 2) heteroatom (e.g., oxygen, nitrogen, or sulfur).

[0110] Examples of monocyclic heteroaryl groups include furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g., N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 2-oxadiazolyl, 5-oxadiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrazolyl (e.g., 3-pyrazolyl, 4-pyrazolyl), pyrrolyl (e.g., 1-pyrazolyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), triazolyl (e.g., 2-triazolyl, 5-triazolyl), tetrazolyl (e.g., tetrazolyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrimidinyl, pyridinyl, and pyridazinyl.

[0111] The term "heterocyclyl" refers to a monocyclic non-aromatic ring group containing 3 to 7 ring atoms (i.e., "3-7 members") selected from carbon atoms and 1 or 2 heteroatoms. Each heteroatom is independently selected from nitrogen, quaternary nitrogen, nitrogen oxide (e.g., NO); oxygen; and sulfur, including sulfoxides and sulfones. Representative heterocyclyls include morpholinyl, thiomorpholinyl, pyrrolidonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrophenylthio, tetrahydrothiopyranyl, and the like. "Substituted heterocyclyl" is substituted at any one or more substitutable ring atoms, wherein the substitutable ring atoms are ring carbon or ring nitrogen atoms bonded to hydrogen.

[0112] As used herein, many moieties (e.g., alkyl, alkylene, cycloalkyl, cycloalkylene, aryl, arylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene) are referred to as "substituted" or "optionally substituted." When a moiety is modified by one of these terms, unless otherwise indicated, it indicates that any portion of the moiety known to those skilled in the art for substitution may be substituted, including one or more substituents. In the event that there is more than one substituent, each substituent may be independently selected. Such means for substitution are well known in the art and / or taught by the present disclosure. An optional substituent may be any substituent suitable for attachment to the moiety.

[0113] Suitable substituents are those that do not significantly adversely affect the ability of the compound to induce HMOX1. When suitable substituents are not specifically listed, exemplary substituents include, but are not limited to: (C1-C5) alkyl, (C1-C5) hydroxyalkyl, (C1-C5) haloalkyl, (C1-C5) alkoxy, (C1-C5) haloalkoxy, halogen, hydroxy, -CN, -NH2, -NO2, -OR c1 、-NR a1 R b1 、-S(O) ii R a1 、-NR a1 S(O) ii R b1 、-S(O) ii NR a1 R b1 、-C(=O)OR a1 、-OC(=O)OR a1 、-C(=S)OR a1 、-O(C=S)R a1 、-C(=O)NR a1 R b1 、-NR a1 C(=O)R b1 、-C(=S)NR a1 R b1 、-NR a1 C(=S)R b1 、-NR a1 (C=O)OR b1 、-O(C=O)NR a1 R b1 、-NR a1 (C=S)OR b1 、-O(C=S)NR a1 R b1 、-NR a1 (C=O)NR a1 Rb1 、-NR a1 (C=S)NR a1 R b1 、-C(=S)R a1 、-C(=O)R a1 , phenyl or 5-6 membered heteroaryl. a1 and each R b1 R is independently selected from -H and (C1-C5)alkyl optionally substituted with hydroxy or (C1-C3)alkoxy; c1 is -H, (C1-C5)haloalkyl or (C1-C5)alkyl, wherein the (C1-C5)alkyl is optionally substituted with hydroxy or (C1-C3)alkoxy; and ii is 1 or 2.

[0114] Pharmaceutical composition

[0115] The compounds disclosed herein are HMOX1 inducers. The pharmaceutical compositions of the present invention include one or more HMOX1 inducers or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier or diluent.

[0116] "Pharmaceutically acceptable carrier" and "pharmaceutically acceptable diluent" refer to substances that facilitate the formulation and / or administration of the active agent to an individual and / or absorption by an individual, and can be included in the compositions of the present disclosure without causing significant adverse toxicological effects on the individual. Non-limiting examples of pharmaceutically acceptable carriers and / or diluents include water, NaCl, standard physiological saline solution, lactated Ringer's solution, ordinary sucrose, ordinary glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavorings, salt solutions (such as Ringer's solution), alcohols, oils, gelatin, carbohydrates (such as lactose, amylose or starch), hydroxymethylcellulose, fatty acid esters, polyvinylpyrrolidine and pigments. Such preparations can be sterilized and, if necessary, mixed with adjuvants that do not adversely react with the compounds provided herein or interfere with their activity, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for affecting osmotic pressure, buffers, colorants and / or aromatic substances. Those skilled in the art will recognize that other pharmaceutical excipients are suitable for use with the disclosed compounds.

[0117] The pharmaceutical composition of the present invention optionally comprises one or more pharmaceutically acceptable carriers and / or diluents, such as lactose, starch, cellulose and dextrose. Other excipients may also be included, such as flavoring agents, sweeteners and preservatives, such as methylparaben, ethylparaben, propylparaben and butylparaben. A more complete list of suitable excipients can be found in "Handbook of Pharmaceutical Excipients" (5th edition, Pharmaceutical Press (2005)). Those skilled in the art will know how to prepare formulations suitable for different types of routes of administration. Conventional procedures and compositions for selecting and preparing suitable formulations are, for example, described in "Remington's Pharmaceutical Sciences" (2003-20th edition) and in "The United States Pharmacopeia: The National Formulary" (USP 24NF19), published in 1999. The carrier, diluent and / or excipient is "acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.

[0118] Treatment

[0119] In certain embodiments, the present invention provides a method for increasing the activity or amount of HMOX1 in a human subject, comprising administering to the human subject an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition thereof.

[0120] In certain embodiments, the present invention provides a method for activating the transcription factor Nrf2 in a human subject, comprising administering to the human subject an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition thereof.

[0121] In certain embodiments, the present invention provides a method of reducing the amount of ROS in a human subject, comprising administering to the human subject an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition thereof.

[0122] In certain embodiments, the present invention provides a method for using an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition thereof. The compounds of the present invention and pharmaceutical compositions thereof may be suitable for a variety of therapeutic applications, including, for example, treating and / or reducing a wide variety of diseases and conditions, including, for example, fibrotic diseases, neurodegenerative diseases, cardiovascular diseases, kidney diseases, inflammatory diseases, liver diseases, eye diseases, thyroid diseases, viral infections, osteoporosis, pregnancy conditions, endometriosis, diabetes, cancer, skin diseases, mitochondrial diseases, blood conditions, and muscle diseases. The method includes administering a pharmaceutically effective amount of one or more compounds of the present invention, pharmaceutically acceptable salts thereof, and / or pharmaceutical compositions thereof to an individual in need thereof.

[0123] Compounds that increase the level or activity of HMOX1 may be useful in treating diseases or conditions that may be at least partially associated with oxidative stress, such as, but not limited to, fibrotic diseases, neurodegenerative diseases, cardiovascular diseases, kidney diseases, inflammatory diseases, liver diseases, eye diseases, thyroid diseases, viral infections, osteoporosis, pregnancy disorders, endometriosis, diabetes, cancer, skin diseases, mitochondrial diseases, blood disorders, and muscle diseases. As used herein, diseases or conditions associated with oxidative stress also include chronic effects (e.g., tissue damage, chronic inflammation) associated with persistent or long-term increased oxidative stress due to the diseases or conditions described herein.

[0124] Fibrotic diseases associated with oxidative stress include, but are not limited to, pulmonary fibrosis, such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and sarcoidosis; liver fibrosis, including those caused by alcoholic cirrhosis, steatosis, cholestasis, drug side effects, and viral infection; and skin fibrosis, including autoimmune diseases such as scleroderma and psoriasis.

[0125] Neurodegenerative diseases associated with oxidative stress include, but are not limited to, Friedreich's ataxia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, brain neurodegenerative diseases, and Shiller-Mars disease. Figure 3 Charcot-Marie-Tooth syndrome.

[0126] Cardiovascular diseases associated with oxidative stress include, but are not limited to, hypertension, heart failure, hypercholesterolemia, atherosclerosis, arteriosclerosis, thrombosis, acute coronary thrombosis, deep vein thrombosis, peripheral vascular disease, congestive heart failure, acute coronary syndrome, arterial fistula dialysis failure, ischemia-reperfusion injury, primary pulmonary hypertension, primary pulmonary arterial hypertension, and secondary pulmonary arterial hypertension.

[0127] Kidney diseases associated with oxidative stress include, but are not limited to, acute kidney injury, polycystic kidney disease, Alport syndrome, diabetic nephropathy, glomerulonephritis, lupus nephritis, sickle cell nephropathy, and acute tubular necrosis.

[0128] Inflammatory diseases associated with oxidative stress include, but are not limited to, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, inflammatory bowel syndrome, Crohn's disease, celiac disease, ulcerative colitis, chronic inflammatory bowel disease, scleroderma, dermatitis, systemic lupus erythematosus, esophagitis, vasculitis, pancreatitis, tendinitis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and chronic encephalitis.

[0129] Liver diseases associated with oxidative stress include, but are not limited to, drug-induced hepatotoxicity, nonalcoholic steatohepatitis, and hepatitis, such as hepatitis B infection and hepatitis C infection.

[0130] Ocular diseases and conditions associated with oxidative stress include, but are not limited to, conjunctivitis, glaucoma, uveitis, wound healing (e.g., after surgery such as LASIK), ocular trauma, corneal transplantation, Fox's corneal endothelial dystrophy, macular degeneration, cataracts, mild retinopathy, retinitis pigmentosa, diabetic retinopathy, and retinopathy of prematurity, as well as the inflammation and tissue damage associated with these diseases.

[0131] Thyroid diseases associated with oxidative stress include, but are not limited to, Graves' disease, follicular adenoma, and papillary and follicular carcinoma.

[0132] Pulmonary diseases associated with oxidative stress include, but are not limited to, bronchitis, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary bronchitis, bronchiectasis, pulmonary edema, and emphysema.

[0133] Skin diseases associated with oxidative stress include, but are not limited to, dermatitis, scleroderma, and psoriasis.

[0134] Viral infections associated with oxidative stress include viral replication and tissue damage (e.g., fibrosis) caused by oxidative stress due to chronic viral infection, including but not limited to human immunodeficiency virus, hepatitis B, hepatitis C, and herpes virus.

[0135] Diabetic conditions include, but are not limited to, type 1 diabetes, type 2 diabetes, gestational diabetes, prediabetes, hyperglycemia, and metabolic syndrome, as well as secondary conditions resulting from diabetic conditions (eg, congestive heart failure and kidney disease).

[0136] Mitochondrial diseases associated with oxidative stress include, but are not limited to, mitochondrial myopathy, Leber's hereditary optic neuropathy (LHON), myoclonic epilepsy with ragged red fibers (MERFF), mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), or Leigh's syndrome.

[0137] Hematological disorders associated with oxidative stress include, but are not limited to, Diamond Black anemia, myelodysplastic syndrome, sickle cell disease, and beta-thalassemia.

[0138] Muscle diseases associated with oxidative stress include, but are not limited to, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, and rhabdomyolysis.

[0139] Cancers associated with oxidative stress include, but are not limited to, breast cancer, colorectal cancer, lung cancer, ovarian cancer, uterine cancer, prostate cancer, leukemia, lymphoma, brain cancer (including glioblastoma multiforme and neuroblastoma), head and neck cancer, pancreatic cancer, melanoma, hepatocellular carcinoma, kidney cancer, and soft tissue sarcoma. In one embodiment, the cancer is breast cancer, colon cancer, and ovarian cancer. In one embodiment, the cancer is selected from leukemia, acute myeloid leukemia, chronic myeloid leukemia, breast cancer, brain cancer, colon cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma, lung adenocarcinoma, metastatic melanoma, pancreatic cancer, prostate cancer, ovarian cancer, and kidney cancer. In one embodiment, the cancer is lung cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme, or ovarian cancer. In another embodiment, the cancer is lung cancer, breast cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme, or ovarian cancer. In yet another embodiment, the cancer is breast cancer, colon cancer, and lung cancer. In another embodiment, the cancer is breast cancer. In yet another embodiment, the cancer is basal subtype breast cancer or tubular B subtype breast cancer. In yet another embodiment, the cancer is basal subtype breast cancer. In yet another embodiment, the basal subtype breast cancer is estrogen receptor (ER), HER2, and progesterone receptor (PR) negative breast cancer. In yet another embodiment, the cancer is soft tissue cancer. "Soft tissue cancer" is an art-recognized term that covers tumors originating from any soft tissue of the body. Such soft tissues connect, support, or surround various structures and organs of the body, including but not limited to smooth muscle, skeletal muscle, tendons, fibrous tissue, adipose tissue, blood and lymphatic vessels, perivascular tissue, nerves, mesenchymal cells, and synovial tissue. Therefore, soft tissue cancer can be adipose tissue, muscle tissue, nerve tissue, joint tissue, blood vessels, lymphatic vessels, and fibrous tissue. Soft tissue cancer can be benign or malignant. Generally speaking, malignant soft tissue cancer is called sarcoma or soft tissue sarcoma.There are many types of soft tissue tumors including lipoma, lipoblastoma, hibernoma, liposarcoma, leiomyomas, leiomyosarcomas, rhabdomyomas, rhabdomyosarcomas, neurofibromas, schwannoma (neurilemoma), neuromas, malignant schwannoma, neurofibrosarcoma, neurosarcoma, nodular tenosynovitis, synovial sarcoma, hemangiomas, glomus tumors, hemangiopericytomas, hemangioendothelioma, angiosarcoma, Kaposi sarcoma, lymphangioma, fibroma, fibroelastoma, superficial fibromatosis, fibrous histiocytoma, fibrosarcoma, fibromatosis, dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), myxoma, granular cell tumor, malignant stromal tumor, alveolar soft tissue sarcoma, epithelioid sarcoma, clear cell sarcoma, and desmoplastic small cell tumor. In a specific embodiment, the soft tissue cancer is a sarcoma selected from the group consisting of fibrosarcoma, gastrointestinal sarcoma, leiomyosarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, malignant fibrous histiocytoma, round cell sarcoma, and synovial sarcoma.

[0140] Thus, the present invention provides a method of treatment comprising administering to a subject a compound of formula (I) or a pharmaceutically acceptable salt thereof, to treat at least one of the diseases or conditions listed above.

[0141] A "subject" is a mammal, preferably a human, but may also be an animal requiring veterinary treatment, such as companion animals (e.g., dogs, cats, etc.), farm animals (e.g., cattle, sheep, pigs, horses, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.).

[0142] Administration method and dosage form

[0143] The precise amount of compound administered to provide an "effective amount" of the compound to an individual will depend on the mode of administration, the type and severity of the disease or condition, and on individual characteristics such as general health, age, sex, weight, and drug tolerance. One skilled in the art will be able to determine the appropriate dosage based on these and other factors. When administered in combination with other therapeutic agents, such as anticancer agents, the "effective amount" of any additional therapeutic agent will depend on the type of drug used. Suitable dosages are known for approved therapeutic agents and can be adjusted by one skilled in the art based on the individual's condition, the type of condition being treated, and the amount of the compound of the invention used, for example, as reported in the literature and recommended in the Physician's Desk Reference (57th edition, 2003).

[0144] The term "effective amount" means an amount that, when administered to a subject, produces a beneficial or desired result, including a clinical result, such as inhibition, suppression, or reduction of symptoms of the subject's condition being treated as compared to a control. For example, a therapeutically effective amount can be given in unit dosage form (e.g., 0.1 mg to about 50 g / day, alternatively 1 mg to about 5 grams / day; and further alternatively, 10 mg to 1 gram / day).

[0145] As used herein, the term "administer / administering / administration" refers to methods that can be used to enable the delivery of a composition to a desired site of biological action. These methods include, but are not limited to, intra-articular (in a joint), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, oral, topical, intrathecal, inhalation, transdermal, rectal, and the like. The administration techniques that can be used for the agents and methods described herein can be found, for example, in Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition; Pergamon and Remington, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.

[0146] In addition, the disclosed HMOX1 inducers can be co-administered with other therapeutic agents. As used herein, the terms "co-administered," "administered in combination with," and grammatical equivalents thereof are intended to encompass the administration of two or more therapeutic agents to a single individual and are intended to encompass treatment regimens in which the agents are administered by the same or different routes of administration or at the same or different times. In some embodiments, one or more compounds described herein are co-administered with other agents. These terms encompass the administration of two or more agents to an individual such that the agents and / or their metabolites are present in the individual simultaneously. This includes simultaneous administration in separate compositions, administration at different times in separate compositions, and / or administration in a composition in which two agents are present. Thus, in some embodiments, the compounds described herein and the other agent are administered in a single composition. In some embodiments, the compounds described herein and the other agent are incorporated into a composition.

[0147] The specific mode of administration and dosing regimen will be selected by the attending clinician taking into account the specifics of the case (e.g., the individual, the disease, the disease condition involved, the specific treatment). Treatment may involve administration once a day, multiple times a day, or less than once a day (e.g., once a week, once a month, etc.) over a period of several days to several months or even years. However, one of ordinary skill in the art will readily recognize appropriate and / or equivalent dosing, provided that the dosage of the approved compositions for the treatment of diseases disclosed with the HMOX1 inducers is directed to use.

[0148] As will be understood by those skilled in the art, the compounds taught herein or corresponding pharmaceutical compositions may be administered to the patient in various forms depending on the selected route of administration. The compounds taught herein may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration and corresponding formulated pharmaceutical compositions. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, epithelial, nasal, intrapulmonary, intrathecal, rectal and topical administration modes. Parenteral administration can be performed by continuous infusion within the selected time period.

[0149] The pharmaceutical compositions of the present invention are formulated to be compatible with their intended route of administration. In one embodiment, the compositions are formulated according to conventional procedures as pharmaceutical compositions suitable for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to humans. In a preferred embodiment, the pharmaceutical compositions are formulated for intravenous administration.

[0150] Typically, for oral therapeutic administration, the compounds taught by the present invention may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

[0151] Typically for parenteral administration, solutions of the compounds taught herein can be prepared in water suitable for mixing with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, DMSO, and mixtures thereof (with or without alcohol), and oils. Under typical storage and use conditions, these preparations contain preservatives to prevent microbial growth.

[0152] Generally, for injectable use, sterile aqueous solutions or dispersions and sterile powders of the compounds described herein are appropriate for the extemporaneous preparation of sterile injectable solutions or dispersions.

[0153] example

[0154] Abbreviations used throughout the specification may be summarized herein below with their specific meanings:

[0155] ACN-acetonitrile;

[0156] AcOH-acetic acid;

[0157] Ac2O-acetic anhydride;

[0158] AlCl3-aluminum chloride;

[0159] anh.-without water;

[0160] Aq.-aqueous / water solution;

[0161] BOC-tert-butyloxycarbonyl;

[0162] bs-broad singlet;

[0163] Conc.-thick;

[0164] ℃-Celsius;

[0165] CDI-carbonyldiimidazole;

[0166] CH3MgBr-methylmagnesium bromide;

[0167] CS2-carbon disulfide

[0168] d-doublet;

[0169] δ-delta;

[0170] DCM - dichloromethane;

[0171] DIPEA-N,N-diisopropylethylamine;

[0172] DMFA-N,N-dimethylformamide;

[0173] DMSO-dimethyl sulfoxide;

[0174] DMSO-d6-deuterated dimethyl sulfoxide;

[0175] D2O-deuterated water;

[0176] DPPA-diphenylphosphorylazide;

[0177] EDC.HCl-1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride;

[0178] EtOH-ethanol;

[0179] EtOAc-ethyl acetate;

[0180] g-gram;

[0181] h-hour;

[0182] 1 H-proton;

[0183] H2-hydrogen;

[0184] HATU-N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanium hexafluorophosphate N-oxide;

[0185] HBTU-N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate;

[0186] 1 HNMR - proton nuclear magnetic resonance;

[0187] HNO3-nitric acid;

[0188] H2O-water;

[0189] HCl-hydrochloric acid;

[0190] Hz-Hertz;

[0191] H2SO4-sulfuric acid;

[0192] J-coupling constant;

[0193] K2CO3-potassium carbonate;

[0194] KOH-potassium hydroxide;

[0195] K3PO4-potassium phosphate;

[0196] LC-Liquid Chromatography;

[0197] LiOH.H2O - lithium hydroxide monohydrate;

[0198] M + -molecular ions;

[0199] m-multiplet;

[0200] M-molar concentration;

[0201] m-CPBA-m-chloroperbenzoic acid;

[0202] MeI-methyl iodide;

[0203] MeOH-methanol;

[0204] mg-milligram;

[0205] min-minutes;

[0206] MHz - megahertz (frequency);

[0207] mL-milliliter;

[0208] mM-millimolar concentration;

[0209] mmol-millimolar;

[0210] MS-mass spectrometry;

[0211] m / z - mass-to-charge ratio;

[0212] N-equivalent concentration;

[0213] NaBH4-sodium borohydride;

[0214] NaH-sodium hydride;

[0215] NaHCO3 - sodium bicarbonate;

[0216] NaNO2-sodium nitrite;

[0217] NaNO3 - sodium nitrate;

[0218] NaOEt-sodium ethoxide; NaOH-sodium hydroxide;

[0219] NaOMe - sodium methoxide;

[0220] NBS-N-bromosuccinimide

[0221] Pd / C-palladium on carbon;

[0222] Pd(OAc)2-palladium(II) acetate;

[0223] POCl3-phosphorus oxychloride;

[0224] P2S5-phosphorus pentasulfide;

[0225] PtO2-platinum dioxide:

[0226] %-percentage;

[0227] pH-acidity;

[0228] psi - pounds per square inch;

[0229] q-quartet;

[0230] RT - room temperature;

[0231] s-singlet;

[0232] SOCl2-thionyl chloride;

[0233] t-triplet;

[0234] TBAF-tetra-n-butylammonium fluoride;

[0235] TBDMSCl-tert-butyldimethylsilyl chloride;

[0236] TEA-triethylamine;

[0237] TFA-trifluoroacetic acid;

[0238] THF - tetrahydrofuran;

[0239] TLC - thin layer chromatography.

[0240] Examples 1h and 1i. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-(Benzo[d]oxazol-2-ylamino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide:

[0241]

[0242] Conditions: a) carbon disulfide, KOH, ethanol, reflux, 16 h; b) K2CO3, methyl iodide, acetonitrile, 0°C-RT, 5 h; c) m-CPBA, DCM, 0°C-RT, 4 h; d) methylamine, DMF, 60°C, 16 h; e) 10% Pd / C, MeOH, H2, RT, 5 h; f) cyanogen bromide, THF, H2O, 50°C, 16 h; g) NaH, 2-(methylsulfonyl)benzo[d]oxazole, 1,4-dioxane, RT, 16 h; h) LiOH.H2O, THF, ethanol, water, 60°C, 16 h; i) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0243] Step-a: Synthesis of benzo[d]oxazole-2-thiol (1a)

[0244] To a solution of 2-aminophenol (4.0 g, 36.7 mmol) in ethanol (80 mL) at room temperature (RT) was added powdered potassium hydroxide (3.59 g, 64.2 mmol) and carbon disulfide (20 mL, 330.3 mmol), and the reaction mixture was refluxed for 16 hours (h). The reaction mixture was concentrated, diluted with water (100 mL) and acidified with 1N HCl. The resulting solid was filtered and dried in vacuo to give the title compound (4.0 g, 72%); 1 H NMR (400MHz, DMSO-d6): δ13.85 (bs, 1H), 7.51-7.49 (m, 1H), 7.32-7.23 (m, 3H); LC-MS: m / z 152.0 (M+1) + .

[0245] Step-b: Synthesis of 2-(methylthio)benzo[d]oxazole (1b)

[0246] To a solution of benzo[d]oxazole-2-thiol (3.0 g, 19.9 mmol) in acetonitrile (50 mL) at 0°C was added potassium carbonate (3.01 g, 21.9 mmol) and methyl iodide (1.36 mL, 21.9 mmol), and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was diluted with water (60 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the product, which was used in the next step without any further purification (2.5 g, 76%). 1 H NMR (400MHz, DMSO-d6): δ7.65-7.62(m,2H),7.34-7.30(m,2H),2.76(s,3H); LC-MS: m / z 166.0(M+1) + .

[0247] Step-c: Synthesis of 2-(methylsulfonyl)benzo[d]oxazole (1c)

[0248] To a solution of 2-(methylthio)benzo[d]oxazole (500 mg, 3.0 mmol) in DCM (20 mL) at 0 ° C. was added m-chloroperbenzoic acid (938 mg, 9.1 mmol), and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with water (40 mL), and the aqueous layer was extracted with DCM (2×100 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (6×150 mL), water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the product (300 mg), which was used immediately in the next step without any further purification; LC-MS: m / z 198.0 (M+1) + .

[0249] Step-d: Synthesis of ethyl 4-(methylamino)-3-nitrobenzoate (1d)

[0250] To a solution of ethyl 4-chloro-3-nitrobenzoate (30.0 g, 131 mmol) in DMFA (100 mL) at room temperature was added methylamine (26.8 mL (40% aqueous solution), 262 mmol), and the reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with cold water (1000 mL) and stirred at room temperature for 1 h. The resulting solid was filtered and dried in vacuo to give the product as a yellow solid (26.0 g, 89%); 1H NMR (400MHz, DMSO-d6): δ8.62(d,J=2.0Hz,1H),8.59(bs,1H),7.99(dd,J=2.0Hz,J=8.8Hz,1H),7. 07(d,J=8.8Hz,1H),4.29(q,J=6.8Hz,2H),3.01(d,J=5.2Hz,3H),1.31(t,J=6.8Hz,3H); LC-MS:m / z 225.0(M+1) + .

[0251] Step-e: Synthesis of ethyl 3-amino-4-(methylamino)benzoate (1e)

[0252] Under nitrogen atmosphere, to a solution of ethyl 4-(methylamino)-3-nitrobenzoate (13.0 g, 58 mmol) in methanol (180 mL) was added a slurry of 10% Pd / C (1.3 g in 10 mL of ethanol). The flask was kept in a Parr shaker at room temperature under hydrogen pressure (60 psi) for 5 h. The reaction mixture was filtered through a bed of celite and concentrated in vacuo to give the title compound (10.0 g, 88%). 1 H NMR (400MHz, DMSO-d6): δ7.23 (dd, J=1.6Hz, J=8.4Hz 1H),7.16(d,J=1.6Hz,1H),6.39(d,J=8.4Hz,1H),5.38-5.37(m,1H),4.66(s,2H ), 4.18 (q, J = 7.2Hz, 2H), 2.77 (d, J = 5.2Hz, 3H), 1.26 (t, J = 7.2Hz, 3H); LC-MS: m / z 195.1(M+1) + .

[0253] Step-f: Synthesis of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (1f)

[0254] To a solution of ethyl 3-amino-4-(methylamino)benzoate (5.6 g, 28.8 mmol) in THF (23 mL) and water (56 mL) at room temperature was added cyanogen bromide (3.7 g, 34.6 mmol), and the reaction mixture was stirred at 50 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with water (50 mL) and ethyl acetate (50 mL). The aqueous layer was basified with saturated sodium bicarbonate solution and extracted with EtOAc (2×250 mL). The combined organic layer was washed with water (100 mL), brine (100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the product (5.2 g, 82%), which was used in the next step without further purification; 1HNMR (400MHz, DMSO-d6): δ7.70(d,J=1.2Hz,1H),7.59(dd,J=1.2Hz,J=8.4Hz,1H),7.20( d, J=8.4Hz, 1H), 6.64 (s, 2H), 4.27 (q, J=6.8Hz, 2H), 3.53 (s, 3H), 1.32 (t, J=6.8Hz, 3H).

[0255] Step-g: Synthesis of ethyl 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (1 g)

[0256] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (150 mg, 0.68 mmol) in 1,4-dioxane (4 mL) at room temperature was added sodium hydride (96 mg, 2.4 mmol) and the reaction mixture was stirred for 15 minutes (min) followed by the addition of 2-(methylsulfonyl)benzo[d]oxazole (202 mg, 1.0 mmol). The reaction mixture was stirred at room temperature for 16 h and concentrated, diluted with water (20 mL) and acidified with 1N HCl (pH ~ 6). The resulting solid was filtered, dried under vacuum and purified by combiflash column chromatography using 100% DCM as eluent to give the title compound (50 mg, 22%). 1 HNMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.24(s,1H),7.88(d,J=8.4Hz,1H),7.53-7.43(m,3H),7.22(t, J=7.2Hz,1H),7.13(t,J=7.6Hz,1H),4.33(q,J=7.2Hz,2H),3.64(s,3H),1.35(t,J=7.2Hz,3H); LC-MS: m / z 337.0(M+1) + .

[0257] Step-h: Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (1h)

[0258] To a stirred solution of ethyl 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (50 mg, 0.15 mmol) in a solvent mixture of THF (1 mL), ethanol (1 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (19 mg, 0.45 mmol). The reaction mixture was heated at 60 ° C for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (35 mg, 76%); 1 H NMR (400MHz, DMSO-d6): δ12.60(bs,2H),8.20(d,J=1.6Hz,1H),7.87(dd,J=1.6Hz,J=8.0Hz,1H),7.5 1-7.48(m,2H),7.44(d,J=7.2Hz,1H),7.23-7.20(m,1H),7.15-7.11(m,1H),3.64(s,3H); LC-MS:m / z 308.6(M+1) + .

[0259] Step-i: Synthesis of 2-(benzo[d]oxazol-2-ylamino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide (1i)

[0260] To a stirred solution of 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (30 mg, 0.1 mmol) in DMFA (1.0 mL) at 0 ° C was added N-ethyldiisopropylamine (0.02 mL, 0.1 mmol) and diphenylphosphoryl azide (0.02 mL, 0.1 mmol). The reaction mixture was stirred for 30 min, followed by the addition of 2-methoxyethylamine (8 mg, 0.1 mmol). The reaction mixture was then stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (15 mL) and stirred for 15 min. The resulting solid was filtered, washed with diethyl ether and dried in vacuo to give the title compound (22 mg, 53%) as a white solid. 1H NMR (400MHz, DMSO-d6): δ12.2 (bs, 1H), 8.45 (t, J=4.9Hz, 1H), 8.08 (s, 1H), 7.76 (dd, J=1.5Hz, J=8.3Hz, 1H), 7.47 (d, J=8. 3Hz, 1H), 7.44-7.39(m, 2H), 7.25-7.19(m, 1H), 7.13-7.10(m, 1H), 3.63(s, 3H), 3.48-3.44(m, 4H), 3.29(s, 3H); LC-MS: m / z 364.0(M-1).

[0261] Examples 2d and 2e. Synthesis of 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide:

[0262]

[0263] Conditions: a) Tetrahydro-2H-pyran-4-amine, K2CO3, DMSO, 70°C, 16h; b) 10% Pd / C, MeOH, H2, RT, 5h; c) 2-amino-(trifluoromethoxy)benzothiazole, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 16h; d) LiOH.H2O, THF, MeOH, water, 60°C, 16h; e) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0264] Step-a: Synthesis of ethyl 3-nitro-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate (2a)

[0265] To a stirred solution of ethyl 4-chloro-3-nitrobenzoate (1.0 g, 4.4 mmol) in DMSO (10 mL) was added potassium carbonate (1.2 g, 8.7 mmol) and tetrahydro-2H-pyran-4-amine (0.53 g, 5.2 mmol) at room temperature. Subsequently, the reaction mixture was heated to 70 ° C and stirred for 16 h, and then cooled to room temperature. The reaction mixture was diluted with cold water, and the resulting solid was filtered and dried in vacuo to give the title compound (1.1 g, 86%); 1H NMR (400MHz, DMSO-d6): δ8.62 (d, J=2.0Hz, 1H), 8.23 ​​(d, J=7.8Hz, 1H), 7.97 (dd, J=1.9Hz, J=8.8Hz, 1H), 7.29 (d, J=9.3Hz, 1H), 4.29 (q, J=7 .3Hz, 2H), 3.96-3.94(m, 1H), 3.90-3.83(m, 2H), 3.51-3.45(m, 2H), 1.96-1.93(m, 2H), 1.66-1.61(m, 2H), 1.31(t, J=7.3Hz, 3H); LC-MS: m / z 294.8(M+1) + .

[0266] Step-b: Synthesis of ethyl 3-amino-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate (2b)

[0267] The title compound was synthesized using the same procedure as intermediate 1e using ethyl 3-nitro-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate as the starting material (yield: 100%); 1 H NMR (400MHz, DMSO-d6): δ7.19(d,J=8.0Hz,1H),7.17(s,1H),6.52(d,J=8.3Hz,1H),4.99(d,J=7.3Hz,1H),4.97(s,2H),4.18(q,J=7.3H z,2H),3.89-3.87(m,2H),3.57-3.53(m,1H),3.45-3.40(m,2H),1.92-1.89(m,2H),1.48-1.38(m,2H),1.25(t,J=7.4Hz,3H); LC-MS: m / z 264.8(M+1) + .

[0268] Step-c: Synthesis of ethyl 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (2c)

[0269] To a stirred solution of 2-amino-6-(trifluoromethoxy)benzothiazole (177 mg, 0.76 mmol) in DMFA (55 mL) was added 1,1'-thiocarbonyldiimidazole (270 mg, 1.5 mmol), and the solution was heated at 100 ° C for 4 h. The reaction mixture was cooled to room temperature. EDC.HCl (291 mg, 1.5 mmol) was added, and the reaction mixture was heated at 60 ° C for 10 min, followed by the addition of ethyl 3-amino-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate (200 mg, 0.76 mmol). The reaction mixture was then heated at 100 ° C for 16 h. It was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 100% DCM as eluent to give the title compound (120 mg, 31%); LC-MS: m / z 505.0 (M-1).

[0270] Step-d: Synthesis of 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (2d)

[0271] The title compound was synthesized using the same procedure as intermediate 1h using ethyl 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 53%); 1 H NMR (400MHz, DMSO-d6): δ12.91(bs,1H),12.57(bs,1H),8.24(s,1H),8.02-7.64(m,4H),7.37(s,1H),4. 96-4.94(m,1H),4.20-4.05(m,2H),3.59-3.52(m,2H),2.60-2.44(m,2H),1.79-1.76(m,2H); LC-MS:m / z 477.0(M-1).

[0272] Step-e: Synthesis of N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide (2e)

[0273] The title compound was synthesized using the same procedure as intermediate 1i using 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 18%); 1 H NMR (400MHz, DMSO-d6): δ8.25(t,J=5.4Hz,1H),7.90(d,J=1.5Hz,1H),7.71-7.64(m,2H),7.33(d,J=0.9Hz,1H),7.16-7.13(m,1H),6.87(d,J=8.8Hz ,1H),5.23-5.17(m,1H),4.11-4.10(m,2H),3.65(t,J=11.2Hz,2H),3.35- 3.32(m,4H),3.28(s,3H),2.66-2.60(m,2H),1.92-1.90(m,2H); LC-MS:m / z 536.0(M+1) + .

[0274] Examples 3d and 3e. Synthesis of 1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0275]

[0276] Conditions: a) 1-methylpiperidin-4-amine, DIPEA, DMF, 70°C, 16h; b) 10% Pd / C, MeOH, H2, RT, 2h; c) 2-amino-6-(trifluoromethoxy)benzothiazole, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 16h; d) LiOH.H2O, THF, EtOH, water, 60°C, 16h; e) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0277] Step-a: Synthesis of ethyl 4-((1-methylpiperidin-4-yl)amino)-3-nitrobenzoate (3a)

[0278] To a stirred solution of ethyl 4-chloro-3-nitrobenzoate (500 mg, 2.2 mmol) in DMFA (5 mL) was added 1-methylpiperidin-4-amine (0.30 mL, 2.6 mmol) and N-ethyldiisopropylamine (0.8 mL, 5.0 mmol). The reaction mixture was heated to 70 ° C and continued to stir at the same temperature for 16 h. The reaction mixture was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with water (50 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (620 mg, 92%). 1 H NMR (400MHz, DMSO-d6): δ 8.62 (s, 1H), 8.25 (d, J = 8.0Hz, 1H), 7.97 (d, J = 9.2Hz, 1H), 7.23 (d, J = 9.2Hz, 1H), 4.30 (q, J = 7.6Hz, 2H), 3.7 1(bs, 1H), 2.69-2.66(m, 2H), 2.18(s, 3H), 2.16-2.13(m, 2H), 1.96-1.93(m, 2H), 1.67-1.58(m, 2H), 1.33(t, J=7.6Hz, 3H); LC-MS: m / z 307.7(M+1) + .

[0279] Step-b: Synthesis of ethyl 3-amino-4-((1-methylpiperidin-4-yl)amino)benzoate (3b)

[0280] The title compound was synthesized using the same procedure as Intermediate 1e, using ethyl 4-((1-methylpiperidin-4-yl)amino)-3-nitrobenzoate as the starting material and stirring for 2 hours (yield: 100%); 1 H NMR (400MHz, DMSO-d6): δ7.19-7.16 (m, 2H), 6.47 (d, J=8.4Hz, 1H), 4.96 (d, J=7.2Hz, 1H), 4.78 (bs, 2H), 4.18 (q, J=7.2Hz, 2H), 3. 37-3.31(m,1H),2.86-2.83(m,2H),2.25(s,3H),2.19-2.13(m,2H),1.94-1.91(m,2H),1.54-1.45(m,2H),1.26(t,J=6.8Hz,3H);

[0281] LC-MS: m / z 278.2 (M+1) + .

[0282] Step-c: Synthesis of ethyl 1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (3c)

[0283] The title compound was synthesized using the same procedure as Intermediate 2c using ethyl 3-amino-4-((1-methylpiperidin-4-yl)amino)benzoate as the starting material (yield: 15%); 1 H NMR (400MHz, DMSO-d6): δ12.6(bs,1H),8.14(s,1H),7.91(s,1H),7.79(d,J=8.3 Hz,1H),7.62(d,J=8.3Hz,1H),7.55(s,1H),7.35(d,J=8.8Hz,1H),4.74-4.68(m 1H),4.34(q,J=6.8Hz,2H),3.01-2.98(m,2H),2.67-2.56(m,2H),2.30(s,3 H),2.20-2.15(m,2H),1.79-1.76(m,2H),1.35(t,J=6.9Hz,3H); LC-MS:m / z 520.1(M+1) + .

[0284] Step-d: Synthesis of 1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (3d)

[0285] The title compound was synthesized using the same procedure as Intermediate 1h using ethyl 1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 56%); 1 H NMR (400MHz, DMSO-d6): δ12.40(bs,1H),8.12(s,1H),7.91(s,1H),7.78(d,J=8.3Hz,1H),7.60(d,J=8.3Hz,1H),7.58(bs,1H),7.34(d ,J=8.9Hz,1H),4.79-4.68(m1H),3.02-2.99(m,2H),2.57-2.54(m,2H),2.30(s,3H),2.21-2.15(m,2H),1.79-1.77(m,2H); LC-MS: m / z 491.6(M+1) + .

[0286] Step-e: Synthesis of N-(2-methoxyethyl)-1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide (3e)

[0287] The title compound was synthesized using the same procedure as intermediate 1i using 1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 40%); 1 H NMR (400MHz, DMSO-d6): δ12.40(bs,1H),8.44(s,1H),8.09(s,1H),7.91(s,1H),7.70-7.58(m,3H),7.35(d,J=6.8Hz,1H),4.75-4.65(m, 1H),3.50-3.43(m,4H),3.28(s,3H),3.02-2.99(m,2H),2.60-2.54(m,2H),2.31(s,3H),2.20-2.15(m,2H),1.79-1.76(m,2H); LC-MS: m / z 549.2(M+1) + .

[0288] Examples 4d and 4e. Synthesis of 1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide:

[0289]

[0290] Conditions: a) 1-methylpyrrolidin-3-amine, DIPEA, DMF, 70°C, 16h; b) 10% Pd / C, MeOH, H2, 2h; c) 2-amino-6-(trifluoromethoxy)benzothiazole, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 16h; d) LiOH.H2O, THF, MeOH, water, 60°C, 16h; e) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0291] Step-a: Synthesis of ethyl 4-((1-methylpyrrolidin-3-yl)amino)-3-nitrobenzoate (4a)

[0292] The title compound was synthesized using the same procedure as Intermediate 3a using ethyl 4-chloro-3-nitrobenzoate and 1-methylpyrrolidin-3-amine as starting materials (yield: 79%); 1 H NMR (400MHz, DMSO-d6): δ8.62 (d, J=1.9Hz, 1H), 8.39 (d, J=6.8Hz, 1H), 7.98 (dd, J=2.0Hz, J=8.8Hz, 1H), 7.15 (d, J=9.3Hz, 1H), 4.32-4 .36 (m, 3H), 2.80-2.75 (m, 1H), 2.70-2.59 (m, 2H), 2.42-2.30 (m, 2H), 2.29 (s, 3H), 1.73-1.65 (m, 1H), 1.31 (t, J=7.4Hz, 3H); LC-MS: m / z 294.1(M+1) + .

[0293] Step-b: Synthesis of ethyl 3-amino-4-((1-methylpyrrolidin-3-yl)amino)benzoate (4b)

[0294] The title compound was synthesized using the same procedure as intermediate 1e, using ethyl 4-((1-methylpyrrolidin-3-yl)amino)-3-nitrobenzoate as the starting material and stirring for 2 h (yield: 78%); 1 H NMR (400MHz, DMSO-d6): δ7.19-7.15 (m, 2H), 6.38 (d, J=8.3Hz, 1H), 5.16 (d, J=6.9Hz, 1H), 4.81 (s, 2H), 4.18 (q, J=7.3Hz, 2H), 3.95 ( bs, 1H), 2.74-2.70 (m, 1H), 2.44-2.34 (m, 2H), 2.28-2.22 (m, 1H), 2.25 (s, 3H), 1.67-1.63 (m, 1H), 1.25 (t, J=7.3Hz, 3H); LC-MS: m / z 264.1(M+1) + .

[0295] Step-c: Synthesis of ethyl 1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (4c)

[0296] The title compound was synthesized using the same procedure as Intermediate 2c, using ethyl 3-amino-4-((1-methylpyrrolidin-3-yl)amino)benzoate as the starting material. The product was used in the next step without further purification; LC-MS: m / z 506.1 (M+1) + .

[0297] Step-d: Synthesis of 1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (4d)

[0298] The title compound was synthesized using the same procedure as Intermediate 1h, using ethyl 1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material and THF, MeOH and water (2:2:1) as solvents (yield: 13%); 1 H NMR (400MHz, DMSO-d6+D2O): δ8.03 (s, 1H), 7.83 (s, 1H), 7.78 (d, J=8.3Hz, 1H), 7.59-7.54 (m, 2H), 7.32 (d, J=8.8Hz, 1H), 5.50(bs, 1H), 3.86-3.75(m, 2H), 3.35(bs, 1H), 3.07-3.05(m, 1H), 2.91(s, 3H), 2.28-2.0(m, 2H); LC-MS: m / z478.1(M+1) + .

[0299] Step-e: Synthesis of N-(2-methoxyethyl)-1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide (4e)

[0300] The title compound was synthesized using the same procedure as intermediate 1i using 1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 30%); 1 H NMR (400 MHz, DMSO-d6): δ 8.10 (bs, 1H), 8.04 (s, 1H), 7.85 (s, 1H), 7.76 (bs, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.62 (bs, 1H), 7.30 (d, J = 8.8 Hz, 1H), 5.50 (bs, 1H), 3.52-3.44 (m, 4H), 3.30 (s, 3H), 2.76-2.65 (m, 2H), 2.50 (s, 3H, combined with DMSO peak), 2.31-2.30 (m, 2H), 2.15-2.13 (m, 2H); LC-MS: m / z 535.0 (M+1) + .

[0301] Example 5. Synthesis of N-(2-methoxyethyl)-1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide:

[0302]

[0303] Conditions: a) 4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 16h; b) LiOH.H2O, THF, MeOH, water, 60°C, 16h; c) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0304] Step-a: Synthesis of methyl 1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (5a)

[0305] To a stirred solution of 4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (216 mg, 1.4 mmol) in DMFA (5 mL) was added 1,1′-thiocarbonyldiimidazole (494 mg, 2.8 mmol) and the solution was heated at 100 ° C for 2 h. The reaction mixture was cooled to room temperature. EDC.HCl (533 mg, 2.8 mmol) was added and the reaction mixture was heated at 60 ° C for 10 min, followed by the addition of methyl 3-amino-4-(methylamino)benzoate (250 mg, 1.4 mmol). The reaction mixture was heated at 100 ° C for 16 h. It was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 100% DCM as eluent to give the title compound (110 mg, 23%); 1 H NMR (400 MHz, DMSO-d6): δ 12.01 (bs, 1H), 7.97 (s, 1H), 7.73 (dd, J = 1.6 Hz, J = 8.4 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 3.84 (s, 3H), 3.61 (s, 3H), 2.50 (bs, 4H, merged with DMSO peak), 1.78 (bs, 4H); LC-MS: m / z 341.0 (M-1).

[0306] Step-b: Synthesis of 1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (5b)

[0307] The title compound was synthesized using the same procedure as intermediate 1h using 1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid methyl ester as the starting material and THF, MeOH and water (2:2:1) as solvents (yield: 83%); 1 H NMR (400 MHz, DMSO-d6): δ 12.20 (bs, 2H), 7.95 (s, 1H), 7.73 (dd, J = 0.8 Hz, J = 8.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 3.61 (s, 3H), 2.50 (bs, 4H, merged with DMSO peak), 1.78 (bs, 4H); LC-MS: m / z 327.0 (M-1).

[0308] Step-c: Synthesis of N-(2-methoxyethyl)-1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide (5c)

[0309] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 30%); 1 H NMR (400 MHz, DMSO-d6): δ 12.0 (bs, 1H), 8.34 (bs, 1H), 7.95 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 3.60 (s, 3H), 3.48-3.42 (m, 4H), 3.28 (s, 3H), 2.50 (bs, 4H, merged with DMSO peak), 1.78 (bs, 4H); LC-MS: m / z 384.0 (M-1).

[0310] Example 6. Synthesis of 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0311]

[0312] Conditions: a) trimethylsilyl trifluoromethanesulfonate, TEA, DCM, 0°C, 1.5h; b) NBS, sodium acetate, THF, water, RT, 2h; thiourea, 80°C, 6h; RT, 16h; c) ethyl 3-amino-4-(methylamino)benzoate, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 18h; d) LiOH.H2O, THF, EtOH, water, 80°C, 16h; e) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0313] Step-a: Synthesis of ((4,4-dimethylcyclohex-1-en-1-yl)oxy)trimethylsilane

[0314] To a solution of 4,4-dimethylcyclohexan-1-one (3.0 g, 23.8 mmol) in DCM (180 mL) at 0 ° C. triethylamine (9.95 mL, 71.42 mmol) was added. The reaction mixture was stirred for 5 min, followed by the addition of trimethylsilyl trifluoromethanesulfonate (6.5 g, 29.28 mmol in 54 mL DCM). The reaction mixture was stirred at 0 ° C. for 1.5 h, and then quenched with saturated sodium bicarbonate solution (30 mL) and water (100 mL). The organic layer was separated and washed with water (2 × 50 mL), a saline solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (3.8 g, 81%), which was used in the next step without further purification. 1 H NMR (400MHz, CDCl3): δ4.74 (t, J=4.0Hz, 1H), 1.99-1.97 (m, 2H), 1.80 (d, J=2.0Hz, 2H), 1.39 (t, J=6.8Hz, 2H), 1.16 (s, 6H), 0.15 (s, 9H).

[0315] Step-b: Synthesis of 6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine

[0316] To a solution of ((4,4-dimethylcyclohex-1-en-1-yl)oxy)trimethylsilane (3.8 g, 19.16 mmol) in THF (40 mL) and water (40 mL) at room temperature was added N-bromosuccinimide (4.09 g, 23.0 mmol) and sodium acetate (0.22 g, 2.7 mmol). The reaction mixture was then stirred for 2 h. Thiourea (1.43 g, 18.8 mmol) was added, and the reaction mixture was heated at 80 ° C. for 6 h under stirring. It was then cooled to room temperature and stirred for 16 h. The reaction mixture was quenched with water (30 mL) and extracted with DCM (2×50 mL). The aqueous layer was basified with 2 M sodium hydroxide (pH~9) and stirred at room temperature for 2 h. The precipitated solid was filtered and dried in vacuo to give the title compound (1.3 g, 37%), which was used in the next step without further purification. 1 H NMR (400MHz, DMSO-d6): δ6.55 (bs, 2H), 2.35 (t, J=6.4Hz, 2H), 2.26 (s, 2H), 1.46 (t, J=6.0Hz, 2H), 0.95 (s, 6H); LC-MS: m / z 183.1 (M+1) + .

[0317] Step-c: Synthesis of ethyl 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0318] To a stirred solution of 6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (809 mg, 4.44 mmol) in DMFA (10 mL) was added 1,1'-thiocarbonyldiimidazole (1.58 g, 8.88 mmol) and the solution was heated at 100 ° C for 2 h. The reaction mixture was cooled to room temperature and EDC.HCl (1.70 g, 8.88 mmol) was added. The reaction mixture was heated at 50 ° C for 10 min, followed by the addition of ethyl 3-amino-4-(methylamino)benzoate (800 mg, 4.44 mmol). It was then heated at 100 ° C for 16 h and cooled to room temperature. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2×100 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 100% DCM as eluent to give the title compound (500 mg, 32%); 1H NMR (400 MHz, DMSO-d6): δ 12.10 (bs, 1H), 7.98 (s, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 4.30 (q, J = 7.2 Hz, 2H), 3.61 (s, 3H), 2.50 (2H, combined with DMSO peak), 2.33 (s, 2H), 1.56 (t, J = 6.0 Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H), 1.00 (s, 6H); LC-MS: m / z 385.1 (M+1) + .

[0319] Step-d: Synthesis of 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0320] To a stirred solution of ethyl 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (500 mg, 1.30 mmol) in a mixture of THF (4 mL), ethanol (4 mL) and water (2 mL) was added lithium hydroxide monohydrate (136 mg, 3.25 mmol). The reaction mixture was heated at 80 °C for 16 h and then cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in water and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (300 mg, 65%); 1 H NMR (400 MHz, DMSO-d6): δ 8.00 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 3.64 (s, 3H), 2.50 (2H, combined with DMSO peak), 2.38 (s, 2H), 1.58 (t, J = 6.0 Hz, 2H), 1.01 (s, 6H); LC-MS: m / z 357.1 (M+1) + .

[0321] Step-e: Synthesis of 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0322] To a stirred solution of 2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (100 mg, 0.28 mmol) in DMFA (2 mL) at 0 ° C was added N-ethyldiisopropylamine (0.04 mL, 0.28 mmol) and HBTU (106 mg, 0.28 mmol). The reaction mixture was stirred for 30 min, followed by the addition of 2-(2-aminoethoxy)ethan-1-ol (0.02 mL, 0.28 mmol) and continued stirring at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (20 mL) and stirred for 15 min. The resulting solid was filtered and dried in vacuo. The residue was purified by flash column chromatography using 2% MeOH / DCM as eluent to give the title compound (50 mg, 40%). 1 H NMR (400 MHz, DMSO-d6): δ 12.0 (bs, 1H), 8.34 (s, 1H), 7.95 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 4.60 (bs, 1H), 3.60 (s, 3H), 3.56-3.42 (m, 8H), 2.50 (2H, combined with DMSO peak), 2.32 (m, 2H), 1.55 (t, J = 6.0 Hz, 2H), 1.00 (s, 6H); LC-MS: m / z 444.1 (M+1) + .

[0323] Example 7. Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0324]

[0325] Conditions: a) trimethylsilyl trifluoromethanesulfonate, TEA, DCM, 0°C, 1.5h; b) NBS, sodium acetate, EtOH, water, RT, 2h; thiourea, 80°C, 6h; RT, 16h; c) ethyl 3-amino-4-(methylamino)benzoate, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 16h; d) LiOH.H2O, THF, EtOH, water, 60°C, 16h; e) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0326] Step-a: Synthesis of trimethyl((4-methylcyclohex-1-en-1-yl)oxy)silane

[0327] To a solution of 4-methylcyclohexan-1-one (2.0 g, 17.8 mmol) in DCM (50 mL) at 0° C., triethylamine (7.5 mL, 53.4 mmol) was added and stirred for 5 min, followed by the addition of trimethylsilyl trifluoromethanesulfonate (4.95 g, 22.3 mmol in 30 mL of DCM). The reaction mixture was stirred at 0° C. for 1.5 h and then quenched with saturated sodium bicarbonate solution (20 mL) and water (100 mL). The organic layer was separated and washed with water (2×100 mL), brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (3.4 g, 100%). 1 H NMR (400MHz, DMSO-d6): δ4.74-4.71 (m, 1H), 2.66-2.49 (m, 1H), 2.16-1.99 (m, 2H), 1.89 -1.88 (m, 1H), 1.62-1.57 (m, 2H), 1.25-1.22 (m, 1H), 0.89 (d, J=2.4Hz, 3H), 0.27 (s, 9H).

[0328] Step-b: Synthesis of 6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine

[0329] To a solution of trimethyl((4-methylcyclohex-1-en-1-yl)oxy)silane (3.3 g, 17.9 mmol) in THF (25 mL) and water (25 mL) at room temperature was added N-bromosuccinimide (3.83 g, 21.5 mmol) and sodium acetate (0.20 g, 2.5 mmol), and then stirred for 2 h. Thiourea (1.43 g, 18.8 mmol) was added, and the reaction mixture was heated at 80 ° C. under stirring for 6 h. Subsequently, the reaction mixture was cooled to room temperature and continued to stir for 16 h. The reaction mixture was quenched with water (30 mL) and extracted with DCM (2×100 mL). The aqueous layer was basified (pH 7.0) with 2 M sodium hydroxide. ~ 9) and extracted with DCM (3×100 mL). The combined organic layers were washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (1.9 g, 63%); 1 H NMR (400MHz, DMSO-d6): δ6.55(bs,2H),2.57-2.51(m,1H),2.40-2.36(m,2H),2.12- 2.05(m,1H),1.79-1.74(m,2H),1.35-1.34(m,1H),1.00(d,J=6.4Hz,3H); LC-MS:m / z 169.2(M+1) + .

[0330] Step-c: Synthesis of ethyl 1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0331] To a stirred solution of 6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (400 mg, 2.38 mmol) in DMFA (10 mL) was added 1,1'-thiocarbonyldiimidazole (848 mg, 4.76 mmol) and the solution was heated at 100 ° C for 2 h. The reaction mixture was cooled to room temperature and EDC.HCl (914 mg, 4.76 mmol) was added. The reaction mixture was heated at 50 ° C for 10 min, followed by the addition of ethyl 3-amino-4-(methylamino)benzoate (462 mg, 2.38 mmol). The reaction mixture was heated at 100 ° C for 16 h. It was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 100% DCM as eluent to give the title compound (400 mg, 45%); 1 H NMR (400 MHz, DMSO-d6): δ 12.03 (bs, 1H), 7.98 (s, 1H), 7.73 (dd, J = 1.0 Hz, J = 8.3 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 4.30 (q, J = 7.2 Hz, 2H), 3.62 (s, 3H), 2.67-2.60 (m, 1H), 2.50 (2H, combined with DMSO peak), 2.18-2.11 (m, 1H), 1.87-1.84 (m, 2H), 1.46-1.42 (m, 1H), 1.34 (t, J = 7.1 Hz, 3H), 1.05 (d, J = 6.3 Hz, 3H); LC-MS: m / z 371.05 (M+1) + .

[0332] Step-d: Synthesis of 1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0333] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 100%); 1H NMR (400 MHz, DMSO-d6): δ 13.01 (bs, 1H), 12.83 (bs, 1H), 8.01 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 3.67 (s, 3H), 2.67-2.66 (m, 1H), 2.52 (2H, combined with DMSO peak), 2.33-2.21 (m, 1H), 1.91-1.86 (m, 2H), 1.48-1.43 (m, 1H), 1.06 (d, J = 6.4 Hz, 3H); LC-MS: m / z 343.05 (M+1) + .

[0334] Step-e: Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0335] The title compound was synthesized using the same procedure as in Example 6, step-e, using 1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials (yield: 48%); 1 H NMR (400MHz, DMSO-d6): δ11.99 (bs, 1H), 8.35 (t, J=5.6Hz, 1H), 7.95 (s, 1H), 7.64 (d, J=8.0Hz, 1H), 7.32 (d, J=8.4Hz, 1H), 4.62 (t, J=5.0Hz, 1H), 3.61 (s, 3H), 3.55- 3.50 (m, 4H), 3.47-3.42 (m, 4H), 2.67-2.66 (m, 1H), 2.52 (2H, combined with DMSO peak), 2.17-2.16 (m, 1H), 1.90-1.88 (m, 2H), 1.45-1.40 (m, 1H), 1.05 (d, J = 6.4 Hz, 3H); LC-MS: m / z 430.10 (M+1) + .

[0336] Example 8. Synthesis of 2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0337]

[0338] Conditions: a) iodine, thiourea, 110°C, 12h; b) ethyl 3-amino-4-(methylamino)benzoate, 1,1′-thiocarbonyldiimidazole, EDC.HCl, DMF, 100°C, 16h; c) LiOH.H2O, THF, ethanol, water, 60°C, 16h; h) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0339] Step-a: Synthesis of 5,6-dihydro-4H-cyclopenta[d]thiazol-2-amine

[0340] A mixture of cyclopentanone (1.0 g, 11.9 mmol), thiourea (1.8 g, 23.8 mmol) and iodine (3.0 g, 11.9 mmol) was stirred in a sealed test tube at 110 ° C for 12 h. The reaction mixture was cooled to room temperature, and hot water (30 mL) was added and stirred for 30 min. The reaction mixture was extracted with diethyl ether (2×20 mL), and the aqueous layer was alkalized (pH~8) with solid sodium bicarbonate and extracted with DCM (3×30 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting residue was purified by flash chromatography using 10% methanol / DCM and 0.1% ammonia water as eluents to give the title compound (160 mg, 10%). 1 H NMR (400MHz, CDCl3): δ4.77 (bs, 2H), 2.79-2.74 (m, 2H), 2.68-2.64 (m, 2H), 2.41-2.34 (m, 2H); LC-MS: m / z 141.1 (M+1) + .

[0341] Step-b: Synthesis of ethyl 2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0342] The title compound was synthesized using the same procedure as compound 5a using ethyl 3-amino-4-(methylamino)benzoate and 5,6-dihydro-4H-cyclopenta[d]thiazol-2-amine as starting materials (yield: 23%); 1 H NMR (400MHz, DMSO-d6): δ12.0(bs,1H),8.05(s,1H),7.77(d,J=8.0Hz,1H),7.38(d,J=8.4Hz,1H),4.30(q,J= 6.8Hz, 2H), 3.56 (s, 3H), 2.80-2.72 (m, 4H), 2.36-2.33 (m, 2H), 1.33 (t, J = 6.8Hz, 3H); LC-MS: m / z343.0 (M+1) +.

[0343] Step-c: Synthesis of 2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0344] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 55%); LC-MS: m / z 315.1 (M+1) + .

[0345] Step-d: Synthesis of 2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0346] The title compound was synthesized using the same procedure as compound 1i using 2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 13%); 1 HNMR (400MHz, DMSO-d6): δ12.0(bs,1H),8.36(bs,1H),7.95(s,1H),7.67(d,J=7.6Hz,1H),7.33(d,J=8. 4Hz,1H),3.56(s,3H),3.47-3.42(m,4H),3.28(s,3H),2.77-2.67(m,4H),2.36-2.33(m,2H); LC-MS:m / z 372.0(M+1) + .

[0347] Example 9. Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide hydrochloride

[0348]

[0349]

[0350] Conditions: a) i) pyrrolidone hydrobromide, THF, reflux, 10 min ii) thiourea, EtOH, reflux, 3 h; b) ethyl 3-amino-4-(methylamino)benzoate, 1,1′-thiocarbonyldiimidazole, EDC, DMF, 100°C, 18 h; c) LiOH.H2O, THF, MeOH, H2O, 50°C, 16 h; d) 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-amine, HBTU, DIPEA, DMF, 0°C-RT, 16 h; e) 1,4-dioxane containing 4 M HCl, 1,4-dioxane, 0°C-RT, 16 h

[0351] Step-a: Synthesis of tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate

[0352] To a stirred solution of tert-butyl 4-oxopiperidine-1-carboxylate (3.0 g, 15.07 mmol) in THF (70 mL) at room temperature was added pyrrolidone hydrobromide (7.47 g, 15.07 mmol), and the reaction mixture was refluxed for 10 min. The reaction mixture was cooled to room temperature, the precipitated solid was removed by filtration, and the filtrate was concentrated. The resulting residue was dissolved in ethanol (80 mL), followed by addition of thiourea (1.53 g, 20.14 mmol), and the reaction mixture was refluxed for 3 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by flash chromatography using 5% methanol / DCM as eluent to give the title compound (450 mg, 12%). 1 H NMR (400MHz, DMSO-d6): δ6.80 (s, 2H), 4.29 (s, 2H), 3.56 (t, J=5.6Hz, 2H), 2.43 (bs, 2H), 1.41 (s, 9H); LC-MS: m / z 256.2 (M+1) + .

[0353] Step-b: Synthesis of tert-butyl 2-((5-(ethoxycarbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate

[0354] To a stirred solution of tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (424 mg, 1.66 mmol) in DMFA (6 mL) was added 1,1′-thiocarbonyldiimidazole (593 mg, 3.33 mmol) and the solution was heated at 100° C. for 2 h. The reaction mixture was cooled to room temperature and EDC.HCl (639 mg, 3.33 mmol) was added. The reaction mixture was heated at 50° C. for 10 min, followed by the addition of ethyl 3-amino-4-(methylamino)benzoate (300 mg, 1.66 mmol). The reaction mixture was heated at 100° C. for 16 h. It was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using 0.4% methanol / DCM as eluent to give the title compound (130 mg, 18%); 1 H NMR (400 MHz, DMSO-d6): δ 12.10 (bs, 1H), 8.03 (bs, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 4.39 (bs, 2H), 4.30 (q, J = 6.8 Hz, 2H), 3.67-3.59 (m, 5H), 2.50 (2H, combined with DMSO peak), 1.43 (s, 9H), 1.34 (t, J = 6.8 Hz, 3H); LC-MS: m / z 458.2 (M+1) + .

[0355] Step-c: Synthesis of 2-((5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0356] The title compound was synthesized using the same procedure as compound 1h, using tert-butyl 2-((5-(ethoxycarbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate as the starting material and THF, methanol, and water (2:2:1) as the solvent. (Yield: 70%) 1H NMR (400MHz, DMSO-d6): δ12.50(bs,1H),8.00(s,1H),7.78(d,J=8.4Hz,1H),7.40(d,J=8.4Hz,1 H), 4.40 (s, 2H), 3.66 (t, J = 4.8Hz, 2H), 3.60 (s, 3H), 2.66-2.63 (m, 2H), 1.43 (s, 9H); LC-MS: m / z 430.1(M+1) + .

[0357] Step-d: Synthesis of tert-butyl 2-((5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)carbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate

[0358] The title compound was synthesized using the same procedure as in Example 6, step e, using 2-((5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-amine as starting materials (yield: 40%); LC-MS: m / z 631.2 (M+1) + .

[0359] Step-e: Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((4,5,6,7-tetrahydrothiazolo-[5,4-c]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide hydrochloride

[0360] To a stirred solution of tert-butyl 2-((5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)carbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (50 mg, 0.08 mmol) in 1,4-dioxane (0.8 mL) at 0° C. was added 4M HCl in 1,4-dioxane (0.3 mL) and stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was triturated with diethyl ether and the solvent was decanted. The resulting solid was dried in vacuo to give the title compound (12 mg, 33%). 1H NMR (400MHz, CD3OD): δ8.01(s,1H),7.87(d,J=8.0Hz,1H),7.55(d,J=8.4Hz,1H) ,4.35(s,2H),3.74(s,3H),3.71-3.53(m,10H),3.05(t,J=6.0Hz,2H); LC-MS:m / z 417.1(M+1) + .

[0361] Example 10. Synthesis of 2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0362]

[0363] Conditions: a) TFA, DCM, 0°C-RT, 16h; b) Ac2O, pyridine, 0°C-RT, 16h; c) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 1δh

[0364] Step-a: Synthesis of 1-methyl-2-((4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid trifluoroacetate

[0365] To a stirred solution of 2-((5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (170 mg, 0.39 mmol) in DCM (5 mL) at 0° C. was added TFA (0.1 mL, 1.19 mmol) and stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure, and the obtained residue was triturated with diethyl ether, and the solvent was decanted. The residue was dried in vacuo to give the title compound (180 mg, 100%); 1 H NMR (400MHz, DMSO-d6): δ9.22 (s, 2H), 8.04 (s, 1H), 7.81 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.4 2(d, J=8.4Hz, 1H), 4.23(s, 2H), 3.60(s, 3H), 3.48-3.46(m, 2H), 2.89(bs, 2H); LC-MS: m / z 330.1(M+1) + .

[0366] Step-b: Synthesis of 2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0367] To a stirred solution of 1-methyl-2-((4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid trifluoroacetate (180 mg, 0.55 mmol) in pyridine (2 mL) at 0°C was added acetic anhydride (0.06 mL, 0.6 mmol) and stirred at room temperature for 16 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with 1N HCl (30 mL), water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo, and the obtained residue was triturated with diethyl ether, and the solvent was decanted. The resulting solid was dried in vacuo to give the title compound (70 mg, 46%); LC-MS: m / z 372.1 (M+1) + .

[0368] Step-c: Synthesis of 2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0369] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methyl-iH-benzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials (yield: 29%); 1 H NMR (400 MHz, DMSO-d6): δ 12.0 (bs, 1H), 8.38 (s, 1H), 7.96 (d, J = 3.6 Hz, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 4.62-4.49 (m, 3H), 3.78-3.73 (m, 2H), 3.60-3.41 (m, 10H), 3.30 (2H, combined with DMSO water peak), 2.09 (s, 3H); LC-MS: m / z 459.1 (M+1) + .

[0370] Example 11. Synthesis of 2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0371]

[0372] Conditions: a) methyl 3-amino-4-(methylamino)benzoate, 1,1′-thiocarbonyldiimidazole, EDC, DMF, 100°C, 16h; b) LiOH.H2O, THF, MeOH, H2O, 60°C, 16h; c) 2-methoxyethane-1-amine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0373] Step-a: Synthesis of methyl 2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0374] The title compound was synthesized using the same procedure as compound 5a, using methyl 3-amino-4-(methylamino)benzoate and 6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-amine as starting materials and stirring for 16 h (yield: 20%); 1 HNMR (400 MHz, DMSO-d6): δ 12.20 (bs, 1H), 8.02 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 4.58 (s, 2H), 3.93 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 3.60 (s, 3H), 2.50 (2H, merged with DMSO peak); LC-MS: m / z 343.0 (M-1).

[0375] Step-b: Synthesis of 2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0376] The title compound was synthesized (yield: 52%) using the same procedure as compound 1h, using methyl 2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material and THF, methanol and water (2:2:1) as solvents; δ 12.40 (bs, 2H), 7.98 (s, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 4.58 (s, 2H), 3.92 (t, J=4.8 Hz, 2H), 3.59 (s, 3H), 2.50 (2H, merged with DMSO peak); LC-MS: m / z 330.7 (M+1) + .

[0377] Step-c: Synthesis of 2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzoimidazole-5-carboxamide

[0378] The title compound was synthesized using the same procedure as compound 1i, using 2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials. The crude product was purified by flash chromatography using 1.2% methanol / DCM as the eluent (yield: 34%). 1 H NMR (400 MHz, DMSO-d6): δ 12.20 (bs, 1H), 8.40 (bs, 1H), 7.96 (s, 1H), 7.66 (bs, 1H), 7.35 (d, J = 8.4 Hz, 1H), 4.58 (bs, 2H), 3.93 (s, 2H), 3.58 (s, 3H), 3.48-3.42 (m, 4H), 3.27 (s, 3H), 2.50 (2H, combined with DMSO peak); LC-MS: m / z 387.6 (M+1) + .

[0379] Example 12. Synthesis of 2-((1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazol-5-carboxamide:

[0380]

[0381] Conditions: a) 1,1′-thiocarbonyldiimidazole, acetonitrile, RT, 16 h; b) methyl 3-amino-4-(methylamino)benzoate, EDC.HCl, DMF, 100°C, 16 h; d) LiOH.H2O, THF, MeOH, water, 60°C, 16 h; e) 2-methoxyethane-1-amine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0382] Step-a: Synthesis of N-(1H-benzo[d]imidazol-2-yl)-1H-imidazole-1-carbothioamide

[0383] To a room temperature solution of 1H-benzo[d]imidazol-2-amine (1.0 g, 7.5 mmol) in acetonitrile (10 mL) was added 1,1′-thiocarbonyldiimidazole (1.34 g, 7.5 mmol) and stirred at room temperature for 16 h. The reaction mixture was filtered and the resulting solid was dried under vacuum to give the title compound (1.1 g, 60%). 1H NMR (400MHz, DMSO-d6): δ 13.18 (bs, 2H), 8.55 (s, 1H), 7.93 (d, J=1.2Hz, 1H), 7.63-7.59 (m, 2H), 7.36-7.32 (m, 2H), 6.99 (d, J=1.2Hz, 1H).

[0384] Step-b: Synthesis of methyl 2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-5-carboxylate

[0385] To a stirred solution of N-(1H-benzo[d]imidazol-2-yl)-1H-imidazole-1-thiocarbonamide (188 mg, 0.77 mmol) in DMFA (5 mL) was added EDC.HCl (297 mg, 1.5 mmol) and heated to 60 ° C for 10 min. The reaction mixture was cooled to room temperature, followed by the addition of methyl 3-amino-4-(methylamino)benzoate (150 mg, 0.77 mmol) and heated at 100 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with water (30 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 2% methanol / DCM as eluent to give the title compound (40 mg, 16%). 1 H NMR (400MHz, DMSO-d6): δ12.12 (bs, 2H), 8.05 (d, J=1.6Hz, 1H), 7.73 (dd, J=1.6Hz, J=8 .4Hz, 1H), 7.37-7.34(m, 3H), 7.12-7.08(m, 2H), 3.85(s, 3H), 3.65(s, 3H); LC-MS: m / z 322.0(M+1) + .

[0386] Step-c: Synthesis of 2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0387] The title compound was synthesized using the same procedure as intermediate 1h using methyl 2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material and methanol, THF and water as solvents (yield: 92%); 1H NMR (400MHz, DMSO-d6): δ13.0 (bs, 3H), 7.92 (s, 1H), 7.89 (d, J=1.6Hz, 1H), 7.60 (d, J=8.4Hz, 1H), 7.45-7.41 (m, 2H), 7.29-7.26 (m, 2H), 3.68 (s, 3H); LC-MS: m / z 308.1(M+1) + .

[0388] Step-d: Synthesis of 2-((1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazol-5-carboxamide

[0389] The title compound was synthesized using the same procedure as compound 1i using 2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 14%); 1 H NMR (400MHz, DMSO-d6): δ12.10 (bs, 2H), 8.33 (t, J=4.8Hz, 1H), 7.98 (d, J=0.8Hz, 1H), 7.62 (dd, J=1.2Hz, J=8.0H z, 1H), 7.35-7.30 (m, 3H), 7.11-7.07 (m, 2H), 3.64 (s, 3H), 3.50-3.42 (m, 4H), 3.29 (s, 3H); LC-MS: m / z365.0 (M+1) + .

[0390] Examples 13 and 14. Synthesis of 1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide:

[0391]

[0392] Conditions: a) 10% Pd / C, MeOH, H2, RT, 16h; b) 1,1′-thiocarbonyldiimidazole, acetonitrile, 60°C, 16h; c) 4-(trifluoromethoxy)benzene-1,2-diamine, EDC.HCl, DMF, 100°C, 16h; d) LiOH.H2O, THF, EtOH, water, 60°C, 16h; e) 2-methoxyethane-1-amine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0393] Step-a: Synthesis of 4-(trifluoromethoxy)benzene-1,2-diamine

[0394] Under a nitrogen atmosphere, 10% Pd / C (1.0 g) was added to a solution of methyl 2-nitro-5-(trifluoromethoxy)aniline (2.0 g, 9.0 mmol) in methanol (40 mL). The reaction mixture was then stirred under hydrogen for 16 h. The reaction mixture was filtered through a celite bed and concentrated in vacuo to give the title compound (1.6 g, 93%). 1 H NMR (400MHz, DMSO-d6): δ6.48 (d, J=8.0Hz, 1H), 6.45 (d, J=1.6Hz, 1H), 6.29 (dd, J=2.0Hz, J=8.0Hz, 1H), 4.80 (s, 2H), 4.58 (s, 2H); LC-MS: m / z 193.0(M+1) + .

[0395] Step-b: Synthesis of ethyl 2-(1H-imidazole-1-carbosulfamido)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0396] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (500 mg, 2.28 mmol) in acetonitrile (10 mL) at room temperature was added 1,1'-thiocarbonyldiimidazole (529 mg, 2.97 mmol) and the reaction mixture was stirred at 60 ° C for 16 h. It was cooled to room temperature and stirred for 30 min. The resulting solid was filtered and dried in vacuo to give the title compound (500 mg, 66%); 1 H NMR (400MHz, DMSO-d6): δ13.40(bs,1H),8.68(s,1H),8.40(d,J=1.2Hz,1H),8.03(s,1H),7.99(dd,J=1.2Hz,J=8. 4Hz, 1H), 7.75 (d, J = 8.4Hz, 1H), 7.01 (s, 1H), 4.35 (q, J = 7.2Hz, 2H), 3.79 (s, 3H), 1.36 (t, J = 7.2Hz, 3H); LC-MS: m / z 328.2(M-1).

[0397] Step-c: Synthesis of ethyl 1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0398] The title compound was synthesized using the same procedure as in Example 12 step-b using ethyl 2-(1H-imidazole-1-carbonylsulfamido)-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 4-(trifluoromethoxy)benzene-1,2-diamine as starting materials (yield: 27%); 1 HNMR-VT, at 90℃ (400MHz, DMSO-d6): δ12.0(bs,2H),8.09(s,1H),7.77(d,J=8.4Hz,1H),7.35(d,J=8.4Hz,2H ),7.28(s,1H),7.0(d,J=8.4Hz,1H),4.35(q,J=6.8Hz,2H),3.63(s,3H),1.35(t,J=6.8Hz,3H); LC-MS: m / z 420.0(M+1) + .

[0399] Step-d: Synthesis of 1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0400] The title compound was synthesized using the same procedure as intermediate 1h using ethyl 1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (yield: 77%); 1 H NMR (400MHz, DMSO-d6): δ12.60(bs,3H),8.05(d,J=1.6Hz,1H),7.82(dd,J=1.6Hz,J=8.4Hz,1H),7.45(d,J =8.4Hz, 1H), 7.40 (d, J = 8.8Hz, 1H), 7.34 (s, 1H), 7.09 (dd, J = 1.2Hz, J = 8.8Hz, 1H), 3.65 (s, 3H); LC-MS: m / z 392.0(M+1) + .

[0401] Step-e: Synthesis of N-(2-methoxyethyl)-1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0402] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 43%); 1HNMR (400MHz, DMSO-d6): δ12.20 (bs, 2H), 8.37 (bs, 1H), 8.0 (d, J=1.2Hz, 1H), 7.68 (dd, J=1.2Hz, J=8.4Hz, 1H), 7 .36 (d, J=8.4Hz, 2H), 7.30 (s, 1H), 7.01 (d, J=8.4Hz, 1H), 3.63 (s, 3H), 3.59-3.43 (m, 4H), 3.29 (s, 3H); LC-MS: m / z 449.0(M+1) + .

[0403] Example 15. Synthesis of 1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0404]

[0405] Conditions: a) NaH, methyl iodide, DMF, 0°C-RT, 1h; b) 10% Pd / C, MeOH, H2, RT, 6h; c) N1-methyl-4-(difluoromethoxy)benzene-1,2-diamine, EDC.HCl, DMF, 100°C, 16h; d) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h

[0406] Step-a: Synthesis of N-methyl-2-nitro-4-(trifluoromethoxy)aniline

[0407] To a stirred solution of 2-nitro-4-(trifluoromethoxy)aniline (2.0 mg, 9.0 mmol) in DMFA (20 mL) at 0° C. was added sodium hydride (60% dispersion in mineral oil) (0.4 g, 10.0 mmol), and the reaction mixture was stirred for 10 min. Methyl iodide (0.56 mL, 9.0 mmol) was added to the reaction mixture and stirred at room temperature for 1 h. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using 5% ethyl acetate / hexane as eluent to give the title compound (1.8 g, 85%). 1H NMR (400MHz, DMSO-d6): δ8.28 (d, J=4.0Hz, 1H), 8.00 (d, J=2.4Hz, 1H), 7.61 (dd, J=2.4Hz, J=9.2Hz, 1H), 7.10 (d, J=9.2Hz, 1H), 2.98 (d, J=5.2Hz, 3H); LC-MS: m / z 237.0(M+1) + .

[0408] Step-b: N 1 Synthesis of methyl-4-(trifluoromethoxy)benzene-1,2-diamine

[0409] The title compound was synthesized using the same procedure as compound 1e, using N-methyl-2-nitro-4-(trifluoromethoxy)aniline as the starting material and stirring for 6 h (yield: 92%); 1 H NMR (400MHz, DMSO-d6): δ6.44 (s, 1H), 6.42 (d, J=10.4Hz, 1H), 6.33 (d, J=8.4Hz, 1H), 4.84 (bs, 2H), 2.70 (s, 3H); LC-MS: m / z 207.0 (M+1) + .

[0410] Step-c: Synthesis of ethyl 1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0411] The same procedure as in step b of Example 12 was used to synthesize the title compound (yield: 37%) using ethyl 2-(1H-imidazole-1-carbonylsulfamido)-1-methyl-1H-benzo[d]imidazole-5-carboxylate and N1-methyl-4-(trifluoromethoxy)benzene-1,2-diamine as starting materials; LC-MS: m / z 434.2 (M+1) + .

[0412] Step-d: Synthesis of 1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0413] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 53%); 1H NMR (400MHz, DMSO-d6): δ12.5 (bs, 2H), 8.10 (d, J=1.2Hz, 1H), 7.79 (dd, J=1.6Hz, J=8.4Hz, 1H ), 7.44 (s, 1H), 7.41-7.37 (m, 2H), 7.08 (d, J=8.8Hz, 1H), 3.70 (s, 3H), 3.68 (s, 3H); LC-MS: m / z 406.1(M+1) + .

[0414] Example 16. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0415]

[0416] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0417] To a stirred solution of 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (50 mg, 0.16 mmol) in DMFA (1.0 mL) at 0 ° C was added N-ethyldiisopropylamine (0.03 mL, 0.16 mmol) and HBTU (62 mg, 0.16 mmol). The reaction mixture was stirred for 30 min, followed by the addition of 2-aminoethane-1-ol (10 mg, 0.16 mmol), and continued to stir at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (20 mL) and stirred for 15 min. The resulting solid was filtered, washed with diethyl ether and dried in vacuo to give the title compound (25 mg, 44%) as a white solid. 1 H NMR (400MHz, DMSO-d6): δ12.30 (bs, 1H), 8.36 (t, J=5.4Hz, 1H), 8.08 (d, J=0.9Hz, 1H), 7.78-7.76 (m, 1H), 7.48 (d, J=8.3Hz, 2H), 7.43 (d, J =7.8Hz, 1H), 7.21 (t, J = 7.3Hz, 1H), 7.12 (t, J = 7.3Hz, 1H), 4.72 (bs, 1H), 3.63 (s, 3H), 3.54 (t, J = 6.4Hz, 2H), 3.37-3.34 (m, 2H); LC-MS: m / z 352.2(M+1) + .

[0418] Example 17. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0419]

[0420] Conditions: a) methylamine, DMF, 60°C, 16 h; b) 10% Pd / C, MeOH, H2, RT, 3 h; c) cyanogen bromide, THF, H2O, 60°C, 16 h; d) NaH, 2-chlorobenzo[d]oxazole, 1,4-dioxane, RT, 16 h; e) LiOH.H2O, THF, ethanol, water, 60°C, 16 h; f) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16 h

[0421] Step-a: Synthesis of ethyl 4-(methylamino)-3-nitrobenzoate

[0422] To a solution of ethyl 4-chloro-3-nitrobenzoate (30.0 g, 131 mmol) in DMFA (100 mL) at room temperature was added methylamine (26.8 mL (40% aqueous solution), 262 mmol), and the reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with cold water (1000 mL) and stirred for 1 h. The resulting solid was filtered and dried in vacuo to give the product as a yellow solid (28.0 g, 96%); 1 H NMR (400MHz, DMSO-d6): δ8.62 (d, J=2.0Hz, 1H), 8.59 (bs, 1H), 7.99 (dd, J=2.0Hz, J=8.8Hz, 1H), 7. 07 (d, J=8.8Hz, 1H), 4.29 (q, J=6.8Hz, 2H), 3.01 (d, J=5.2Hz, 3H), 1.31 (t, J=6.8Hz, 3H); LC-MS: m / z 225.0(M+1) + .

[0423] Step-b: Synthesis of ethyl 3-amino-4-(methylamino)benzoate

[0424] Under nitrogen atmosphere, to a solution of ethyl 4-(methylamino)-3-nitrobenzoate (27.0 g, 120 mmol) in methanol (300 mL) was added a slurry of 10% Pd / C (2.8 g in 15 mL of ethanol). The flask was kept in a Parr shaker at room temperature under hydrogen (60 psi) for 3 h. The reaction mixture was filtered through a bed of celite and concentrated in vacuo to give the title compound (19.0 g, 82%). 1H NMR (400MHz, DMSO-d6): δ7.23 (dd, J=1.6Hz, J=8.4Hz 1H), 7.16 (d, J=1.6Hz, 1H), 6.39 (d, J=8.4Hz, 1H), 5.38-5.37 (m, 1H), 4.66 (s, 2H ), 4.18 (q, J=7.2Hz, 2H), 2.77 (d, J=5.2Hz, 3H), 1.26 (t, J=7.2Hz, 3H); LC-MS: m / z 195.1(M+1) + .

[0425] Step-c: Synthesis of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0426] To a solution of ethyl 3-amino-4-(methylamino)benzoate (17.0 g, 87.6 mmol) in THF (68 mL) and water (170 mL) at room temperature was added cyanogen bromide (11.13 g, 105.2 mmol), and the reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature and basified with saturated sodium bicarbonate solution. The resulting solid was filtered and dried in vacuo to give the title compound (18.0 g, 94%), which was used in the next step without further purification; 1 H NMR (400MHz, DMSO-d6): δ7.70 (d, J=1.2Hz, 1H), 7.59 (dd, J=1.2Hz, J=8.4Hz, 1H), 7.20 (d, J=8 .4Hz, 1H), 6.64 (s, 2H), 4.27 (q, J=6.8Hz, 2H), 3.53 (s, 3H), 1.32 (t, J=6.8Hz, 3H); LC-MS: m / z 220.1(M+1) + .

[0427] Step-d: Synthesis of ethyl 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0428] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (4.0 g, 18.3 mmol) in 1,4-dioxane (40 mL) at 0°C was added sodium hydride (60% dispersion in mineral oil) (1.09 g, 27.4 mmol) portionwise and stirred for 10 min. 2-Chlorobenzo[d]oxazole (2.79 g, 18.3 mmol) was added to the reaction mixture and stirred at room temperature for 16 h. The reaction mixture was poured onto cold water (100 mL) and stirred at room temperature for 5 to 10 min. The resulting solid was filtered, dried under vacuum and purified by flash column chromatography using 100% DCM as eluent to give the title compound (4.0 g, 60%). 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.24(s,1H),7.88(d,J=8.4Hz,1H),7.53-7.43(m,3H),7.22(t,J =7.2Hz, 1H), 7.13 (t, J = 7.6Hz, 1H), 4.33 (q, J = 7.2Hz, 2H), 3.64 (s, 3H), 1.35 (t, J = 7.2Hz, 3H); LC-MS: m / z 337.0(M+1) + .

[0429] Step-e: Synthesis of 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0430] To a stirred solution of ethyl 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (4.0 g, 11.90 mmol) in a solvent mixture of THF (20 mL), ethanol (20 mL) and water (10 mL) was added lithium hydroxide monohydrate (1.25 g, 29.76 mmol). The reaction mixture was heated at 60 ° C with stirring for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water (60 mL) and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (3.4 g, 93%); 1 H NMR (400MHz, DMSO-d6): δ12.60(bs,2H),8.20(d,J=1.6Hz,1H),7.87(dd,J=1.6Hz,J=8.0Hz,1H),7.5 1-7.48(m,2H),7.44(d,J=7.2Hz,1H),7.23-7.20(m,1H),7.15-7.11(m,1H),3.64(s,3H); LC-MS:m / z 309.1(M+1) + .

[0431] Step-f: Synthesis of 2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0432] To a stirred solution of 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (3.0 g, 9.74 mmol) in DMFA (30 mL) at 0 ° C was added N-ethyldiisopropylamine (4.36 mL, 24.25 mmol) and HBTU (4.06 g, 10.71 mmol). The reaction mixture was stirred for 30 min, followed by the addition of 2-(2-aminoethoxy)ethane-1-ol (1.02 g, 9.74 mmol) and continued stirring at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (300 mL) and stirred for 30 min. The resulting solid was filtered, dried in vacuo and purified by flash column chromatography using 5% methanol / DCM as eluent to give the title compound (2.9 g, 75%) as a white solid. 1 H NMR (400MHz, DMSO-d6): δ12.20(bs,1H),8.43(t,J=5.3Hz,1H),8.07(s,1H),7.76(d,J=8.4Hz,1H),7.48(d,J=7.9Hz,2H),7 .43(d,J=7.8Hz,1H),7.21(t,J=7.3Hz,1H),7.11(t,J=7.3Hz,1H),4.60(bs,1H),3.63(s,3H),3.57-3.42(m,8H); LC-MS:m / z 396.2(M+1) + .

[0433] Example 18. Synthesis of N-(2-aminoethyl)-2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide hydrochloride

[0434]

[0435] Conditions: a) tert-butyl (2-aminoethyl)carbamate, HBTU, DIPEA, DMF, 0°C-RT, 16h; b) 4N HCl in 1,4-dioxane, THF, 0°C-RT, 3h

[0436] Step-a: Synthesis of tert-butyl (2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethyl)carbamate

[0437] The title compound was synthesized using the same procedure as in Example 6 step-e using 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and tert-butyl (2-aminoethyl)carbamate as starting materials (yield: 51%); 1 H NMR (400 MHz, DMSO-d6): δ 12.20 (bs, 1H), 8.41 (t, J = 5.1 Hz, 1H), 8.08 (s, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.23-7.19 (m, 1H), 7.14-7.09 (m, 1H), 6.92 (d, J = 5.4 Hz, 1H), 3.64 (s, 3H), 3.34-3.33 (m, 2H, combined with DMSO water peak), 3.15-3.10 (m, 2H), 1.38 (s, 9H); LC-MS: m / z 451.55 (M+1) + .

[0438] Step-b: Synthesis of N-(2-aminoethyl)-2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide hydrochloride

[0439] To a solution of tert-butyl (2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-carboxamido)ethyl)carbamate (50 mg, 0.11 mmol) in THF (2 mL) at 0°C was added 4N HCl in 1,4-dioxane (0.5 mL), and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated on a rotary evaporator and stirred in diethyl ether (10 mL). The resulting solid was filtered and dried under vacuum to give the title compound (35 mg, 81%); 1 H NMR (400MHz, DMSO-d6): δ12.40 (bs, 1H), 8.70 (s, 1H), 8.13 (s, 1H), 7.96 (bs, 3H), 7.86 (d, J = 8.3Hz, 1H), 7.56 (d, J = 8.3Hz, 1H), 7.4 8 (d, J=7.9Hz, 2H), 7.25 (t, J=7.6Hz, 1H), 7.17 (t, J=7.8Hz, 1H), 3.67 (s, 3H), 3.55 (q, J=5.7Hz, 2H), 3.03-2.99 (m, 2H); LC-MS: m / z 351.10(M+1) + .

[0440] Example 19. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-(2-(dimethylamino)acetamido)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0441]

[0442] Conditions: a) tert-butyl (2-aminoethyl)carbamate, HBTU, DIPEA, DMF, 0°C-RT, 16h; b) TFA, DCM, 0°C-RT, 16h; c) N-(2-aminoethyl)-2-(dimethylamino)acetamide difluoroacetate, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0443] Step-a: Synthesis of tert-butyl (2-(2-(dimethylamino)acetamido)ethyl)carbamate

[0444] To a stirred solution of dimethylglycine (1.0 g, 9.71 mmol) in DMFA (10 mL) at 0 ° C, N-ethyldiisopropylamine (1.69 mL, 9.71 mmol) and HBTU (3.68 g, 9.71 mmol) were added. The reaction mixture was stirred for 30 min, followed by the addition of tert-butyl (2-aminoethyl)carbamate (1.55 g, 9.71 mmol). The reaction mixture was stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (50 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with water (3 × 30 mL), a saline solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting solid was stirred in diethyl ether (20 mL) for 5 min, filtered and dried in vacuo to give the title compound (600 mg, 25%). 1 HNMR (400MHz, DMSO-d6): δ7.77 (t, J=5.6Hz, 1H), 6.83 (t, J=5.2Hz, 1H), 3.11 (q, J=6 .2Hz, 2H), 2.99 (q, J=6.1Hz, 2H), 2.82 (s, 2H), 2.18 (s, 6H), 1.37 (s, 9H); LC-MS: m / z 246.15(M+1) + .

[0445] Step-b: Synthesis of N-(2-aminoethyl)-2-(dimethylamino)acetamide trifluoroacetate

[0446] To a solution of tert-butyl (2-(2-(dimethylamino)acetamido)ethyl)carbamate (600 mg, 2.45 mmol) in DCM (15 mL) at 0° C. was added TFA (0.56 mL, 7.34 mmol) and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated on a rotary evaporator and dried in vacuo to give the title compound (600 mg, 100%); 1 H NMR (400MHz, DMSO-d6): δ9.75 (bs, 1H), 8.75 (t, J=5.6Hz, 1H), 7.90 (bs, 2H), 3. 88 (s, 2H), 3.38 (q, J=6.2Hz, 2H), 2.91 (q, J=5.9Hz, 2H), 2.82 (s, 6H); LC-MS: m / z 146.20(M+1) + .

[0447] Step-c: Synthesis of 2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-(dimethylamino)acetamido)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0448] To a stirred solution of 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (100 mg, 0.32 mmol) in DMFA (4 mL) at 0 ° C was added N-ethyldiisopropylamine (0.17 mL, 0.97 mmol) and HBTU (123 mg, 0.32 mmol). The reaction mixture was stirred for 30 min, followed by the addition of N-(2-aminoethyl)-2-(dimethylamino)acetamide trifluoroacetate (145 mg, 0.39 mmol). The reaction mixture was then stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (15 mL). The resulting solid was filtered, washed with diethyl ether and dried in vacuo to give the title compound (40 mg, 28%) as a white solid. 1 H NMR (400 MHz, DMSO-d6): δ 12.20 (bs, 1H), 8.44 (t, J = 4.9 Hz, 1H), 8.07 (s, 1H), 7.92 (bs, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.49-7.47 (m, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 3.63 (s, 3H), 3.37 (t, J = 5.2 Hz, 2H), 3.35 (2H, combined with DMSO water peak), 2.86 (s, 2H), 2.19 (s, 6H); LC-MS: m / z 436.0 (M+1)+ .

[0449] Example 20. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-1-methyl-N-(2-morpholinoethyl)-1H-benzo[d]imidazole-5-carboxamide

[0450] The title compound was synthesized using the same procedure as compound 1i using 2-morpholinoeth-1-amine and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400 MHz, DMSO-d6): δ 12.21 (bs, 1H), 8.33 (s, 1H), 8.06 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.21 (t, J = 7.2 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1H), 3.63 (s, 3H), 3.58 (t, J = 3.6 Hz, 4H), 3.41 (q, J = 6.4 Hz, 2H), 3.30 (2H, combined with DMSO water peak), 2.43 (bs, 4H); LC-MS: m / z 421.2 (M+1) + .

[0451] Example 21. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-(dimethylamino)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0452] The title compound was synthesized using the same procedure as compound 1i using N,N-dimethylethane-1,2-diamine and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.21(bs,1H),8.29(t,J=5.2Hz,1H),8.07(s,1H),7.74(d,J=8.4Hz,1H),7.48-7.42(m,3H),7 .21(t,J=7.6Hz,1H),7.11(t,J=8.0Hz,1H),3.63(s,3H),3.39-3.35(m,2H),2.50-2.42(m,2H),2.19(s,6H); LC-MS:m / z 379.2(M+1) + .

[0453] Example 22. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-((4,5-dihydro-1H-imidazol-2-yl)amino)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0454] The same procedure as for compound 1i was used, using N 1 The title compound was synthesized from 1,2-diamine (4,5-dihydro-1H-imidazol-2-yl)ethane) and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,2H),8.52(bs,1H),8.20(bs,1H),8.09(s,1H),7.75(d,J=8.4Hz,1H),7.52-7.43(m,3H ),7.21(t,J=7.2Hz,1H),7.12(t,J=8.0Hz,1H),3.64(s,3H),3.59(s,2H),3.45-3.43(m,2H),3.36-3.34(m,4H); LC-MS: m / z 417.05(M-1) - .

[0455] Example 23. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-hydroxypropyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0456] The title compound was synthesized using the same procedure as compound 1i using 1-aminopropan-2-ol and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.36(t,J=5.6Hz,1H),8.19(d,J=1.2Hz,1H),7.78(dd,J=1.2Hz,J=8.4Hz,1H),7.52-7.36(m,3H),7.21-7.1 9(m,1H),7.14-7.09(m,1H),4.87-4.78(m,1H),3.81(q,J=6.0Hz,1H),3.6 4(s,3H),3.24-3.20(m,2H),1.14(d,J=6.8Hz,3H); LC-MS:m / z366.2(M+1) + .

[0457] Example 24. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2,3-dihydroxypropyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0458] The title compound was synthesized using the same procedure as compound 1i using 3-aminopropane-1,2-diol and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.31(t,J=5.2Hz,1H),8.08(s,1H),7.77(dd,J=1.6Hz,J=8.4Hz,1H),7.49-7.42(m,3H),7.21(t,J=8. 0Hz,1H),7.11(t,J=7.2Hz,1H),4.82(d,J=4.4Hz,1H),4.58(bs,1H),3.64(s,3H),3.45-3.37(m,3H),3.26-3.19(m,2H); LC-MS: m / z382.1(M+1) + .

[0459] Example 25. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxypropoxy)ethyl)-1,6-dimethyl-1H-benzo[d]imidazole-5-carboxamide

[0460] The title compound was synthesized using the same procedure as compound 1i using 1-(2-aminoethoxy)propan-2-ol and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30 (bs, 1H), 8.42 (t, J = 5.2Hz, 1H), 8.07 (s, 1H), 7. 75(dd,J=1.2Hz,J=8.4Hz,1H),7.49-7.42(m,3H),7.21(t,J=7.6Hz,1H),7.11( t,J=8.0Hz,1H),4.57(bs,1H),3.75(q,J=5.6Hz,1H),3.63(s,3H),3.57-3.54( m,2H),3.46-3.43(m,2H),3.29-3.23(m,2H),1.03(d,J=6.4Hz,3H); LC-MS:m / z 410.2(M+1) + .

[0461] Example 26. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-((3-hydroxyoxetan-3-yl)methyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0462] The title compound was synthesized using the same procedure as compound 1i using 3-(aminomethyl)oxetan-3-ol and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.55(t,J=5.2Hz,1H),8.10(d,J=1.2Hz,1H),7.79(dd,J=1.6Hz,J=8.4Hz,1H),7.51-7.42(m,3H),7.21( t,J=7.6Hz,1H),7.14(t,J=7.6Hz,1H),5.90(s,1H),4.52(d,J=6.8Hz,2H),4.41(d,J=6.4Hz,2H),3.64(s,3H),3.59(d,J=6.0Hz,2H); LC-MS: m / z 394.2(M+1) + .

[0463] Example 27. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxy-2-methylpropoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0464] The title compound was synthesized using the same procedure as compound 1i using 1-(2-aminoethoxy)-2-methylpropan-2-ol and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 HNMR (400MHz, DMSO-d6): δ12.30 (bs, 1H), 8.43 (t, J=5.2Hz, 1H), 8.07 (d, J=1. 2Hz, 1H), 7.75 (dd, J=2.4Hz, J=8.4Hz, 1H), 7.49-7.42 (m, 3H), 7.21 (dd, J=1.2H z, J=7.6Hz, 1H), 7.12 (dd, J=1.2Hz, J=7.6Hz, 1H), 4.34 (bs, 1H), 3.63 (s, 3H), 3.57 (t, J=6.4Hz, 2H), 3.47-3.43 (m, 2H), 3.20 (s, 2H), 1.09 (s, 6H); LC-MS: m / z 424.2(M+1) + .

[0465] Example 28. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-1-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide

[0466] The title compound was synthesized using the same procedure as compound 1i using 2-(pyrrolidin-1-yl)ethan-1-amine and 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400 MHz, DMSO-d6): δ 12.24 (bs, 1H), 8.38 (t, J = 5.6 Hz, 1H), 8.07 (s, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.49-7.42 (m, 3H), 7.21 (t, J = 6.8 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H) 3.69 (s, 3H), 3.48-3.37 (m, 2H), 2.64-2.57 (m, 2H), 2.50 (4H, merged with DMSO peak), 1.66 (bs, 4H); LC-MS: m / z 405.2 (M+1) + .

[0467] Example 29. Synthesis of 2-(2-(2-(Benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetic acid

[0468]

[0469] Conditions: a) ethyl 2-bromoacetate, NaH, Kl, THF, 0°C-RT, 2h; b) TFA, DCM, RT, 5h; c) ethyl 2-(2-aminoethoxy)acetate trifluorate, HBTU, DIPEA, DMF, 0°C-RT, 16h; d) LiOH.H2O, ethanol, THF, water, RT, 3h

[0470] Step-a: Synthesis of ethyl 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate

[0471] To a solution of tert-butyl (2-hydroxyethyl)carbamate (1.0 g, 6.21 mmol) in THF (10 mL) at 0 ° C., sodium hydride (60% dispersion in mineral oil) (397 mg, 9.93 mmol) was added in portions, followed by potassium iodide (164 mg, 0.99 mmol) and ethyl bromoacetate (2.07 g, 12.42 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with cold water (60 mL) and extracted with ethyl acetate (3×60 mL). The combined organic layers were washed with water (30 mL), brine solution (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 1% methanol / dichloromethane as eluent to give the title compound (1.0 g, 65%). 1 H NMR (400MHz, DMSO-d6): δ6.74 (bs, 1H), 4.14-4.08 (m, 4H), 3.45 (t, J = 5.6Hz, 2H), 3.08 (q, J = 6.2Hz, 2H), 1.37 (s, 9H), 1.19 (t, J = 6.8Hz, 3H); LC-MS: m / z 148.1(M-Boc) + .

[0472] Step-b: Synthesis of ethyl 2-(2-aminoethoxy)acetate trifluoroacetate

[0473] To a stirred solution of ethyl 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate (1.0 g, 4.05 mmol) in DCM (5 mL) at room temperature was added trifluoroacetic acid (1 mL) and stirred at room temperature for 5 h. The reaction mixture was concentrated under reduced pressure to give the title compound (1.1 g, 100%), which was used in the next step without any further purification; 1 H NMR (400MHz, DMSO-d6): δ7.88(bs,3H),4.17(s,2H),4.14(q,J=6.8Hz,2H),3.68(t,J=5.0Hz,2H),3.01(q,J=5.2Hz,2H),1.21(t,J=7.0Hz,3H); LC-MS: m / z 148.2(M+1) + .

[0474] Step-c: Synthesis of ethyl 2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetate

[0475] To a stirred solution of 2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (150 mg, 0.48 mmol) in DMFA (2 mL) at 0 ° C was added N-ethyldiisopropylamine (0.26 mL, 1.46 mmol) and HBTU (184 mg, 0.48 mmol). The reaction mixture was stirred for 30 min, followed by the addition of ethyl 2-(2-aminoethoxy)acetate trifluoroacetate (129 mg, 0.53 mmol). The reaction mixture was then stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (6 mL) and stirred for 5 min. The precipitated solid was filtered and dried in vacuo to give the title compound (125 mg, 59%). 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.46(bs,1H),8.08(s,1H),7.76(d,J=8.4Hz,1H),7.49-7.47(m,2H),7.43(d,J=7.6Hz,1H),7.21(t,J=8 .0Hz,1H),7.14(t,J=7.6Hz,1H),4.15(s,2H),4.12(q,J=7.0Hz,2H),3.65-3.62(m,5H),3.47(q,J=5.8Hz,2H),1.19(t,J=7.0Hz,3H); LC-MS: m / z 438.1(M+1) + .

[0476] Step-d: Synthesis of 2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetic acid

[0477] To a solution of ethyl 2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetate (110 mg, 0.25 mmol) in a solvent mixture of THF (1 mL), ethanol (1 mL), and water (0.5 mL) was added lithium hydroxide monohydrate (26 mg, 0.63 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in water (5 mL) and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (80 mg, 78%); 1H NMR (400MHz, DMSO-d6): δ12.60 (bs, 1H), 8.47 (s, 1H), 8.08 (s, 1H), 7.77 (d, J=8.4Hz, 1H), 7.50-7.43 (m, 3H) , 7.22 (t, J=7.6Hz, 1H), 7.13 (t, J=7.2Hz, 1H), 4.06 (s, 2H), 3.64 (bs, 5H), 3.45 (q, J=5.2Hz, 2H); LC-MS: m / z 410.4(M+1) + .

[0478] Example 30. DL-Valine 2-(2-(2-(Benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)ethyl ester hydrochloride

[0479]

[0480] Conditions: a) di-tert-butyl dicarbonate, sodium hydroxide, THF, water, RT, 16 h; b) (tert-butoxycarbonyl) valine, HATU, DIPEA, DMF, 0°C-RT, 16 h; c) 1,4-dioxane containing 4N HCl, 1,4-dioxane, 10°C-RT, 16 h

[0481] Step-a: Synthesis of (tert-butoxycarbonyl)-DL-valine

[0482] To a stirred solution of DL-valine (2.0 g, 17.07 mmol) in THF (25 mL) and water (20 mL) at room temperature was added sodium hydroxide (0.82 g, 20.5 mmol) and di-tert-butyl dicarbonate (4.09 g, 18.77 mmol), and the reaction mixture was stirred for 16 h. The mixture was cooled to 0 ° C, acidified with 1N HCl and extracted with EtOAc (2 × 50 mL). The combined organic layer was washed with brine solution (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product (1.8 g) was used in the next step without any further purification.

[0483] Step-b: Synthesis of (tert-butoxycarbonyl)-DL-valine 2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)ethyl ester

[0484] To a stirred solution of 2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide (70 mg, 0.18 mmol) and (tert-butoxycarbonyl)-DL-valine (42 mg, 0.19 mmol) in DMFA (5 mL) at 0 ° C was added N-ethyldiisopropylamine (0.04 mL, 0.21 mmol) and HATU (80 mg, 0.21 mmol). The reaction mixture was stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (20 mL) and extracted with ethyl acetate (2×30 mL). The combined organic layers were washed with water (20 mL), brine solution (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 4.1% methanol / dichloromethane as eluent to give the title compound (40 mg, 38%); LC-MS: m / z 595.7 (M+1) + .

[0485] Step-c: Synthesis of DL-valine 2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)ethyl ester hydrochloride

[0486] To a stirred solution of (tert-butoxycarbonyl)-DL-valine 2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethoxy)ethyl ester (40 mg, 0.07 mmol) in 1,4-dioxane (5 mL) at 10° C. was added 4N HCl in 1,4-dioxane (0.03 mL, 0.13 mmol), and the reaction mixture was stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was concentrated under reduced pressure and lyophilized for 18 h to give the title compound as a hydrochloride salt (19 mg, 53%); 1H NMR (400MHz, DMSO-d6): δ12.50 (s, 1H), 8.52 (bs, 1H), 8.40 (bs, 3H), 8.09 (s, 1H), 7.80 (d, J=8. 4Hz, 1H), 7.54 (d, J=7.6Hz, 1H), 7.48 (d, J=7.6Hz, 2H), 7.25 (t, J=7.2Hz, 1H), 7.17 (t, J=8.0Hz, 1H), 4.43-4.40(m, 2H), 4.28-4.25(m, 2H), 3.95(bs, 1H), 3.70-3.67(s, 3H), 3.61-3.57(m, 2H) , 3.45-3.44 (m, 2H), 2.15-2.11 (m, 1H), 0.97 (d, J=6.8Hz, 3H), 0.92 (d, J=6.8Hz, 3H); LC-MS: m / z 495.1(M+1) + .

[0487] Examples 31 and 32. Synthesis of 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0488]

[0489] Conditions: a) HNO3, acetic acid, 0℃-RT, 16h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) potassium ethylxanthate, ethanol, reflux, 16h; d) SOCl2, catalytic DMF, reflux, 3h; e) NaH, 2-chloro-6-(trifluoromethyl)benzo[d]oxazole, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, ethanol, water, 60℃, 16h; g) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0℃-RT, 16h

[0490] Step-a: Synthesis of 2-nitro-5-(trifluoromethyl)phenol

[0491] To a solution of 3-(trifluoromethyl)phenol (5.0 g, 30.86 mmol) in acetic acid (50 mL) was added 60% aqueous nitric acid solution (3.5 mL) dropwise at 0 ° C. Subsequently, the mixture was stirred at this temperature for 1.5 h, and continued to stir at room temperature for 16 h. The mixture was poured into ice water (80 mL) and extracted with EtOAc (2×100 mL). The combined organic layers were washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 5% ethyl acetate / hexane as eluent to give the title compound (1.0 g, 16%). 1 H NMR (400MHz, DMSO-d6): δ11.75 (bs, 1H), 8.06 (d, J = 8.3Hz, 1H), 7.41 (d, J = 1.4Hz, 1H), 7.32 (dd, J = 1.4Hz, J = 8.3Hz, 1H); LC-MS: m / z206.0 (M-1) - .

[0492] Step-b: Synthesis of 2-amino-5-(trifluoromethyl)phenol

[0493] Under a nitrogen atmosphere, 10% Pd / C (100 mg) was added to a solution of 2-nitro-5-(trifluoromethyl)phenol (1.0 g, 4.83 mmol) in methanol (15 mL). The reaction mixture was stirred under a hydrogen balloon for 16 h. The reaction mixture was filtered through a bed of celite, and the filtrate was concentrated in vacuo to give the title compound (850 mg, 99%). 1 H NMR (400MHz, DMSO-d6): δ9.58 (bs, 1H), 6.88 (s, 1H), 6.86 (s, 1H), 6.66 (d, J = 7.8Hz, 1H), 5.18 (s, 2H); LC-MS: m / z 178.0 (M+1) + .

[0494] Step-c: Synthesis of 6-(trifluoromethyl)benzo[d]oxazole-2-thiol

[0495] To a solution of 2-amino-5-(trifluoromethyl)phenol (850 mg, 4.8 mmol) in ethanol (10 mL) at room temperature was added potassium ethyl xanthate (1.69 g, 10.56 mmol), and the reaction mixture was refluxed for 16 h. The reaction mixture was concentrated in vacuo and diluted with cold water (50 mL) and acidified with 1N HCl. The resulting solid was filtered and dried in vacuo to give the title compound (1.0 g, 95%). 1H NMR (400MHz, DMSO-d6): δ14.2 (bs, 1H), 7.98 (s, 1H), 7.66 (d, J = 8.4Hz, 1H), 7.41 (d, J = 7.8Hz, 1H); LC-MS: m / z 217.9 (M-1) - .

[0496] Step-d: Synthesis of 2-chloro-6-(trifluoromethyl)benzo[d]oxazole

[0497] To a solution of 6-(trifluoromethyl)benzo[d]oxazole-2-thiol (500 mg, 2.28 mmol) in thionyl chloride (4 mL) at room temperature was added dimethylformamide (catalytic amount) and the reaction mixture was refluxed for 3 h. The reaction mixture was concentrated, diluted with cold water (30 mL) and extracted with EtOAc (2×30 mL). The combined organic layers were washed with brine solution (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (290 mg, 57%). 1 H NMR (400MHz, DMSO-d6): δ8.31 (s, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H).

[0498] Step-e: Synthesis of ethyl 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0499] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (240 mg, 1.09 mmol) in 1,4-dioxane (8 mL) at 0° C. was added sodium hydride (60% dispersion in mineral oil) (109 mg, 2.74 mmol) followed by 2-chloro-6-(trifluoromethyl)benzo[d]oxazole (290 mg, 1.31 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated, diluted with cold water (15 mL) and stirred at room temperature for 30 min. The resulting solid was filtered, dried under vacuum and purified by flash column chromatography using 100% DCM as eluent to give the title compound (150 mg, 34%). 1H NMR (400MHz, DMSO-d6): δ12.40(bs,1H),8.25(d,J=1.5Hz,1H),7.89(dd,J=1.5Hz,J=8.3Hz,1H),7. 83(s,1H),7.61-7.51(m,3H),4.33(q,J=6.9Hz,2H),3.66(s,3H),1.36(t,J=6.9Hz,3H); LC-MS:m / z 405.30(M+1) + .

[0500] Step-f: Synthesis of 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (Example 31)

[0501] To a stirred solution of ethyl 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (80 mg, 0.20 mmol) in a solvent mixture of THF (0.5 mL), ethanol (0.5 mL) and water (0.25 mL) was added lithium hydroxide monohydrate (20 mg, 0.50 mmol). The reaction mixture was heated at 60 °C for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (55 mg, 81%); 1 H NMR (400MHz, DMSO-d6): δ12.80(bs,1H),12.40(bs,1H),8.22(s,1H),7.89(d,J=8.3Hz,1H),7.84(s,1H),7.63-7.53(m,3H),3.67(s,3H); LC-MS: m / z 377.05(M+1) + .

[0502] Step-g: Synthesis of N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide (Example 32)

[0503] To a stirred solution of 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (50 mg, 0.13 mmol) in DMFA (1.5 mL) at 0 ° C was added N-ethyldiisopropylamine (0.02 mL, 0.13 mmol) and diphenylphosphoryl azide (0.02 mL, 0.13 mmol). The reaction mixture was stirred for 30 min, then 2-methoxyethylamine (0.01 mL, 0.13 mmol) was added, and the reaction mixture was then stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (15 mL) and stirred for 15 min. The resulting solid was filtered, washed with diethyl ether and dried under vacuum to give the title compound (28 mg, 49%); 1 H NMR (400MHz, DMSO-d6): δ12.40(bs,1H),8.48(s,1H),8.10(s,1H),7.83(s,1H),7.79(d, J=8.4Hz,1H),7.61-7.51(m,3H),3.67(s,3H),3.48-3.44(m,4H),3.30(s,3H); LC-MS:m / z 434.1(M+1) + .

[0504] Example 33. Synthesis of N-(2-hydroxyethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0505]

[0506] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0507] The title compound was synthesized using the same procedure as in Example 6, step-e, using 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 34%); 1 H NMR (400MHz, DMSO-d6): δ12.40 (bs, 1H), 8.39 (t, J=5.3Hz, 1H), 8.10 (s, 1H), 7.82 (s, 1H), 7.80 (d, J=8.3Hz, 1H), 7.61-7.51(m, 3H), 4.72(t, J=5.2Hz, 1H), 3.67(s, 3H), 3.54-3.51(m, 2H), 3.37-3.34(m, 2H); LC-MS: m / z 420.0(M+1) +.

[0508] Example 34. Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0509]

[0510] Conditions: a) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0511] The title compound was synthesized using the same procedure as in Example 6, step-e, using 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials (yield: 50%); 1 H NMR (400MHz, DMSO-d6): δ12.40(bs, 1H), 8.46(bs, 1H), 8.10(s, 1H), 7.83(s, 1H), 7.79(d, J=8.3Hz, 1H), 7.62-7.52(m, 3H), 4.60(bs, 1H), 3.67(s, 3H), 3.58-3.44(m, 8H); LC-MS: m / z 464.20(M+1) + .

[0512] Example 35. Synthesis of N-(2-hydroxypropyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0513] The title compound was synthesized using the same procedure as compound 1i using 1-aminopropan-2-ol and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30 (bs, 1H), 8.35 (t, J=1.2Hz, 1H), 8.10 (d, J=1.2Hz, 1H), 7.82-7.79 (m, 2H), 7.61-7.51 (m, 3H), 4.76 (d, J=4.0Hz, 1H), 3.84-3.80 (m, 1H), 3.67 (s, 3H), 3.26-3.21 (m, 2H), 1.09 (d, J=6.4Hz, 3H); LC-MS: m / z 434.2(M+1) + .

[0514] Example 36. Synthesis of 1-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0515] The title compound was synthesized using the same procedure as compound 1i using 2-(pyrrolidin-1-yl)ethan-1-amine and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400 MHz, DMSO-d6): δ 12.30 (bs, 1H), 8.39 (t, J = 5.2 Hz, 1H), 8.09 (s, 1H), 7.82 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.61-7.51 (m, 3H), 3.66 (s, 3H), 3.43-3.38 (m, 2H), 2.61 (t, J = 7.2 Hz, 2H), 2.5 (m, 4H, merged with DMSO peak), 1.69 (bs, 4H); LC-MS: m / z 473.1 (M+1) + .

[0516] Example 37. Synthesis of 1-methyl-N-(2-(piperidin-1-yl)ethyl)-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0517] The title compound was synthesized using the same procedure as compound 1i using 2-(piperidin-1-yl)ethan-1-amine and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.32(t,J=5.6Hz,1H),8.07(s,1H),7.82(s,1H),7.75(d,J=8.0Hz ,1H),7.61-7.51(m,3H),3.66(s,3H),3.41-3.36(m,2H),2.43-2.32(m,6H),1.53-1.38(m,6H); LC-MS:m / z 487.15(M+1) + .

[0518] Example 38. Synthesis of N-(2-(2-hydroxypropoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0519] The title compound was synthesized using the same procedure as compound 1i using 1-(2-aminoethoxy)propan-2-ol and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.46(t,J=5.6Hz,1H),8.09(s,1H),7.83(s,1H),7.78(d,J=8.8Hz,1H),7.62-7.52(m,3H),4.58(d,J= 4.4Hz,1H),3.77-3.73(m,1H),3.66(s,3H),3.56(t,J=6.0Hz,2H),3.45(t,J=5.2Hz,2H),2.29-2.23(m,2H),1.04(d,J=6.4Hz,3H); LC-MS: m / z 478.2(M+1) + .

[0520] Example 39. Synthesis of N-(2,3-dihydroxypropyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0521] The title compound was synthesized using the same procedure as compound 1i using 3-aminopropane-1,2-diol and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400 MHz, DMSO-d6): δ 12.40 (bs, 1H), 8.39 (t, J = 5.2 Hz, 1H), 8.10 (s, 1H), 7.84 (s, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.62-7.53 (m, 3H), 4.87 (d, J = 4.4 Hz, 1H), 4.62 (bs, 1H), 3.67 (s, 4H), 3.45-3.40 (m, 1H), 3.30 (2H, combined with DMSO water peak), 3.25-3.19 (m, 1H); LC-MS: m / z 450.15 (M+1) + .

[0522] Example 40. Synthesis of N-(2-(2-(dimethylamino)acetamido)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0523] The title compound was synthesized using the same procedure as in Example 19 step-c using N-(2-aminoethyl)-2-(dimethylamino)acetamide trifluoroacetate and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs, 1H), 8.47(bs, 1H), 8.09(s, 1H), 7.92(bs, 1H), 7.83(s, 1H), 7.76(d , J=8.4Hz, 1H), 7.61-7.52(m, 3H), 3.66(s, 3H), 3.38-3.35(m, 4H), 2.86(s, 2H), 2.19(s, 6H); LC-S: m / z 504.2(M+1) + .

[0524] Example 41. Synthesis of 2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetic acid

[0525]

[0526] Conditions: a) ethyl 2-(2-aminoethoxy)acetate trifluoroacetate, HBTU, DIPEA, DMF, 0°C-RT, 16h; b) LiOH.H2O, ethanol, THF, water, RT, 3h

[0527] Step-a: Synthesis of ethyl 2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetate

[0528] The title compound was synthesized using the same procedure as in Example 29 step-c using 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and ethyl 2-(2-aminoethoxy)acetate trifluoroacetate as starting materials (yield: 65%); 1 H NMR (400MHz, DMSO-d6): δ12.38 (bs, 1H), 8.49 (bs, 1H), 8.10 (s, 1H), 7.82 (s, 1H), 7.79 (d, J=8.8Hz, 1H), 7. 61-7.52 (m, 3H), 4.15-4.09 (m, 4H), 3.66-3.62 (m, 5H), 3.48-3.46 (m, 2H), 1.19 (t, J=7.0Hz, 3H); LC-MS: m / z 506.1(M+1)+ .

[0529] Step-b: Synthesis of 2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetic acid

[0530] The title compound was synthesized using the same procedure as in Example 29, step-d, using ethyl 2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamido)ethoxy)acetate as a starting material (yield: 75%); 1 H NMR (400MHz, DMSO-d6): δ12.70 (bs, 1H), 12.30 (bs, 1H), 8.49 (bs, 1H), 8.10 (s, 1H), 7.82-7. 78(m, 2H), 7.61-7.51(m, 3H), 4.06(s, 2H), 3.66-3.62(m, 5H), 3.48-3.41(m, 2H); LC-MS: m / z 478.2(M+1) + .

[0531] Example 42. Synthesis of N-(2-(2-hydroxy-2-methylpropoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0532] The title compound was synthesized using the same procedure as compound 1i using 1-(2-aminoethoxy)-2-methylpropan-2-ol and 1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.40 (bs, 1H), 8.83 (s, 1H), 8.08 (s, 1H), 7.81 (s, 1H), 7.77 (d, J=8.4Hz, 1H), 7.58-7.5 2(m, 3H), 4.32(bs, 1H), 3.66(s, 3H), 3.58-3.56(m, 2H), 3.46-3.44(m, 2H), 3.21(s, 2H), 1.08(s, 6H); LC-MS: m / z 492.1(M+1) + .

[0533] Example 43. Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0534]

[0535] Conditions: a) NaOH, DMSO, 60°C, 16h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) potassium ethylxanthate, ethanol, reflux, 16h; d) SOCl2, catalytic DMF, reflux, 1h; e) NaH, 2-chloro-5-(trifluoromethyl)benzo[d]oxazole, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, methanol, water, 50°C, 16h; g) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0536] Step-a: Synthesis of 2-nitro-4-(trifluoromethyl)phenol

[0537] To a solution of 1-chloro-2-nitro-4-(trifluoromethyl)benzene (10.0 g, 44.3 mmol) in DMSO (100 mL) at room temperature was added sodium hydroxide (4.44 g, 110.7 mmol), and the mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with water (250 mL) and extracted with EtOAc (200 mL). The aqueous layer was acidified to pH ~ 1 with 3N HCl and extracted with EtOAc (2×250 mL), the organic layer was washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (7.0 g, 81%); 1 H NMR (400MHz, DMSO-d6): δ 11.99 (bs, 1H), 8.22 (d, J=1.6Hz, 1H), 7.88 (dd, J=2.0Hz, J=8.8Hz, 1H), 7.30 (d, J=8.8Hz, 1H).

[0538] Step-b: Synthesis of 2-amino-4-(trifluoromethyl)phenol

[0539] Under a nitrogen atmosphere, 10% Pd / C (2.5 g) was added to a solution of 2-nitro-4-(trifluoromethyl)phenol (5.0 g, 24.15 mmol) in methanol (50 mL). The reaction mixture was stirred under a hydrogen balloon for 16 h. The reaction mixture was filtered through a bed of celite, and the filtrate was concentrated in vacuo to give the title compound (3.0 g, 70%). 1 H NMR (400MHz, DMSO-d6): δ9.85 (bs, 1H), 6.87 (d, J=2.0Hz, 1H), 6.77-6.70 (m, 2H), 5.0 (bs, 2H); LC-MS: m / z 178.1 (M+1) + .

[0540] Step-c: Synthesis of 5-(trifluoromethyl)benzo[d]oxazole-2-thiol

[0541] To a solution of 2-amino-4-(trifluoromethyl)phenol (3.0 g, 16.9 mmol) in ethanol (45 mL) at room temperature was added potassium ethyl xanthate (6.78 g, 42.4 mmol), and the reaction mixture was refluxed for 16 h. The reaction mixture was concentrated in vacuo and diluted with cold water (100 mL) and acidified with 3N HCl. The precipitated solid was filtered and dried in vacuo to give the title compound (3.0 g, 81%). 1 H NMR (400MHz, DMSO-d6): δ14.2 (bs, 1H), 7.72 (d, J = 8.4Hz, 1H), 7.64 (d, J = 8.4Hz, 1H), 7.51 (s, 1H); LC-MS: m / z 220.0 (M+1) + .

[0542] Step-d: Synthesis of 2-chloro-5-(trifluoromethyl)benzo[d]oxazole

[0543] To a solution of 5-(trifluoromethyl)benzo[d]oxazole-2-thiol (2.0 g, 9.1 mmol) in thionyl chloride (10 mL) at room temperature was added N,N-dimethylformamide (catalytic amount) and the reaction mixture was refluxed for 1 h. The reaction mixture was concentrated, diluted with cold water (60 mL) and extracted with EtOAc (2×100 mL). The combined organic layers were washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (1.3 g, 65%). 1 H NMR (400MHz, DMSO-d6): δ8.23 (s, 1H), 8.02 (d, J = 8.8Hz, 1H), 7.85 (d, J = 8.8Hz, 1H).

[0544] Step-e: Synthesis of ethyl 1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0545] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (200 mg, 0.91 mmol) in 1,4-dioxane (10 mL) at 0°C was added sodium hydride (60% dispersion in mineral oil) (91 mg, 2.27 mmol) and stirred for 15 min, followed by the addition of 2-chloro-5-(trifluoromethyl)benzo[d]oxazole (222 mg, 1.0 mmol) and continued stirring at room temperature for 16 h. The reaction mixture was concentrated, diluted with cold water (50 mL), acidified with 3N HCl and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with water (30 mL), brine solution (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 100% dichloromethane as eluent to give the title compound (150 mg, 40%). 1 HNMR (400MHz, DMSO-d6): δ12.41(bs,1H),8.25(s,1H),7.90(dd,J=1.2Hz,J=8.4Hz,1H),7.67-7.64(m,2H),7.5 7(d,J=8.4Hz,1H),7.49(d,J=8.4Hz,1H),4.33(q,J=7.2Hz,2H),3.66(s,3H),1.35(t,J=7.2Hz,3H); LC-MS: m / z 405.00(M+1) + .

[0546] Step-f: Synthesis of 1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0547] To a stirred solution of ethyl 1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate (150 mg, 0.37 mmol) in a solvent mixture of THF (2 mL), methanol (2 mL) and water (2 mL) was added lithium hydroxide monohydrate (78 mg, 1.85 mmol). The reaction mixture was heated at 50°C for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water (30 mL), acidified to pH ~2 with 3N HCl and stirred for 1 h. The precipitated solid was filtered and dried under vacuum to give the title compound (140 mg, 100%); 1H NMR (400MHz, DMSO-d6): δ12.85 (bs, 1H), 12.40 (bs, 1H), 8.18 (s, 1H), 7.87 (d, J=8.4Hz, 1H), 7.67 ( s, 1H), 7.63 (d, J=8.4Hz, 1H), 7.52 (d, J=8.4Hz, 1H), 7.46 (d, J=8.0Hz, 1H), 3.64 (s, 3H); LC-MS: m / z 377.1(M+i) + .

[0548] Step-g: Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0549] To a stirred solution of 1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (80 mg, 0.21 mmol) in DMFA (5 mL) at 0 ° C was added N-ethyldiisopropylamine (0.04 mL, 0.21 mmol) and HBTU (81 mg, 0.21 mmol). The reaction mixture was stirred for 15 min, followed by the addition of 2-(2-aminoethoxy)ethan-1-ol (22 mg, 0.21 mmol). The reaction mixture was then stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (30 mL) and stirred for 1 h. The precipitated solid was filtered and dried in vacuo. The solid was stirred in diethyl ether (15 mL), filtered and dried in vacuo to give the title compound (80 mg, 85%). 1 H NMR (400MHz, DMSO-d6): δ12.33 (bs, 1H), 8.46 (t, J=5.4Hz, 1H), 8.09 (d, J=1.2Hz, 1H), 7.78 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.68 (s, 1H), 7.64 ( d, J=8.4Hz, 1H), 7.52 (d, J=8.0Hz, 1H), 7.48 (d, J=8.4Hz, 1H), 4.60 (t, J=5.2Hz, 1H), 3.66 (s, 3H), 3.58-3.43 (m, 8H); LC-MS: m / z464.2 (M+1) + .

[0550] Examples 44 and 45. Synthesis of 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide:

[0551]

[0552] Conditions: a) HNO3, acetic acid, 15°C-RT, 16h; b) 10% Pd / C, MeOH, H2, RT, 5h; c) carbon disulfide, KOH, ethanol, reflux, 6h; d) K2CO3, methyl iodide, acetonitrile, RT, 16h; e) m-CPBA, DCM, 0°C-RT, 6h; f) NaH, 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16h; g) LiOH.H2O, THF, ethanol, water, 60°C, 16h; h) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0553] Step-a: Synthesis of 2-nitro-5-(trifluoromethoxy)phenol

[0554] To a solution of 3-(trifluoromethoxy)phenol (1 g, 5.6 mmol) in acetic acid (10 mL) was added 60% aqueous nitric acid solution (1 mL) dropwise at 10-15 ° C. The mixture was stirred at this temperature for 1.5 h and continued to stir at room temperature for 16 h. The mixture was poured into ice water (20 mL) and extracted with EtOAc (2×25 mL). The combined organic layers were washed with brine solution (25 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using 5% EtOAc / hexane as eluent to give the title compound (300 mg, 24%). 1 H NMR (400MHz, CDCl3): δ10.73 (s, 1H), 8.18 (d, J=9.6Hz, 1H), 6.99 (s, 1H), 6.83 (d, J=9.2Hz, 1H); LC-MS: m / z 222.0 (M-1).

[0555] Step-b: Synthesis of 2-amino-5-(trifluoromethoxy)phenol

[0556] Under a nitrogen atmosphere, 10% Pd / C (60 mg) was added to a solution of 2-nitro-5-(trifluoromethoxy)phenol (300 mg, 1.35 mmol) in methanol (6 mL). The reaction mixture was stirred under hydrogen for 5 h. The reaction mixture was filtered through a celite bed and concentrated in vacuo to give the title compound (250 mg, 96%). 1 H NMR (400MHz, DMSO-d6): δ9.60 (s, 1H), 6.59-6.57 (m, 2H), 6.53-6.50 (m, 1H), 4.68 (bs, 2H); LC-MS: m / z 194.0 (M+1) + .

[0557] Step-c: Synthesis of 6-(trifluoromethoxy)benzo[d]oxazole-2-thiol

[0558] To a solution of 2-amino-5-(trifluoromethoxy)phenol (250 mg, 1.3 mmol) in ethanol (5 mL) at room temperature was added powdered potassium hydroxide (127 mg, 2.3 mmol) and carbon disulfide (1 mL, 17.0 mmol). The reaction mixture was refluxed for 6 h. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was diluted with cold water (100 mL) and acidified with 1N HCl. The resulting solid was filtered and dried in vacuo to give the title compound (200 mg, 66%). 1 H NMR (400MHz, DMSO-d6): δ14.10(bs,1H),7.73(s,1H),7.32(s,2H); LC-MS: m / z 235.9(M+1) + .

[0559] Step-d: Synthesis of 2-(methylthio)-6-(trifluoromethoxy)benzo[d]oxazole

[0560] The title compound was synthesized using the same procedure as compound 1b, using 6-(trifluoromethoxy)benzo[d]oxazole-2-thiol as the starting material and stirring at room temperature for 16 h (yield: 94%); 1 H NMR (400MHz, DMSO-d6): δ7.85 (d, J=1.6Hz, 1H), 7.73 (d, J=8.0Hz, 1H), 7.37-7.34 (m, 1H), 2.77 (s, 3H); LC-MS: m / z 250.1 (M+1) + .

[0561] Step-e: Synthesis of 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole

[0562] The title compound was synthesized using the same procedure as compound 1c, using 2-(methylthio)-6-(trifluoromethoxy)benzo[d]oxazole as the starting material and stirring at room temperature for 6 h (yield: 94%); 1 H NMR (400MHz, DMSO-d6): δ8.22 (s, 1H), 8.15 (d, J = 8.8Hz, 1H), 7.62 (d, J = 8.8Hz, 1H), 3.67 (s, 3H).

[0563] Step-f: Synthesis of ethyl 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0564] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (100 mg, 0.46 mmol) in 1,4-dioxane (2 mL) at room temperature was added sodium hydride (60% dispersion in mineral oil) (64 mg, 1.6 mmol) followed by 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole (167 mg, 0.6 mmol). The reaction mixture was stirred at room temperature for 16 h. It was then concentrated, diluted with cold water (15 mL) and acidified with 1N HCl. The resulting solid was filtered, dried under vacuum and purified by flash column chromatography using 100% DCM as eluent to give the title compound (30 mg, 16%). 1 H NMR (400MHz, DMSO-d6): δ12.40(bs,1H),8.24(s,1H),7.89(dd,J=1.6Hz,J=8.4Hz,1H),7.58-7.50( m,3H),7.22(d,J=8.0Hz,1H),4.33(q,J=7.6Hz,2H),3.65(s,3H),1.35(t,J=7.2Hz,3H); LC-MS:m / z 421.0(M+1) + .

[0565] Step-g: Synthesis of 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0566] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 72%); 1HNMR (400MHz, DMSO-d6): δ12.80(bs,1H),12.30(bs,1H),8.20(s,1H),7.88(d,J=8.4Hz,1H), 7.58(s,1H),7.52(d,J=8.8Hz,2H),7.22(d,J=8.0Hz,1H),3.65(s,3H); LC-MS: m / z393.0(M+1) + .

[0567] Step-h: Synthesis of N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0568] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 23%); 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.47(t,J=5.2Hz,1H),8.08(s,1H),7.78(d,J=8.4Hz,1H),7.57( s,1H),7.52-7.49(m,2H),7.21(d,J=8.4Hz,1H),3.64(s,3H),3.48-3.44(m,4H),3.28(s,3H); LC-MS:m / z 450.0(M+1) + .

[0569] Example 46. Synthesis of 1-methyl-N-(1H-pyrazol-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0570] The title compound was synthesized using the same procedure as compound 1i using 1H-pyrazol-4-amine and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1H NMR (400MHz, DMSO-d6): δ12.65(bs,1H),12.30(bs,1H),10.40(s,1H),8.17(d,J=1.2Hz,1H),8.02(bs,1H),7. 89(dd,J=1.2Hz,J=8.4Hz,1H),7.69(bs,1H),7.58-7.49(m,3H),7.21(d,J=8.4Hz,1H),3.67(s,3H); LC-MS:m / z 458.0(M+1) + .

[0571] Example 47. Synthesis of N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0572] The title compound was synthesized using the same procedure as compound 1i using 2-amino-2-(hydroxymethyl)propane-1,3-diol and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 HNMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.05(s,1H),7.43(d,J=8.4Hz,1H),7.57(s,1H),7.50(d,J =5.8Hz,2H),7.26(s,1H),7.21(d,J=8.4Hz,1H),4.83(bs,3H),3.71(bs,6H),3.65(s,3H); LC-MS: m / z 496.3(M+1) + .

[0573] Example 48. Synthesis of N-(1,3-dihydroxypropan-2-yl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0574] The title compound was synthesized using the same procedure as compound 1i using 2-amino-propane-1,3-diol and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.09(s,1H),7.88(d,J=7.6Hz,1H),7.81(d,J=8.4Hz,1H),7.57(d,J=1.2Hz,1H),7.51(d,J=8.0Hz ,2H),7.21(dd,J=1.6Hz,J=8.4Hz,1H),4.66(t,J=6.0Hz,2H),4.00-3.95(m,1H),3.65(s,3H),3.54(t,J=6.0Hz,4H); LC-MS: m / z466.0(M+1) + .

[0575] Example 49. Synthesis of N-(2-(2-(dimethylamino)acetamido)ethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0576] The title compound was synthesized using the same procedure as in Example 19 step-c using N-(2-aminoethyl)-2-(dimethylamino)acetamide trifluoroacetate and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400 MHz, DMSO-d6): δ 12.0 (bs, 1H), 8.45 (t, J = 4.4 Hz, 1H), 8.07 (s, 1H), 7.91 (t, J = 5.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.56 (s, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.0 Hz, 1H), 3.64 (s, 3H), 3.36 (t, J = 5.6 Hz, 2H), 3.30 (2H, combined with DMSO water peak), 2.85 (s, 2H), 2.18 (s, 6H); LC-MS: m / z 520.5 (M+1) + .

[0577] Example 50. Synthesis of 1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0578] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-1H-pyrazol-4-amine and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),10.40(s,1H),8.17(s,1H),8.03(s,1H),7.88(d,J=8.0H z,1H),7.58-7.51(m,4H),7.22(d,J=7.6Hz,1H),3.83(s,3H),3.66(s,3H); LC-MS:m / z472.0(M+1) + .

[0579] Example 51. Synthesis of 1-methyl-N-(oxetan-3-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0580] The title compound was synthesized using the same procedure as compound 1i using oxetan-3-amine and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),9.07(d,J=6.0Hz,1H),8.10(s,1H),7.85(d,J=8.4Hz,1H),7.57(s,1H),7.52(t,J= 8.8Hz, 2H), 7.21 (d, J = 8.4Hz, 1H), 5.05-5.00 (m, 1H), 4.78 (t, J = 6.4Hz, 2H), 4.62 (t, J = 6.4Hz, 2H), 3.65 (s, 3H); LC-MS: m / z 448.0(M+1) + .

[0581] Example 52. Synthesis of N-((3-hydroxyoxetan-3-yl)methyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0582] The title compound was synthesized using the same procedure as compound 1i using 3-(aminomethyl)oxetan-3-ol and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.54(t,J=6.0Hz,1H),8.10(d,J=1.2Hz,1H),7.80(dd,J=1.2Hz,J=8.8Hz,1H),7.57(d,J=1.6Hz,1H),7.53-7 .49(m,2H),7.21(dd,J=1.6Hz,J=8.8Hz,1H),5.88(s,1H),4.52(d,J=6.4Hz ,2H),4.41(d,J=6.4Hz,2H),3.65(s,3H),3.59(d,J=6.0Hz,2H); LC-MS:m / z 478.2(M+1) + .

[0583] Example 53. Synthesis of N-(2-hydroxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0584] The title compound was synthesized using the same procedure as compound 1i using 2-aminoethan-1-ol and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.38(t,J=5.2Hz,1H),8.09(d,J=1.2Hz,1H),7.78(dd,J=1.6Hz,J=8.8Hz,1H),7.57(s,1H),7.52 -7.49(m,2H),7.22(d,J=8.0Hz,1H),4.72(t,J=5.2Hz,1H),3.64(s,3H),3.54(q,J=6.0Hz,2H),3.37-3.30(m,2H); LC-MS: m / z436.0(M+1) + .

[0585] Example 54. Synthesis of 1-methyl-N-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0586] The title compound was synthesized using the same procedure as compound 1i using 2-(methylsulfonyl)ethan-1-amine hydrochloride and 1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting materials. 1H NMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.68(t,J=5.2Hz,1H),8.09(d,J=1.6Hz,1H),7.76(dd,J=1.6Hz,J=8.4Hz,1H),7.57(s ,1H),7.53-7.50(m,2H),7.27-7.20(m,1H),3.70(q,J=6.0Hz,2H),3.65(s,3H),3.40(t,J=6.8Hz,2H),3.05(s,3H); LC-MS: m / z 497.9(M+1) + .

[0587] Examples 55 and 56. Synthesis of 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0588]

[0589] Conditions: a) 2-methoxyethan-1-ol, sodium, 100°C, 16h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) potassium ethylxanthate, ethanol, reflux, 16h; d) SOCl2, catalytic DMF, reflux, 2h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, ethanol, water, 60°C, 8h; g) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0590] Step-a: Synthesis of 5-(2-methoxyethoxy)-2-nitrophenol

[0591] To the stirred 2-methoxyethane-1-ol (50 mL) at 0° C. was added sodium metal (2.29 g, 95.46 mmol), and the reaction mixture was stirred at room temperature for 30 min, followed by the addition of 5-fluoro-2-nitrophenol (5.0 g, 31.82 mmol). The reaction mixture was heated to 100° C. for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was cooled to 0° C., diluted with cold water (200 mL) and acidified with 1N HCl. The resulting solid was filtered and dried in vacuo to give the title compound (4.0 g, 59%) as a yellow solid. 1H NMR (400MHz, DMSO-d6): δ 10.93 (s, 1H), 7.96 (d, J = 9.3Hz, 1H), 6.64-6.58 (m, 2H), 4.19-4.17 (m, 2H), 3.67-3.65 (m, 2H), 3.30 (s, 3H).

[0592] Step-b: Synthesis of 2-amino-5-(2-methoxyethoxy)phenol

[0593] The title compound was synthesized using the same procedure as compound 1e using 5-(2-methoxyethoxy)-2-nitrophenol as the starting material (yield: 96%); LC-MS: m / z 184.1 (M+1) + .

[0594] Step-c: Synthesis of 6-(2-methoxyethoxy)benzo[d]oxazole-2-thiol

[0595] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-(2-methoxyethoxy)phenol as a starting material (yield: 76%); 1 H NMR (400MHz, DMSO-d6): 613.78 (s, 1H), 7.29 (d, J = 2.4Hz, 1H), 7.19 (d, J = 8.8Hz, 1H), 6.96 (dd, J=2.4Hz, J=8.8Hz, 1H), 4.18-4.16 (m, 2H), 3.73-3.71 (m, 2H), 3.36 (s, 3H); LC-MS: m / z 226.0(M+1) + .

[0596] Step-d: Synthesis of 2-chloro-6-(2-methoxyethoxy)benzo[d]oxazole

[0597] The title compound was synthesized using the same procedure as in Example 32 step-d using 6-(2-methoxyethoxy)benzo[d]oxazole-2-thiol as the starting material and stirring for 2 h (yield: 69%); LC-MS: m / z 228.05 (M+1) + .

[0598] Step-e: Synthesis of ethyl 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0599] The title compound was synthesized using the same procedure as in Compound Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(2-methoxyethoxy)benzo[d]oxazole as starting materials (yield: 24%); 1 H NMR (400MHz, DMSO-d6): δ12.20(bs,1H),8.21(d,J=1.5Hz,1H),7.86(dd,J=1.5Hz ,J=8.3Hz,1H),7.49(d,J=8.3Hz,1H),7.35(d,J=8.8Hz,1H),7.14(d,J=2.4Hz,1H ),6.83(dd,J=2.4Hz,J=8.8Hz,1H),4.33(q,J=7.2Hz,2H),4.12(t,J=4.6Hz,2H), 3.67(t,J=4.6Hz,2H),3.62(s,3H),3.32(s,3H),1.35(t,J=7.1Hz,3H); LC-MS:m / z 411.0(M+1) + .

[0600] Step-f: Synthesis of 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0601] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 77%); 1 H NMR (400MHz, DMSO-d6): δ12.15(bs,2H),8.17(d,J=1.5Hz,1H),7.85(dd,J=2.0Hz,J=8.8Hz,1H),7.47(d,J=8.3Hz,1H),7.36(d,J=8.3Hz,1H ), 7.13 (d, J = 2.4Hz, 1H), 6.82 (dd, J = 2.4Hz, J = 8.3Hz, 1H), 4.12 (t, J = 4.6Hz, 2H), 3.67 (t, J = 4.6Hz, 2H), 3.62 (s, 3H), 3.32 (s, 3H); LC-MS: m / z 383.0(M+1) + .

[0602] Step-g: Synthesis of 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0603] The title compound was synthesized using the same procedure as compound 1i using 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 29%); 1 HNMR (400MHz, DMSO-d6): δ12.15(bs,1H),8.44(t,J=5.4Hz,1H),8.05(d,J=1.5Hz, 1H),7.75(dd,J=1.4Hz,J=8.3Hz,1H),7.45(d,J=8.3Hz,1H),7.35(d,J=8.3Hz,1H) ,7.13(d,J=2.4Hz,1H),6.82(dd,J=2.4Hz,J=8.3Hz,1H),4.12-4.10(m,2H),3.68- 3.66(m,2H),3.62(s,3H),3.49-3.43(m,4H),3.32(s,3H),3.28(s,3H); LC-MS:m / z 440.60(M+1) + .

[0604] Example 57. Synthesis of N-(2-hydroxyethyl)-2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0605]

[0606] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0607] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as a starting material (yield: 27%); 1HNMR (400MHz, DMSO-d6): δ12.16 (bs, 1H), 8.35 (t, J=5.4Hz, 1H), 8.05 (d, J=1.0Hz, 1H), 7.7 5 (dd, J=1.5Hz, J=8.3Hz, 1H), 7.45 (d, J=8.3Hz, 1H), 7.35 (d, J=8.8Hz, 1H), 7.12 (d, J=2.4H z, 1H), 6.81 (dd, J=2.5Hz, J=8.4Hz, 1H), 4.72 (bs, 1H), 4.11 (t, J=4.6Hz, 2H), 3.67 (t, J=4. 6Hz, 2H), 3.61 (s, 3H), 3.53 (t, J=5.3Hz, 2H), 3.35 (t, J=6.0Hz, 2H), 3.32 (s, 3H); LC-MS: m / z 426.45(M+1) + .

[0608] Example 58. Synthesis of N-(2-(2-hydroxyethoxy)ethyl)-2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0609]

[0610] Conditions: a) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0611] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials (yield: 61%); 1 H NMR (400MHz, DMSO-d6): δ12.15 (bs, 1H), 8.41 (t, J=5.4Hz, 1H), 8.05 (d, J=0.9Hz, 1H), 7 .74 (dd, J=1.5Hz, J=8.3Hz, 1H), 7.45 (d, J=8.3Hz, 1H), 7.35 (d, J=8.8Hz, 1H), 7.12 (d, J =1.9Hz, 1H), 6.82 (dd, J=2.4Hz, J=8.8Hz, 1H), 4.60 (bs, 1H), 4.13 (t, J=4.6Hz, 2H), 3.6 7(t, J=4.6Hz, 2H), 3.62(s, 3H), 3.57-3.42(m, 8H), 3.32(s, 3H); LC-MS: m / z470.25(M+1) +.

[0612] Examples 59 and 60. Synthesis of 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0613]

[0614] Conditions: a) NaNO3, NaNO2, 3M H2SO4, DCM, RT, 24h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) potassium ethylxanthate, ethanol, reflux, 16h; d) SOCl2, catalytic DMF, reflux, 2h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, ethanol, water, 60°C, 5h; g) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0615] Step-a: Synthesis of 5-isopropyl-2-nitrophenol

[0616] At room temperature, sodium nitrate (1.37 g, 16.18 mmol) and sodium nitrite (10 mg, 0.14 mmol) were added to a solution of 3-isopropylphenol (2.0 g, 14.7 mmol) in DCM (30 mL) and 3M sulfuric acid (25 mL). Subsequently, the mixture was stirred for 24 h. The mixture was poured into ice water (100 mL) and extracted with DCM (2 × 50 mL). The combined organic layer was washed with saline solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using 5% ethyl acetate / hexane as eluent to give the title compound (500 mg, 19%). 1 H NMR (400MHz, DMSO-d6): δ10.76 (s, 1H), 7.86 (d, J=8.8Hz, 1H), 6.98 (d, J=1.5Hz, 1H), 6. 89 (dd, J=1.5Hz, J=8.3Hz, 1H), 2.92-2.89 (m, 1H), 1.19 (d, J=6.9Hz, 6H); LC-MS: m / z 180.0(M-1).

[0617] Step-b: Synthesis of 2-amino-5-isopropylphenol

[0618] The title compound was synthesized using the same procedure as compound 1e using 5-isopropyl-2-nitrophenol as the starting material (yield: 86%); 1 H NMR (400MHz, DMSO-d6): δ8.88 (bs, 1H), 6.50 (dd, J=1.9Hz, J=10.7Hz, 1H), 6.41 (d, J=2.0Hz, 1H), 6.39 (d, J=2.0Hz, 1H), 4.25 (s, 2H), 2.68-2.61 (m, 1H), 1.10 (d, J=6.8Hz, 6H); LC-MS: m / z 152.15(M+1) + .

[0619] Step-c: Synthesis of 6-isopropylbenzo[d]oxazole-2-thiol

[0620] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-isopropylphenol as a starting material (yield: 68%); 1 H NMR (400MHz, DMSO-d6): δ13.74 (s, 1H), 7.41 (s, 1H), 7.20-7.13 (m, 2H), 3.0-2.93 (m, 1H), 1.21 (d, J=6.9Hz, 6H); LC-MS: m / z 194.15 (M+1) + .

[0621] Step-d: Synthesis of 2-chloro-6-isopropylbenzo[d]oxazole

[0622] The title compound was synthesized using the same procedure as in Example 32 step-d using 6-isopropylbenzo[d]oxazole-2-thiol as the starting material and stirring for 2 h (yield: 85%); 1 H NMR (400MHz, DMSO-d6): δ7.17 (s, 1H), 7.02-6.97 (m, 2H), 2.96-2.86 (m, 1H), 1.19 (d, J = 6.8Hz, 6H); LC-MS: m / z 196.0 (M+1) + .

[0623] Step-e: Synthesis of ethyl 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0624] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-isopropylbenzo[d]oxazole as starting materials (yield: 77%); 1H NMR (400MHz, DMSO-d6): δ12.15(bs,1H),8.22(d,J=1.0Hz,1H),7.86(dd,J=1.0Hz,J=8.3Hz,1H),7.50(d,J=8.3Hz,1H),7.38(d,J=8.3Hz,1H),7. 33(s,1H),7.11(d,J=7.8Hz,1H),4.33(q,J=7.0Hz,2H),3.63(s,3H),3.01-2.95(m,1H),1.35(t,J=7.0Hz,3H),1.25(d,J=6.8Hz,6H); LC-MS: m / z 379.1(M+1) + .

[0625] Step-f: Synthesis of 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0626] The title compound was synthesized using the same procedure as compound 1h, using ethyl 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material and stirring at 60°C for 5h (yield: 92%); 1 H NMR (400MHz, DMSO-d6): δ12.20(bs,2H),8.18(s,1H),7.86(d,J=8.3Hz,1H),7.49(d,J=8.3Hz,1H),7.39(d,J=7 .8Hz,1H),7.33(s,1H),7.10(d,J=7.8Hz,1H),3.63(s,3H),2.98-2.97(m,1H),1.25(d,J=6.8Hz,6H); LC-MS: m / z 351.20(M+1) + .

[0627] Step-g: Synthesis of 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0628] The title compound was synthesized using the same procedure as compound 1i using 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid as the starting material (yield: 69%); 1H NMR (400MHz, DMSO-d6): δ12.15(bs,1H),8.44(s,1H),8.07(s,1H),7.75(d,J=8.3Hz,1H),7.46(d,J=8.3Hz,1H),7.37(d,J=8.3Hz,1H) ,7.32(s,1H),7.09(d,J=7.8Hz,1H),3.63(s,3H),3.48-3.44(m,4H),3.28(s,3H),2.98-2.97(m,1H),1.25(d,J=6.8Hz,6H); LC-MS: m / z 408.0(M+1) + .

[0629] Example 61. Synthesis of N-(2-hydroxyethyl)-2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide.

[0630] The title compound was synthesized using the same procedure as in Example 6 step-e using 2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials. 1 H NMR (400MHz, DMSO-d6): δ12.50(bs,1H),8.43(bs,1H),8.08(s,1H),7.82(d,J=8.0Hz,1H),7.55(d,J=8.2Hz,1H),7.38-7.36(m,2H),7.16( d,J=8.0Hz,1H),3.67(s,3H),3.54(d,J=5.6Hz,2H),3.36(q,J=6.0Hz,2H),3.02-2.99(m,1H),1.25(d,J=7.2Hz,6H); LC-MS: m / z394.0(M+1) + .

[0631] Example 62. Synthesis of 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0632]

[0633] Conditions: a) K2CO3, benzyl bromide, DMF, RT, 16 h; b) KOH, water, 100°C, 30 h; c) diethyl phosphonate (bromodifluoromethyl ester), KOH, ACN and water (1:1), RT, 1 h; d) 10% Pd / C, MeOH, H2, RT, 16 h; e) potassium ethyl xanthate, ethanol, reflux, 16 h; f) SOCl2, catalytic DMF, reflux, 2 h; g) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; f) LiOH.H 2 O, THF, ethanol, water, 60℃, 16h

[0634] Step-a: Synthesis of 2-(benzyloxy)-4-fluoro-1-nitrobenzene

[0635] To a stirred solution of 5-fluoro-2-nitrophenol (10 g, 63.7 mmol) in DMFA (100 mL) at room temperature was added potassium carbonate (10.54 g, 76.43 mmol) and benzyl bromide (7.56 mL, 63.7 mmol). The reaction mixture was subsequently stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic layer was washed with cold water (2 × 200 mL), a saline solution (100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 5% EtOAc / hexane as eluent to give the title compound (12.0 g, 76%). 1 H NMR (400MHz, DMSO-d6): δ8.04 (dd, J=5.8Hz, J=9.3Hz, 1H), 7.48-7.34 (m, 6H), 7.02-6.97 (m, 1H), 5.33 (s, 2H).

[0636] Step-b: Synthesis of 3-(benzyloxy)-4-nitrophenol

[0637] To a stirred solution of KOH (7.93 g, 141.7 mmol) in water (70 mL) at room temperature was added 2-(benzyloxy)-4-fluoro-1-nitrobenzene (7.0 g, 28.3 mmol), and the reaction mixture was stirred at 100 ° C for 30 h. The reaction mixture was cooled to room temperature, diluted with water (100 mL), acidified with 3N HCl and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 20% ​​EtOAc / hexane as eluent to give the title compound (2.0 g, 29%). 1H NMR (400MHz, DMSO-d6): δ10.88 (s, 1H), 7.90 (d, J=8.8Hz, 1H), 7.47 (t, J=7.4Hz, 2H), 7.41-7.39 (m, 2H), 7.3 6-7.32 (m, 1H), 6.69 (d, J=2.0Hz, 1H), 6.49 (dd, J=2.4Hz, J=9.3Hz, 1H), 5.25 (s, 2H); LC-MS: m / z244.0 (M-1).

[0638] Step-c: Synthesis of 2-(benzyloxy)-4-(difluoromethoxy)-1-nitrobenzene

[0639] To a stirred solution of 3-(benzyloxy)-4-nitrophenol (1.1 g, 4.49 mmol) in acetonitrile (6 mL) at 0°C was added water (6 mL) containing potassium hydroxide (5.02 g, 89.79 mmol) and diethyl phosphonate (bromodifluoromethyl) (1.58 mL, 8.98 mmol). The reaction mixture was stirred at room temperature for 1 h and diluted with water (100 mL). The reaction mixture was extracted with ethyl acetate (3 × 60 mL). The combined organic layers were washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash column chromatography using 10% EtOAc / hexane as eluent to give the title compound (1.2 g, 91%). 1 H NMR (400MHz, DMSO-d6): δ8.04 (d, J = 9.3Hz, 1H), 7.64-7.27 (m, 6H), 7.26 (d, J = 2.5Hz, 1H), 6.93 (dd, J = 2.5Hz, J = 8.8Hz, 1H), 5.34 (s, 2H).

[0640] Step-d: Synthesis of 2-amino-5-(difluoromethoxy)phenol

[0641] To a solution of 2-(benzyloxy)-4-(difluoromethoxy)-1-nitrobenzene (1.2 g, 4.07 mmol) in methanol (20 mL) was added 10% Pd / C (300 mg) under a nitrogen atmosphere. The reaction mixture was stirred under a hydrogen balloon for 16 h. The reaction mixture was filtered through a bed of celite and concentrated in vacuo to afford the title compound (600 mg, 84%); LC-MS: m / z 176.0 (M+1) + .

[0642] Step-e: Synthesis of 6-(difluoromethoxy)benzo[d]oxazole-2-thiol

[0643] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-(difluoromethoxy)phenol as a starting material (yield: 81%); 1 H NMR (400MHz, DMSO-d6): δ13.96 (bs, 1H), 7.49 (d, J = 2.0Hz, 1H), 7.26 (d, J = 8.3Hz, 1H), 7.21 (t, J = 73.2Hz, 1H), 7.13 (dd, J = 2.4Hz, J = 8.8Hz, 1H); LC-MS: m / z 218.0(M+1) + .

[0644] Step-f: Synthesis of 2-chloro-6-(difluoromethoxy)benzo[d]oxazole

[0645] The title compound was synthesized using the same procedure as in Example 32 step-d using 6-(difluoromethoxy)benzo[d]oxazole-2-thiol as the starting material and stirring for 2 h (yield: 82%); 1 H NMR (400MHz, DMSO-d6): δ7.80 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 2.5 Hz, 1H), 7.29-7.27 (m, 2H).

[0646] Step-g: Synthesis of ethyl 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0647] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(difluoromethoxy)benzo[d]oxazole as starting materials (yield: 27%); 1 HNMR (400MHz, DMSO-d6): δ12.20(bs,1H),8.23(d,J=1.0Hz,1H),7.88(dd,J=1.5Hz,J=8.4Hz,1H),7.53(d,J=8.3Hz,1H),7.46(d,J=8.3Hz ,1H),7.38-7.37(m,1H),7.19(s,1H),7.07-7.00(m,1H),4.33(q,J=7.0Hz,2H),3.64(s,3H),1.35(t,J=7.1Hz,3H); LC-MS: m / z403.0(M+1) + .

[0648] Step-h: Synthesis of 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0649] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 93%); 1 HNMR (400MHz, DMSO-d6): δ12.80(bs,1H),12.40(bs,1H),8.19(d,J=1.0Hz,1H),7.87(dd,J=1 .4Hz, J=8.3Hz, 1H), 7.52-7.46 (m, 2H), 7.38-7.00 (m, 3H), 3.64 (s, 3H); LC-MS: m / z375.0 (M+1) + .

[0650] Example 63. Synthesis of 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0651] The title compound was synthesized using the same procedure as compound 1i using 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethan-1-amine as starting materials; 1 H NMR (400MHz, DMSO-d6): δ12.25(bs,1H),8.45(t,J=5.2Hz,1H),8.07(s,1H),7.77(d,J=8.4Hz,1H),7.49-7.45 (m,2H),7.37(s,1H),7.18(s,1H),7.06-7.00(m,1H),3.63(s,3H),3.48-3.44(m,4H),3.28(s,3H); LC-MS: m / z 432.0(M+1) + .

[0652] Example 64. Synthesis of 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0653] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials; 1 HNMR (400MHz, DMSO-d6): δ12.30(bs,1H),8.38(t,J=5.6Hz,1H),8.08(s,1H),7.78(d,J=8.4Hz,1H),7.50(d,J=8.4Hz ,1H),7.46(d,J=8.4Hz,1H),7.38-7.00(m,3H),3.64(s,3H),3.53(t,J=6.4Hz,2H),3.35(q,J=6.0Hz,2H); LC-MS: m / z 418.0(M+1) + .

[0654] Example 65. Synthesis of N-(2-methoxyethyl)-1-methyl-2-((5-methylbenzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0655]

[0656] Conditions: a) 10% Pd / C, MeOH, H2, RT, 16 h; b) potassium ethylxanthate, EtOH, reflux, 16 h; c) K2CO3, MeI, ACN, 0°C-RT, 3 h; d) m-CPBA, DCM, 0°C-RT, 3 h; e) SOCl2, catalytic DMF, DCM, reflux, 4 h; f) 2-methoxyethan-1-amine, TEA, DCM, 0°C-RT, 16 h; g) 2 M methylamine in THF, DIPEA, DMF, 70°C, 24 h; h) 10% Pd / C, MeOH, H2, RT, 16 h; i) cyanogen bromide, THF, H2O, 50°C to 60°C, 16 h; j) NaH, 5-methyl-2-(methylsulfonyl)benzo[d]oxazole, 1,4-dioxane, RT, 16 h

[0657] Step-a: Synthesis of 2-amino-4-methylphenol

[0658] Under a nitrogen atmosphere, a 10% Pd / C (500 mg in 5 mL of methanol) slurry was added to a solution of 4-methyl-2-nitrophenol (1.75 g, 11.4 mmol) in methanol (15 mL). The reaction mixture was then stirred under a hydrogen balloon for 16 h. The reaction mixture was filtered through a celite bed and concentrated in vacuo to give the title compound (1.3 g, 93%). 1H NMR (400MHz, DMSO-d6): δ8.62 (bs, 1H), 6.49 (d, J=8.0Hz, 1H), 6.38 (s, 1H), 6.17 (d, J=8.0Hz, 1H), 4.36 (bs, 2H), 2.07 (s, 3H); LC-MS: m / z 124.2 (M+1) + .

[0659] Step-b: Synthesis of 5-methylbenzo[d]oxazole-2-thiol

[0660] To a solution of 2-amino-4-methylphenol (1.3 g, 10.5 mmol) in ethanol (15 mL) at room temperature was added potassium ethyl xanthate (3.7 g, 22.2 mmol), and the reaction mixture was refluxed for 16 h. The reaction mixture was concentrated in vacuo and diluted with cold water (30 mL) and acidified with 1N HCl. The resulting solid was filtered and dried in vacuo to give the title compound (1.3 g, 75%). 1 HNMR (400MHz, DMSO-d6): δ13.78 (s, 1H), 7.37 (d, J=8.0Hz, 1H), 7.07-7.05 (m, 2H), 2.36 (s, 3H); LC-MS: m / z 166.1 (M+1) + .

[0661] Step-c: Synthesis of 5-methyl-2-(methylthio)benzo[d]oxazole

[0662] To a solution of 5-methylbenzo[d]oxazole-2-thiol (1.3 g, 7.9 mmol) in acetonitrile (15 mL) at 0°C was added potassium carbonate (1.3 g, 9.4 mmol) and methyl iodide (0.53 mL, 8.7 mmol), and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated in vacuo and diluted with water (30 mL) and acidified with 1N HCl. The resulting solid was filtered and dried in vacuo to give the title compound (1.4 g, 99%); 1 H NMR (400MHz, DMSO-d6): δ7.50 (d, J=8.0Hz, 1H), 7.43 (s, 1H), 7.11 (d, J=8.4Hz, 1H), 2.74 (s, 3H), 2.40 (s, 3H); LC-MS: m / z 180.1 (M+1) + .

[0663] Step-d: Synthesis of 5-methyl-2-(methylsulfonyl)benzo[d]oxazole

[0664] To a solution of 5-methyl-2-(methylthio)benzo[d]oxazole (350 mg, 1.95 mmol) in DCM (10 mL) at 0° C. was added m-chloroperbenzoic acid (2.14 g, 6.8 mmol), and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with DCM (100 mL), washed with saturated sodium bicarbonate solution (2×30 mL), 1N aqueous sodium hydroxide solution (30 mL), water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the product (340 mg), which was used immediately in the next step without any further purification. 1 H NMR (400MHz, DMSO-d6): δ7.84-7.79 (m, 2H), 7.49 (d, J = 8.4Hz, 1H), 3.65 (s, 3H), 2.48 (s, 3H).

[0665] Step-e: Synthesis of 4-chloro-3-nitrobenzoyl chloride

[0666] To a solution of 4-chloro-3-nitrobenzoic acid (15.0 g, 74.6 mmol) in DCM (150 mL) at 10° C. was added thionyl chloride (15.9 mL, 223.8 mmol) and DMFA (1 mL), and the reaction mixture was refluxed for 4 h. The reaction mixture was concentrated in vacuo to give the product (15.0 g), which was used immediately in the next step without any further purification.

[0667] Step-f: Synthesis of 4-chloro-N-(2-methoxyethyl)-3-nitrobenzamide

[0668] To a solution of 2-methoxyethyl-1-amine (5.1 g, 68.2 mmol) in DCM (60 mL) at 0 ° C., triethylamine (20 mL, 138.6 mmol) was added and stirred for 10 min. Subsequently, a solution of 4-chloro-3-nitrobenzoyl chloride (15.0 g, 68.2 mmol) in DCM (50 mL) was added to the reaction mixture, and the contents were stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (150 mL) and water (100 mL). The organic layer was separated and washed with water (150 mL), brine (100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (18.5 g, 100%). 1 H NMR (400MHz, DMSO-d6): δ 8.88 (bs, 1H), 8.51 (d, J = 2.0Hz, 1H), 8.14 (dd, J = 2.0Hz, J = 8.4Hz, 1H), 7.90 (d, J = 8.4Hz, 1H), 3.49-3.42 (m, 4H), 3.30 (s, 3H).

[0669] Step-g: Synthesis of N-(2-methoxyethyl)-4-(methylamino)-3-nitrobenzamide

[0670] To a solution of 4-chloro-N-(2-methoxyethyl)-3-nitrobenzamide (18.0 g, 69.8 mmol) in DMFA (180 mL) at 0°C was added DIPEA (12.5 mL, 69.8 mmol) and 2M methylamine in THF (70 mL, 139.3 mmol). The reaction mixture was stirred at 70°C for 24 h. The reaction mixture was cooled to room temperature, diluted with water (200 mL) and extracted with EtOAc (2 x 250 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the product, which was used in the next step without further purification (17.0 g, 96%). 1 H NMR (400MHz, DMSO-d6): δ8.65(d,J=2.0Hz,1H),8.54(t,J=5.2Hz,1H),8.42(d,J=4.8Hz,1H),8.02(dd,J=1. 6Hz, J=9.2Hz, 1H), 7.03 (d, J=9.2Hz, 1H), 3.46-3.40 (m, 4H), 2.98 (d, J=3.2Hz, 3H), 3.26 (s, 3H); LC-MS: m / z 254.1(M+1) + .

[0671] Step-h: Synthesis of 3-amino-N-(2-methoxyethyl)-4-(methylamino)benzamide

[0672] To a solution of N-(2-methoxyethyl)-4-(methylamino)-3-nitrobenzamide (6.0 g, 23.7 mmol) in methanol (100 mL) was added a slurry of 10% Pd / C (1.2 g in 20 mL of methanol) under a nitrogen atmosphere. The reaction mixture was stirred under a hydrogen balloon for 16 h. The reaction mixture was filtered through a bed of celite and concentrated in vacuo to give the title compound (4.0 g, 75%). 1 H NMR (400MHz, DMSO-d6): δ7.88(t,J=5.2Hz,1H),7.11-7.06(m,2H),6.34(d,J=8.0Hz,1H),5 .07(bs,1H),4.54(bs,2H),3.42-3.34(m,4H)3.27(s,3H),2.75(d,J=2.8Hz,3H); LC-MS:m / z 224.2(M+1) + .

[0673] Step-i: Synthesis of 2-amino-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0674] To a solution of 3-amino-N-(2-methoxyethyl)-4-(methylamino)benzamide (2.0 g, 8.92 mmol) in THF (10 mL) and water (20 mL) at room temperature was added cyanogen bromide (1.04 g, 9.82 mmol), and the reaction mixture was stirred at 50° C. to 60° C. for 16 h. The reaction mixture was cooled to room temperature and basified with saturated sodium bicarbonate solution and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude product which was purified by flash chromatography using 5% methanol / DCM as eluent to give the title compound (1.3 g, 59%). 1 H NMR (400MHz, DMSO-d6): δ8.26(bs,1H),7.66(s,1H),7.48(d,J=7.6Hz,1H),7.14(d, J=8.0Hz,1H),6.52(bs,2H),3.51(s,3H),3.45-3.41(m,4H),3.26(s,3H); LC-MS:m / z 249.2(M+1) + .

[0675] Step-j: Synthesis of N-(2-methoxyethyl)-1-methyl-2-((5-methylbenzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0676] To a solution of 2-amino-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide (300 mg, 1.2 mmol) in 1,4-dioxane (5 mL) at 10° C. was added sodium hydride (60% dispersion in mineral oil) (96 mg, 2.4 mmol) and stirred for 10 min, followed by the addition of 5-methyl-2-(methylsulfonyl)benzo[d]oxazole (306 mg, 1.45 mmol) and stirred at room temperature for 16 h. The reaction mixture was quenched with cold water (20 mL) and extracted with ethyl acetate (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to give the crude product, which was purified by flash chromatography using 2% methanol / DCM as eluent to give the title compound (6 mg, 1%). 1H NMR (400MHz, DMSO-d6): δ12.2(bs,1H),8.45(t,J=5.2Hz,1H),8.08(d,J=1.6Hz,1H),7.76(dd,J=1.2Hz,J=8.0Hz,1H),7.47(d,J=8.4H z,1H),7.30(d,J=8.4Hz,1H),7.26(s,1H),6.93(d,J=7.6Hz,1H),3.62(s,3H),3.50-3.42(m,4H),3.29(s,3H),2.49(s,3H); LC-MS: m / z 380.2(M+1) + .

[0677] Examples 66 and 67. Synthesis of 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0678]

[0679] Conditions: a) 10% Pd / C, MeOH, H2, RT, 16 h; b) potassium ethylxanthate, EtOH, reflux, 16 h; c) K2CO3, MeI, ACN, RT, 16 h; d) m-CPBA, DCM, 0°C-RT, 4 h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; f) LiOH.H2O, THF, ethanol, water, 60°C, 16 h; g) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0680] Step-a: Synthesis of 2-amino-4-fluorophenol

[0681] The title compound was synthesized using the same procedure as in Example 32 step-b using 4-fluoro-2-nitrophenol as a starting material (yield: 91%); 1 H NMR (400MHz, DMSO-d6): δ8.88 (bs, 1H), 6.56-6.53 (m, 1H), 6.35 (dd, J=2.0Hz, J=10.4Hz, 1H), 6.13-6.08 (m, 1H), 4.78 (bs, 2H); LC-MS: m / z 128.1 (M+1) + .

[0682] Step-b: Synthesis of 5-fluorobenzo[d]oxazole-2-thiol

[0683] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-4-fluorophenol as a starting material (yield: 86%); 1 H NMR (400MHz, DMSO-d6): δ14.01 (bs, 1H), 7.55-7.51 (m, 1H), 7.15-7.08 (m, 2H); LC-MS: m / z 170.0 (M+i) + .

[0684] Step-c: Synthesis of 5-fluoro-2-(methylthio)benzo[d]oxazole

[0685] The title compound was synthesized using the same procedure as compound 1b (yield: 92%) using 5-fluorobenzo[d]oxazole-2-thiol as the starting material (stirring for 16 h); 1 H NMR (400MHz, DMSO-d6): δ7.69-7.65 (m, 1H), 7.53 (dd, J=2.4Hz, J=8.8Hz, 1H), 7.19-7.11 (m, 1H), 2.76 (s, 3H); LC-MS: m / z 184.1 (M+1) + .

[0686] Step-d: Synthesis of 5-fluoro-2-(methylsulfonyl)benzo[d]oxazole

[0687] The title compound was synthesized using the same procedure as compound 1c (yield: 99%) using 5-fluoro-2-(methylthio)benzo[d]oxazole as the starting material (stirring for 4 h); 1 H NMR (400MHz, DMSO-d6): δ8.05-8.01 (m, 1H), 7.94 (dd, J=2.4Hz, J=8.0Hz, 1H), 7.57-7.54 (m, 1H), 3.67 (s, 3H); LC-MS: m / z 216.0 (M+1) + .

[0688] Step-e: Synthesis of ethyl 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0689] The title compound was synthesized using the same procedure as compound 1g using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 5-fluoro-2-(methylsulfonyl)benzo[d]oxazole as starting materials (yield: 26%); 1H NMR (400MHz, DMSO-d6): δ12.34 (bs, 1H), 8.23 ​​(s, 1H), 7.88 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.49 (d, J=8.0Hz, 1H), 7.46-7.42 (m, 1 H), 7.23 (dd, J=2.4Hz, J=9.2Hz, 1H), 6.97-6.91 (m, 1H), 4.34 (q, J=6.4Hz, 2H), 3.64 (s, 3H), 1.36 (t, J=4.4Hz, 3H); LC-MS: m / z 355.2(M+1) + .

[0690] Step-f: Synthesis of 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0691] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 58%); 1 H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (s, 1H), 7.87 (d, J=8.4Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.45-7.42 (m, 1H), 7.24 (dd, J=2.4Hz, J=8.8Hz, 1H), 6.96-6.91 (m, 1H), 3.64 (s, 3H); LC-MS: m / z 327.2(M+1) + .

[0692] Step-g: Synthesis of 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0693] The title compound was synthesized using the same procedure as compound 1i using 2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 62%); 1HNMR (400MHz, DMSO-d6): δ12.2 (bs, 1H), 8.20 (s, 1H), 8.06 (s, 1H), 7.76 (d, J=8.4Hz, 1H), 7.44 (d, J=8.4Hz, 1H), 7.40 -7.37 (m, 1H), 7.20 (d, J=8.8Hz, 1H), 6.89 (t, J=10.0Hz, 1H), 3.63 (s, 3H), 3.50-3.45 (m, 4H), 3.09 (s, 3H); LC-MS: m / z 384.2(M+1) + .

[0694] Examples 68 and 69. Synthesis of 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0695]

[0696] Conditions: a) 10% Pd / C, MeOH, H2, RT, 16 h; b) potassium ethylxanthate, EtOH, reflux, 16 h; c) K2CO3, MeI, ACN, 0°C-RT, 5 h; d) m-CPBA, DCM, 0°C-RT, 4 h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; f) LiOH.H2O, THF, ethanol, water, 60°C, 16 h; g) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0697] Step-a: Synthesis of 2-amino-5-fluorophenol

[0698] The title compound was synthesized using the same procedure as in Example 32 step-b using 5-fluoro-2-nitrophenol as a starting material (yield: 92%); 1 H NMR (400MHz, DMSO-d6): δ9.5 (bs, 1H), 6.54-6.51 (m, 1H), 6.46 (dd, J = 2.8Hz, J = 10.0Hz, 1H), 6.37-6.32 (m, 1H); LC-MS: m / z 128.2 (M+1) + .

[0699] Step-b: Synthesis of 6-fluorobenzo[d]oxazole-2-thiol

[0700] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-fluorophenol as a starting material (yield: 89%); 1 H NMR (400MHz, DMSO-d6): δ13.94 (bs, 1H), 7.57 (dd, J=2.0Hz, J=8.4Hz, 1H), 7.25-7.22 (m, 1H), 7.19-7.14 (m, 1H); LC-MS: m / z 170.0 (M+1) + .

[0701] Step-c: Synthesis of 6-fluoro-2-(methylthio)benzo[d]oxazole

[0702] The title compound was synthesized using the same procedure as compound 1b (yield: 99%) using 6-fluorobenzo[d]oxazole-2-thiol as the starting material (stirring for 5 h); 1 H NMR (400MHz, DMSO-d6): δ7.67-7.63(m,2H),7.24-7.18(m,1H),2.75(s,3H); LC-MS: m / z 184.0(M+1) + .

[0703] Step-d: Synthesis of 6-fluoro-2-(methylsulfonyl)benzo[d]oxazole

[0704] The title compound was synthesized using the same procedure as compound 1c (yield: 95%) using 6-fluoro-2-(methylthio)benzo[d]oxazole as the starting material (stirring for 4 h); 1 H NMR (400MHz, DMSO-d6): δ8.08-8.02(m,1H),8.01-7.99(m,1H),7.56-7.46(m,1H),3.67(s,3H).

[0705] Step-e: Synthesis of ethyl 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0706] The title compound was synthesized using the same procedure as compound 1g using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 6-fluoro-2-(methylsulfonyl)benzo[d]oxazole as starting materials (yield: 28%); 1H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.23(d,J=1.6Hz,1H),7.88(dd,J=2.0Hz,J=8.4Hz,1H),7.52(d,J=8.4Hz ,1H),7.45-7.41(m,2H),7.10-7.04(m,1H),4.33(q,J=6.8Hz,2H),3.64(s,3H),1.35(t,J=7.2Hz,3H); LC-MS:m / z 355.1(M+1) + .

[0707] Step-f: Synthesis of 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0708] To a stirred solution of ethyl 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (45 mg, 0.13 mmol) in a solvent mixture of THF (1 mL), ethanol (1 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (10 mg, 0.25 mmol). The reaction mixture was heated at 60 ° C with stirring for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water (15 mL) and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (30 mg, 72%); 1 H NMR (400MHz, DMSO-d6): δ12.8(bs,1H),12.3(bs,1H)8.19(d,J=1.6Hz,1H),7.87(dd,J=1.6Hz,J= 8.4Hz, 1H), 7.50 (d, J=8.8Hz, 1H), 7.46-7.41 (m, 2H), 7.09-7.03 (m, 1H), 3.63 (s, 3H); LC-MS: m / z 327.05(M+1) + .

[0709] Step-g: Synthesis of 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0710] To a stirred solution of 2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (30 mg, 0.09 mmol) in DMFA (2 mL) at 0 ° C was added N-ethyldiisopropylamine (0.03 mL, 0.18 mmol) and diphenylphosphoryl azide (0.02 mL, 0.09 mmol). The reaction mixture was stirred for 30 min, followed by the addition of 2-methoxyethylamine (6 mg, 0.09 mmol), and the reaction mixture was then stirred at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (6 mL) and stirred for 15 min. The resulting solid was filtered, washed with diethyl ether and dried in vacuo to give the title compound (20 mg, 58%) as a white solid; 1 H NMR (400MHz, DMSO-d6): δ12.2 (bs, 1H), 8.45 (t, J=5.2Hz, 1H), 8.07 (d, J=1.2Hz, 1H), 7.75 (dd, J=1.6Hz, J=8.8Hz , 1H), 7.49-7.40(m, 3H), 7.08-7.03(m, 1H), 3.63(s, 3H), 3.50-3.43(m, 4H), 3.39(s, 3H); LC-MS: m / z384.1(M+1) + .

[0711] Examples 70 and 71. Synthesis of 6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 6-fluoro-N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0712]

[0713] Conditions: a) Cyanogen bromide, THF, H2O, 60°C, 16h; b) NaH, 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16h; c) LiOH.H2O, THF, MeOH, H2O, 60°C, 16h; d) 2-Methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0714] Step-a: Synthesis of methyl 2-amino-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0715] The title compound was synthesized using the same procedure as compound 1f, using methyl 5-amino-2-fluoro-4-(methylamino)benzoate as the starting material and heating to 60°C for 16 h. (Yield: 89%) 1 H NMR (400MHz, DMSO-d6): δ7.54 (d, J=6.4Hz, 1H), 7.16 (d, J=11.6Hz, 1H), 6.69 (bs, 2H), 3.80 (s, 3H), 3.51 (s, 3H); LC-MS: m / z224.1 (M+1) + .

[0716] Step-b: Synthesis of methyl 6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0717] The title compound was synthesized using the same procedure as compound 1g using methyl 2-amino-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole as starting materials (yield: 18%); 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.10(d,J=6.0Hz,1H),7.95-7.51(m,3H),7.22(d,J=8.4Hz,1H),3.87(s,3H),3.61(s,3H); LC-MS: m / z 425.1(M+1) + .

[0718] Step-c: Synthesis of 6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0719] The title compound was synthesized using the same procedure as compound 1h (yield: 66%) using methyl 6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as a starting material and THF, methanol, and water (2:2:1) as solvents; 1 H NMR (400MHz, DMSO-d6): δ13.0(bs,1H),12.3(bs,1H),8.08(d,J=6.0Hz,1H),7.59(s ,1H),7.53-7.49(m,2H),7.22(d,J=7.2Hz,1H),3.61(s,3H); LC-MS:m / z411.1(M+1) + .

[0720] Step-d: Synthesis of 6-fluoro-N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)-benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0721] The title compound was synthesized using the same procedure as compound 1i using 6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 48%); 1 HNMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.18(d,J=4.0Hz,1H),7.86(d,J=6.4Hz,1H),7.58(s,1H) ,7.52-7.49(m,2H),7.21(d,J=9.2Hz,1H),3.61(s,3H),3.47-3.44(m,4H),3.29(s,3H); LC-MS:m / z 468.1(M+1) + .

[0722] Example 72. Synthesis of 2-(Benzo[d]oxazol-2-ylamino)-6-fluoro-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0723]

[0724] Conditions: a) NaH, 2-chlorobenzo[d]oxazole, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, MeOH, H2O, 60°C, 16h; g) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0725] Step-a: Synthesis of methyl 2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0726] The title compound was synthesized using the same procedure as in Example 32 step-e using methyl 2-amino-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chlorobenzo[d]oxazole as starting materials (yield: 66%); 1H NMR (400MHz, DMSO-d6): δ12.25 (bs, 1H), 8.09 (d, J=6.0Hz, 1H), 7.55-7.44 (m, 3H), 7. 24-7.22(m, 1H), 7.17-7.12(m, 1H), 3.86(s, 3H), 3.60(s, 3H); LC-MS: m / z341.0(M+1) + .

[0727] Step-b: Synthesis of 2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0728] The title compound was synthesized using the same procedure as compound 1h (yield: 75%) using methyl 2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate as a starting material and methanol, THF, and water (2:2:1) as solvents; 1 H NMR (400MHz, DMSO-d6): δ12.80 (bs, 2H), 8.07 (d, J=6.8Hz, 1H), 7.50-7.44 (m, 3H), 7.22 (t, J=6.8Hz, 1H), 7.15-7.11 (m, 1H), 3.60 (s, 3H); LC-MS: m / z 327.0(M+1) + .

[0729] Step-c: Synthesis of 2-(benzo[d]oxazol-2-ylamino)-6-fluoro-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0730] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials (yield: 49%); 1 H NMR (400MHz, DMSO-d6): δ12.20 (bs, 1H), 8.15 (bs, 1H), 7.86 (d, J=6.4Hz, 1H), 7.50-7.47 (m, 2H), 7.43 (d, J=8.0Hz, 1H ), 7.23-7.19(m, 1H), 7.14-7.10(m, 1H), 4.60(bs, 1H), 3.60(s, 3H), 3.57-3.51(m, 4H), 3.48-3.31(m, 4H); LC-MS: m / z 414.05(M+1) + .

[0731] Example 73. Synthesis of 2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0732]

[0733] Conditions: a) 1,1′-thiocarbonyldiimidazole, ACN, 60°C, 16h; b) 4-fluorobenzene-1,2-diamine, EDC.HCl, DMF, 100°C, 16h; c) LiOH.H2O, THF, MeOH, H2O, 60°C, 16h

[0734] Step-a: Synthesis of ethyl 2-(1H-imidazole-1-carbosulfamido)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0735] To a solution of ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (1.0 g, 4.5 mmol) in acetonitrile (20 mL) at room temperature was added 1,1′-thiocarbonyldiimidazole (1.06 g, 5.9 mmol) and stirred at 60° C. for 16 h. The reaction mixture was cooled to room temperature and stirred for 30 min. The resulting solid was filtered and dried under vacuum to give the title compound (1.1 g, 73%), which was used in the next step without further purification. 1 H NMR (400MHz, DMSO-d6): δ13.4 (bs, 1H), 8.68 (s, 1H), 8.41 (d, J=1.6Hz, 1H), 8.03 (s, 1H), 7.99 (dd, J=1.2Hz, J=8. 8Hz, 1H), 7.75 (d, J=8.4Hz, 1H), 7.01 (d, J=1.2Hz, 1H), 4.35 (q, J=7.2Hz, 2H), 3.79 (s, 3H), 1.36 (t, J=6.8Hz, 3H).

[0736] Step-b: Synthesis of ethyl 2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-5-carboxylate

[0737] To a stirred solution of ethyl 2-(1H-imidazole-1-carbosulfamido)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (900 mg, 2.74 mmol) in DMFA (15 mL) was added EDC·HCl (1.05 g, 5.47 mmol) and heated to 60° C. for 10 min. The reaction mixture was cooled to room temperature before 4-fluorobenzene-1,2-diamine (345 mg, 2.74 mmol) was added and heated at 100° C. for 16 h. The reaction mixture was cooled to room temperature, diluted with water (30 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue that was purified by flash chromatography using 0.5% methanol / DCM as eluent to give the title compound (200 mg, 21%); LC-MS: m / z 354.2 (M+1) + .

[0738] Step-c: Synthesis of 2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0739] To a stirred solution of ethyl 2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-5-carboxylate (200 mg, 0.57 mmol) in a solvent mixture of THF (5 mL), methanol (5 mL) and water (5 mL) was added lithium hydroxide monohydrate (119 mg, 2.83 mmol). The reaction mixture was heated at 60 ° C with stirring for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water (15 mL) and acidified with 1N HCl to give a solid, which was filtered and dried under vacuum to give the title compound (150 mg, 81%); 1 H NMR (400MHz, DMSO-d6): δ12.2 (bs, 2H), 8.04 (s, 1H), 7.75 (d, J=8.0Hz, 1H), 7.32- 7.26 (m, 2H), 7.13 (d, J=8.4Hz, 1H), 6.88 (t, J=8.0Hz, 1H), 3.62 (s, 3H); LC-MS: m / z 326.05(M+1) + .

[0740] Example 74. Synthesis of 1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0741]

[0742] Condition: a)N 1 , N 1 a) dimethylethane-1,2-diamine, DIPEA, DMF, 60°C, 16 h; b) 10% Pd / C, MeOH, H2, RT, 16 h; c) cyanogen bromide, THF, H2O, 60°C, 16 h; d) NaH, 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16 h; e) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h

[0743] Step-a: Synthesis of ethyl 4-((2-(dimethylamino)ethyl)amino)-3-nitrobenzoate

[0744] To a solution of ethyl 4-chloro-3-nitrobenzoate (5.0 g, 21.8 mmol) in DMFA (40 mL) at room temperature were added ethyl 4-chloro-3-nitrobenzoate (9.5 mL, 54.4 mmol) and N 1 , N 1 -dimethylethane-1,2-diamine (2.87 g, 32.7 mmol) was added and the reaction mixture was stirred at 60°C for 16 h. The reaction mixture was cooled to room temperature, diluted with cold water (250 mL) and stirred for 10 min. The precipitated solid was filtered and dried in vacuo to give the title compound (4.8 g, 92%). 1 H NMR (400MHz, DMSO-d6): δ8.65 (t, J=4.4Hz, 1H), 8.62 (d, J=2.0Hz, 1H), 7.79 (dd, J=2.0Hz, J=8.8Hz, 1H), 7.13 (d, J =9.2Hz, 1H), 4.32-4.26(m, 2H), 3.47-3.43(m, 2H), 2.57-2.52(m, 2H), 2.22(s, 6H), 1.33-1.28(m, 3H); LC-MS: m / z 282.2(M+1) + .

[0745] Step-b: Synthesis of ethyl 3-amino-4-((2-(dimethylamino)ethyl)amino)benzoate

[0746] The title compound was synthesized using the same procedure as compound 1e, using ethyl 4-((2-(dimethylamino)ethyl)amino)-3-nitrobenzoate as the starting material and stirring for 16 h. (Yield: 67%). 1H NMR (400MHz, DMSO-d6): δ7.23 (dd, J=2.0Hz, J=8.0Hz, 1H), 7.18 (d, J=2.0Hz, 1H), 6.45 (d, J=8.4Hz, 1H), 5.09 (bs, 1H), 4 .68 (s, 2H), 4.18 (q, J=6.8Hz, 2H), 3.19-3.15 (m, 2H), 2.49-2.46 (m, 2H), 2.18 (s, 6H), 1.26 (t, J=6.8Hz, 3H); LC-MS: m / z 252.2(M+1) + .

[0747] Step-c: Synthesis of ethyl 2-amino-1-(2-(dimethylamino)ethyl)-1H-benzo[d]imidazole-5-carboxylate

[0748] The title compound was synthesized using the same procedure as compound 1f, using ethyl 3-amino-4-((2-(dimethylamino)ethyl)amino)benzoate as the starting material and heating to 60°C for 16 h. (Yield: 26%); LC-MS: m / z 277.2 (M+1) + .

[0749] Step-d: Synthesis of ethyl 1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0750] The title compound was synthesized using the same procedure as compound 1g using ethyl 2-amino-1-(2-(dimethylamino)ethyl)-1H-benzo[d]imidazole-5-carboxylate and 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole as starting materials (yield: 26%); 1 H NMR (400MHz, DMSO-d6): δ12.4 (bs, 1H), 8.25 (d, J=1.2Hz, 1H), 7.87 (dd, J=1.2Hz, J=8.4Hz, 1H), 7.59-7.57 (m, 2H), 7.51 (d, J =8.4Hz, 1H), 7.22 (d, J = 8.8Hz, 1H), 4.36-4.26 (m, 4H), 2.68 (q, J = 6.8Hz, 2H), 2.22 (s, 6H), 1.35 (t, J = 6.8Hz, 3H); LC-MS: m / z 478.1(M+1) + .

[0751] Step-e: Synthesis of 1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0752] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 18%); 1 H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.3 (bs, 1H), 8.20 (d, J=1.6Hz, 1H), 7.86 (dd, J=1.6Hz, J=8.4Hz, 1H) , 7.59-7.51 (m, 3H), 7.21 (d, J=8.4Hz, 1H), 4.27 (t, J=6.4Hz, 2H), 2.79-2.66 (m, 2H), 2.21 (s, 6H); LC-MS: m / z 450.1(M+1) + .

[0753] Examples 75 and 76. Synthesis of 1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of N,1-bis(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0754]

[0755] Conditions: a) 2-methoxyethane-1-amine, DMSO, 60°C, 16h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) cyanogen bromide, THF, H2O, 60°C, 16h; d) 1,1′-thiocarbonyldiimidazole, ACN, 60°C, 16h; e) 4-(trifluoromethoxy)benzene-1,2-diamine, EDC.HCl, DMF, 100°C, 16h; f) LiOH.H2O, THF, MeOH, H2O, 60°C, 16h; g) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0756] Step-a: Synthesis of ethyl 4-((2-methoxyethyl)amino)-3-nitrobenzoate

[0757] To a solution of ethyl 4-chloro-3-nitrobenzoate (10 g, 43.7 mmol) in DMSO (100 mL) at room temperature was added 2-methoxyethyl-1-amine (7.5 mL g, 87.3 mmol), and the reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with cold water (250 mL) and stirred for 1 h. The precipitated solid was filtered and dried in vacuo to give the title compound (12 g, 100%); 1 H NMR (400MHz, DMSO-d6): δ8.61(d,J=2.4Hz,1H),8.54(s,1H),7.97(dd,J=1.6Hz,J=8.8Hz,1H),7.18( d, J=9.2Hz, 1H), 4.29 (q, J=6.8Hz, 2H), 3.60 (bs, 4H), 3.31 (s, 3H), 1.31 (t, J=6.8Hz, 3H); LC-MS: m / z 269.1(M+1) + .

[0758] Step-b: Synthesis of ethyl 3-amino-4-((2-methoxyethyl)amino)benzoate

[0759] The title compound was synthesized using the same procedure as compound 1e using ethyl 4-((2-methoxyethyl)amino)-3-nitrobenzoate as the starting material (yield: 75%); 1 H NMR (400MHz, DMSO-d6): δ7.22-7.17(m,2H),6.46(d,J=8.4Hz,1H),5.20(t,J=7.6Hz,1H),4.74(bs,2 H), 4.18 (q, J = 7.2Hz, 2H), 3.53 (t, J = 5.6Hz, 2H), 3.30-3.26 (m, 5H), 1.26 (t, J = 7.6Hz, 3H); LC-MS: m / z 239.1(M+1) + .

[0760] Step-c: Synthesis of ethyl 2-amino-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate

[0761] The title compound was synthesized using the same procedure as compound 1f, using ethyl 3-amino-4-((2-methoxyethyl)amino)benzoate as the starting material and heating to 60°C for 16 h. (Yield: 73%); LC-MS: m / z 264.1 (M+1) + .

[0762] Step-d: Synthesis of ethyl 2-(1H-imidazole-1-carbosulfamido)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate

[0763] The title compound was synthesized using the same procedure as compound 12a using ethyl 2-amino-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate and 1,1′-thiocarbonyldiimidazole as starting materials (yield: 60%); 1 H NMR (400MHz, DMSO-d6): δ13.5(bs,1H),8.66(s,1H),8.42(s,1H),8.01-7.97(m,2H),7.78(d,J=8.8Hz,1H),7.01 (s, 1H), 4.54 (t, J = 4.8Hz, 2H), 4.35 (q, J = 7.2Hz, 2H), 3.74 (t, J = 4.8Hz, 2H), 3.20 (s, 3H), 1.35 (t, J = 7.2Hz, 3H).

[0764] Step-e: Synthesis of ethyl 1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0765] The title compound was synthesized using the same procedure as compound 12b, using ethyl 2-(1H-imidazole-1-carbosulfamido)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate and 4-(trifluoromethoxy)benzene-1,2-diamine as starting materials (yield: 38%); LC-MS: m / z 464.0 (M+1) + .

[0766] Step-f: Synthesis of 1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0767] The title compound was synthesized using the same procedure as compound 1h, using ethyl 1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material and THF, methanol, and water as solvents. (Yield: 65%); 1H NMR (400MHz, DMSO-d6): δ12.3(bs,3H),8.08(d,J=1.2Hz,1H),7.74(dd,J=1.6Hz,J=8.4Hz,1H),7.41(d,J=8.4Hz,1 H),7.36-7.31(m,2H),7.02(d,J=8.0Hz,1H),4.32(t,J=5.2Hz,2H),3.71(t,J=6.0Hz,2H),3.25(s,3H); LC-MS:m / z 436.0(M+1) + .

[0768] Step-g: Synthesis of N,1-bis(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0769] The title compound was synthesized using the same procedure as compound 1i using 1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 2%); 1 H NMR (400MHz, DMSO-d6): δ12.23 (bs, 1H), 8.26-8.23 (m, 1H), 7.58-7.53 (m, 1H), 7.43-7.38 (m, 1H), 7.30-6 .37(m, 5H), 4.50-4.48(m, 2H), 3.86-3.80(m, 2H), 3.32(s, 3H), 3.27-3.25(m, 4H), 3.16(s, 3H); LC-MS: m / z 493.1(M+1) + .

[0770] Examples 77 and 78. Synthesis of 1-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of N,1-bis(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0771]

[0772] Conditions: a) NaH, 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, 0°C-90°C, 16h; b) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0773] Step-a: Synthesis of 1-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0774] To a solution of ethyl 2-amino-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate (200 mg, 0.76 mmol) in 1,4-dioxane (10 mL) at 0°C was added sodium hydride (60% dispersion in mineral oil) (107 mg, 2.66 mmol) and stirred for 10 min. 2-Chloro-6-(trifluoromethoxy)benzo[d]oxazole (270 mg, 1.14 mmol) was added to the reaction mixture and stirred at 90°C for 16 h. The reaction mixture was cooled to room temperature. The solvent was evaporated and the residue was diluted with cold water (20 mL) and acidified with 1N HCl. The reaction mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography using 2% methanol / DCM as eluent to give the title compound (70 mg, 21%); 1 H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.3 (bs, 1H), 8.20 (d, J=1.6Hz, 1H), 7.86 (dd, J=1.2Hz, J=8.0Hz, 1H), 7.58-7.52 (m, 3H), 7.22 (d, J=7.2Hz, 1H), 4.36 (t, J=4.8Hz, 2H), 3.74 (t, J=5.6Hz, 2H), 3.24 (s, 3H); LC-MS: m / z 437.05(M+1) + .

[0775] Step-b: Synthesis of N,1-bis(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0776] The title compound was synthesized using the same procedure as compound 1i using 1-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 2%); 1H NMR (400MHz, DMSO-d6): δ12.30 (bs, 1H), 8.45 (bs, 1H), 8.08 (s, 1H), 7.75 (d, J=8.4Hz, 1H), 7.56 (s, 1H), 7.53-7.50 (m, 2H), 7.21 (d , J=8.4Hz, 1H), 4.35 (t, J=4.8Hz, 2H), 3.73 (t, J=5.2Hz, 2H), 3.48-3.43 (m, 4H), 3.28 (s, 3H), 3.24 (s, 3H); LC-MS: m / z494.15 (M+1) + .

[0777] Examples 79 and 80. Synthesis of 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzoimidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0778]

[0779] Conditions: a) Cyanogen bromide, THF, H2O, 60°C, 16h; b) NaH, 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16h; c) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; d) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0780] Step-a: Synthesis of ethyl 2-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate

[0781] The title compound was synthesized using the same procedure as compound 1f, using ethyl 3-amino-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate as the starting material and heating to 60°C. (Yield: 92%); 1H NMR (400MHz, DMSO-d6): δ7.71 (s, 1H), 7.55 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.41 (d, J=8.0Hz, 1H), 6.65 (bs, 2H), 4.50-4.48 (m, 1H), 4.28 (q , J=7.2Hz, 2H), 4.05-4.01 (m, 2H), 3.47 (t, J=11.2Hz, 2H), 2.36-2.32 (m, 2H), 1.72 (d, J=10.4Hz, 2H), 1.31 (t, J=6.8Hz, 3H); LC-MS: m / z 290.1(M+1) + .

[0782] Step-b: Synthesis of ethyl 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)-benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0783] To a solution of ethyl 2-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate (100 mg, 0.35 mmol) in 1,4-dioxane (2 mL) at room temperature was added sodium hydride (60% dispersion in mineral oil) (34 mg, 0.86 mmol) and stirred for 10 min. 2-Chloro-6-(trifluoromethoxy)benzo[d]oxazole (99 g, 0.41 mmol) was added to the reaction mixture and stirred at room temperature for 16 h. The reaction mixture was concentrated and diluted with cold water (30 mL) and stirred at room temperature for 5 to 10 min. The resulting solid was filtered, dried under vacuum and purified by flash chromatography using 100% DCM as eluent to give the title compound (60 mg, 35%). 1 H NMR (400MHz, DMSO-d6): δ12.40(bs,1H),8.29(d,J=1.6Hz,1H),7.86(dd,J=1.2Hz,J=8.0 Hz,1H),7.74(d,J=8.4Hz,1H),7.58(d,J=1.6Hz,1H),7.52(d,J=8.4Hz,1H),7.21(dd,J=1 .6Hz,J=8.8Hz,1H),4.97-4.93(m,1H),4.33(q,J=7.6Hz,2H),4.07-4.03(m,2H),3.56(t, J=9.2Hz,2H),2.63-2.55(m,2H),1.79(d,J=9.2Hz,2H),1.35(t,J=6.8Hz,3H); LC-MS:m / z 491.1(M+1) + .

[0784] Step-e: Synthesis of 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0785] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 71%); 1 H NMR (400MHz, DMSO-d6): δ12.8(bs,1H),12.50(bs,1H),8.24(d,J=1.6Hz,1H),7.86 (dd,J=1.2Hz,J=8.8Hz,1H),7.71(d,J=8.0Hz,1H),7.58(d,J=1.2Hz,1H),7.53(d, J=8.8Hz,1H),7.22(d,J=10.4Hz,1H),5.01-4.92(m,1H),4.05(dd,J=4.0Hz,J=11. 2Hz, 2H), 3.58-3.53 (m, 2H), 2.67-2.57 (m, 2H), 1.78 (d, J = 10.0Hz, 2H); LC-MS: m / z 463.1(M+1) + .

[0786] Step-f: Synthesis of N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide The title compound was synthesized using the same procedure as compound 1i using 1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 76%); 1H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.48(t,J=5.2Hz,1H),8.13(d,J=1.2Hz,1H),7 .76(dd,J=1.6Hz,J=8.8Hz,1H),7.68(d,J=8.0Hz,1H),7.57(s,1H),7.52(d,J=8.4Hz, 1H),7.21(d,J=8.8Hz,1H),4.98-4.92(m,1H),4.07-4.04(m,2H),3.56(t,J=1.2Hz,2H ),3.49-3.44(m,4H),3.28(s,3H),2.67-2.58(m,2H),1.78(d,J=9.6Hz,2H); LC-MS:m / z 520.2(M+1) + .

[0787] Example 81. Synthesis of N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0788]

[0789] Conditions: a) 1,1′-thiocarbonyldiimidazole, ACN, 60°C, 16h; b) 4-(trifluoromethoxy)benzene-1,2-diamine, EDC.HCl, DMF, 100°C, 16h; c) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; d) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0790] Step-a: Synthesis of ethyl 2-(1H-imidazole-1-carbosulfamido)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate

[0791] The title compound was synthesized using the same procedure as compound 12a using ethyl 2-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate and 1,1′-thiocarbonyldiimidazole as starting materials (yield: 72%); 1HNMR (400MHz, DMSO-d6): δ13.50 (bs, 1H), 8.64 (s, 1H), 8.43 (s, 1H), 7.98 (d, J=4.4Hz, 1H), 7.96-7.94 (m, 1H), 7.09 (s, 1H), 6.72 (bs, 1H), 5. 05-5.00 (m, 1H), 4.36-4.26 (m, 2H), 4.06-4.02 (m, 2H), 3.60 (t, J=11.6Hz, 2H), 2.54-2.50 (m, 2H), 1.86 (d, J=9.6Hz, 2H), 1.37-1.33 (m, 3H).

[0792] Step-b: Synthesis of ethyl 1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0793] The title compound was synthesized using the same procedure as compound 12b using ethyl 2-(1H-imidazole-1-carbosulfamido)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate and 4-(trifluoromethoxy)benzene-1,2-diamine as starting materials (yield: 46%); 1 H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.12 (d, J=6.4Hz, 1H), 7.95 (s, 1H), 7.74 (dd, J=2 .0Hz, J=8.4Hz, 1H), 7.57 (d, J=8.4Hz, 1H), 7.37-7.32 (m, 2H), 7.06 (dd, J=1.6Hz, J=8.4Hz , 1H), 4.97-4.90 (m, 1H), 4.32 (q, J=6.8Hz, 2H), 4.08-4.05 (m, 2H), 3.51 (t, J=11.6Hz, 2H ), 2.67-2.55 (m, 2H), 1.75 (d, J=9.6Hz, 2H), 1.07 (t, J=8.4Hz, 3H); LC-MS: m / z490.0 (M+1) + .

[0794] Step-c: Synthesis of 1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0795] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 55%); 1 H NMR (400MHz, DMSO-d6): δ12.7 (bs, 3H), 8.04 (s, 1H), 7.80 (d, J=8.4Hz, 1H), 7.65 (d, J=8.8Hz, 1H), 7.42-7.35 (m, 2H), 7.12 ( d, J=8.0Hz, 1H), 4.93 (bs, 1H), 4.08-4.05 (m, 2H), 3.54-3.48 (m, 2H), 2.61-2.58 (m, 2H), 1.77 (d, J=10.0Hz, 2H); LC-MS: m / z 462.15(M+1) + .

[0796] Step-d: Synthesis of N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0797] The title compound was synthesized using the same procedure as compound 1i using 1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 42%); 1 H NMR (400MHz, DMSO-d6): δ12.2 (bs, 2H), 8.37 (t, J=5.6Hz, 1H), 8.02 (d, J=1.6Hz, 1H), 7.64 (dd, J=1.2Hz, J=8.0Hz, 1H), 7.52 (d, J=8.8Hz, 1H), 7.53-7.3 0 (m, 2H), 7.03 (d, J=8.0Hz, 1H), 4.98-4.89 (m, 1H), 4.08-4.05 (m, 2H), 3.51 -3.43(m, 6H), 3.28(s, 3H), 2.67-2.58(m, 2H), 1.75-1.73(m, 2H); LC-MS: m / z 519.1(M+1) + .

[0798] Examples 82 and 83. Synthesis of 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0799]

[0800] Conditions: a) 4-chlorobenzene-1,2-diamine, EDC.HCl, DMF, 100°C, 16h; b) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; c) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0801] Step-a: Synthesis of ethyl 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzoimidazole-5-carboxylate

[0802] The title compound was synthesized using the same procedure as compound 12b using ethyl 2-(1H-imidazole-1-carbosulfamido)-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 4-chlorobenzene-1,2-diamine as starting materials (yield: 24%); 1 HNMR (400MHz, DMSO-d6): δ12.2 (bs, 2H), 8.10 (s, 1H), 7.76 (d, J=8.4Hz, 1H), 7.40-7.29 (m, 3H), 7.0 9 (dd, J=1.2Hz, J=8.4Hz, 1H), 4.31 (q, J=6.8Hz, 2H), 3.64 (s, 3H), 1.35 (t, J=6.8Hz, 3H); LC-MS: m / z 370.05(M+1) + .

[0803] Step-b: Synthesis of 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0804] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 84%); 1H NMR (400MHz, DMSO-d6): 612.3 (bs, 3H), 8.07 (s, 1H), 7.76 (d, J=8.0Hz, 1H), 7.37-7.29 (m, 3H), 7.07 (d, J=7.6Hz, 1H), 3.63 (s, 3H); LC-MS: m / z 342.0(M+1) + .

[0805] Step-c: Synthesis of 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazol-5-carboxamide

[0806] The title compound was synthesized using the same procedure as compound 1i using 2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 49%); 1 H NMR (400MHz, DMSO-d6): δ12.2 (bs, 2H), 8.36 (s, 1H), 7.99 (s, 1H), 7.66 (d, J=7.2Hz, 1H), 7.35 (d, J=8.4H z, 1H), 7.30-7.28 (m, 2H), 7.06 (d, J=8.4Hz, 1H), 3.62 (s, 3H), 3.48-3.43 (m, 4H), 3.17 (s, 3H); LC-MS: m / z 399.1(M+1) + .

[0807] Examples 84 and 85. Synthesis of 1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 1-ethyl-N-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0808]

[0809] Conditions: a) aqueous ethylamine, DMF, 60°C, 16 h; b) 10% Pd / C, MeOH, H2, RT, 16 h; c) cyanogen bromide, THF, H2O, 60°C, 16 h; d) NaH, 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16 h; e) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h; f) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0810] Step-a: Synthesis of ethyl 4-(ethylamino)-3-nitrobenzoate

[0811] To a solution of ethyl 4-chloro-3-nitrobenzoate (4.0 g, 17.5 mmol) in DMFA (100 mL) at room temperature was added ethylamine (2.24 mL (70% aqueous solution), 34.9 mmol), and the reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with cold water (200 mL) and stirred for 15 min. The precipitated solid was filtered and dried in vacuo to give the title compound (3.0 g, 63%); 1 H NMR (400MHz, DMSO-d6): δ8.62 (d, J=2.0Hz, 1H), 8.51 (t, J=5.2Hz, 1H), 7.97 (dd, J=2.0Hz, J=9.2Hz, 1H), 7.14 (d, J=9.2 Hz, 1H), 4.29 (q, J=6.8Hz, 2H), 3.49-3.42 (m, 2H), 1.33 (t, J=5.2Hz, 3H), 1.23 (t, J=7.2Hz, 3H); LC-MS: m / z239.0 (M+1) + .

[0812] Step-b: Synthesis of ethyl 3-amino-4-(ethylamino)benzoate

[0813] The title compound was synthesized using the same procedure as compound 1e using ethyl 4-(ethylamino)-3-nitrobenzoate as the starting material (yield: 79%), and the crude compound was used in the next step without any purification.

[0814] Step-c: Synthesis of ethyl 2-amino-1-ethyl-1H-benzo[d]imidazole-5-carboxylate

[0815] The title compound was synthesized using the same procedure as compound 1f using ethyl 3-amino-4-(ethylamino)benzoate as the starting material (yield: 74%); 1 H NMR (400MHz, DMSO-d6): δ7.70(s,1H),7.58(dd,J=1.6Hz,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),6.66(bs,2 H), 4.27 (q, J = 7.2Hz, 2H), 4.05 (q, J = 6.8Hz, 2H), 1.31 (t, J = 6.8Hz, 3H), 1.20 (t, J = 7.6Hz, 3H); LC-MS: m / z 234.1(M+1) + .

[0816] Step-d: Synthesis of ethyl 1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0817] The title compound was synthesized using the same procedure as compound 1g using ethyl 2-amino-1-ethyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting materials (yield: 54%); 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.25(d,J=1.6Hz,1H),7.88(dd,J=2.0Hz,J=8.8Hz,1H),7.60-7.57(m,2H),7.51(d, J=8.8Hz,1H),7.22(dd,J=1.6Hz,J=8.8Hz,1H),4.33(q,J=7.2Hz,2H),4.22(q,J=7.6Hz,2H),1.37-1.31(m,6H); LC-MS:m / z 435.05(M+1) + .

[0818] Step-e: Synthesis of 1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0819] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 75%); 1 HNMR (400MHz, DMSO-d6): δ12.8(bs,1H),12.3(bs,1H),8.21(s,1H),7.88(d,J=8.0Hz,1H),7.58-7.57(m, 2H), 7.52 (d, J = 8.4Hz, 1H), 7.20 (d, J = 9.6Hz, 1H), 4.22 (q, J = 7.6Hz, 2H), 1.33 (t, J = 6.8Hz, 3H); LC-MS: m / z 407.0(M+1) + .

[0820] Step-f: Synthesis of 1-ethyl-N-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0821] The title compound was synthesized using the same procedure as compound 1i using 1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 58%); 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.46(s,1H),8.09(s,1H),7.77(d,J=8.4Hz,1H),7.56-7.50(m,3H),7 .21(d,J=8.0Hz,1H),4.22(q,J=7.6Hz,2H),3.48-3.44(m,4H),3.28(s,3H),1.32(t,J=7.6Hz,3H); LC-MS:m / z 464.1(M+1) + .

[0822] Example 86. Synthesis of 1-ethyl-N-(2-hydroxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0823]

[0824] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0825] To a stirred solution of 1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid (60 mg, 0.14 mmol) in DMFA (1 mL) at 0 ° C was added N-ethyldiisopropylamine (0.02 mL, 0.14 mmol) and HBTU (52 mg, 0.14 mmol). The reaction mixture was stirred for 30 min, then 2-aminoethan-1-ol (8 mg, 0.14 mmol) was added and stirring was continued at room temperature for 16 h. Once the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (15 mL) and stirred for 15 min. The resulting solid was filtered, washed with diethyl ether and dried in vacuo to give the title compound (20 mg, 30%) as a white solid; 1H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.37 (t, J=4.8Hz, 1H), 8.09 (s, 1H), 7.78 (d, J=8.4Hz, 1H), 7.56-7.49 (m, 3H), 7.21 (d, J=8. 0Hz, 1H), 4.72 (t, J=5.6Hz, 1H), 4.22 (q, J=7.2Hz, 2H), 3.53 (q, J=5.2Hz, 2H), 3.39-3.37 (m, 2H), 1.32 (t, J=8.0Hz, 3H); LC-MS: m / z 450.1(M+1) + .

[0826] Examples 87 and 88. Synthesis of 1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid. Synthesis of N-(2-methoxyethyl)-1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide.

[0827]

[0828] Conditions: a) (tetrahydrofuran-3-yl)methylamine, DIPEA, THF, 60°C, 16h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) cyanogen bromide, THF, H2O, 50°C, 16h; d) NaH, 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16h; e) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; f) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0829] Step-a: Synthesis of ethyl 3-nitro-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate

[0830] To a solution of ethyl 4-chloro-3-nitrobenzoate (2.0 g, 8.7 mmol) in THF (40 mL) at room temperature was added DIPEA (4.6 mL, 26.1 mmol) and (tetrahydrofuran-3-yl)methylamine (1.06 g, 10.5 mmol), and the reaction mixture was stirred at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, diluted with cold water (200 mL) and stirred for 1 h. The precipitated solid was filtered and dried in vacuo to give the title compound (2.4 g, 94%); 1H NMR (400MHz, DMSO-d6): δ8.62-8.59 (m, 2H), 7.97 (dd, J = 2.0Hz, J = 9.2Hz, 1H) ,7.20(d,J=8.8Hz,1H),4.29(q,J=7.6Hz,2H),3.82-3.77(m,1H),3.73-3.69( m,1H),3.66-3.60(m,1H),3.53-3.50(m,1H),3.45-3.40(m,2H),2.67-2.58(m ,1H),2.03-1.95(m,1H),1.69-1.63(m,1H),1.31(t,J=7.2Hz,3H); LC-MS:m / z 295.0(M+1) + .

[0831] Step-b: Synthesis of ethyl 3-amino-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate

[0832] The title compound was synthesized using the same procedure as compound 1e using ethyl 3-nitro-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate as the starting material (yield: 86%); 1 H NMR (400MHz, DMSO-d6): δ7.20 (dd, J=2.0Hz, J=8.0Hz, 1H), 7.16 (d, J=2.0Hz, 1H), 6.46(d,J=8.0Hz,1H),5.26(bs,1H),4.75(s,2H),4.18(q,J=7.2Hz,2H),3.77-3. 73(m,2H),3.64-3.62(m,1H),3.49-3.47(m,1H),3.07(t,J=6.4Hz,2H),2.50-2.4 9(m,1H),2.11-1.98(m,1H),1.63-1.48(m,1H),1.26(t,J=7.2Hz,3H); LC-MS:m / z 265.1(M+1) + .

[0833] Step-c: Synthesis of ethyl 2-amino-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate

[0834] The title compound was synthesized using the same procedure as compound 1f using ethyl 3-amino-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate as the starting material (yield: 79%); 1H NMR (400MHz, DMSO-d6): δ7.70(s,1H),7.58(dd,J=1.6Hz,J=8.4Hz,1H),7.27(d,J=8.4Hz,1H),6.71(s,2H),4.27(q,J=6.8Hz,2H),4.03(d,J=8.0Hz,2H ),3.78-3.71(m,1H),3.63-3.59(m,2H),3.48-3.41(m,1H),2.72-2.68(m,1 H),1.85-1.79(m,1H),1.65-1.58(m,1H),1.31(t,J=7.2Hz,3H); LC-MS:m / z 290.1(M+1) + .

[0835] Step-d: Synthesis of ethyl 1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0836] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-ethyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting materials (yield: 44%); 1 HNMR (400MHz, DMSO-d6): δ12.4(bs,1H),8.26(d,J=1.6Hz,1H),7.88(dd,J=1.6Hz,J=8.4H z,1H),7.63(d,J=8.4Hz,1H),7.59(s,1H),7.52(d,J=8.4Hz,1H),7.22(d,J=7.6Hz,1H),4. 33(q,J=7.2Hz,2H),4.20-4.18(m,2H),3.88-3.86(m,1H),3.70-3.56(m,3H),3.80-3.78(m ,1H),1.94-1.91(m,1H),1.73-1.71(m,1H),1.35(t,J=7.2Hz,3H); LC-MS:m / z491.15(M+1) + .

[0837] Step-e: Synthesis of 1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)-benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0838] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 76%); 1 HNMR (400MHz, DMSO-d6): δ12.8(bs,1H),12.3(bs,1H),8.21(s,1H),7.87(d,J=8.0Hz,1H),7.62-7.58(m,2H),7.53(d,J=8.8Hz,1H),7.21(d,J =8.4Hz,1H),4.19(d,J=7.6Hz,2H),3.89-3.84(m,1H),3.70-3.58(m,3H),2.89-2.85(m,1H),1.98-1.90(m,1H),1.76-1.68(m,1H); LC-MS: m / z 463.1(M+1) + .

[0839] Step-f: Synthesis of N-(2-methoxyethyl)-1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0840] The title compound was synthesized using the same procedure as compound 1i using 1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 18%); 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.47(s,1H),8.09(s,1H),7.77(d,J=7.6Hz,1H),7.60-7.50(m,3H),7.21(d,J=8.0Hz,1H),4.18( bs,2H),3.87(bs,1H),3.67-3.57(m,3H),3.47(bs,4H),3.28(s,3H),2.88(bs,1H),1.92(bs,1H),1.73(bs,1H); LC-MS: m / z520.15(M+1) + .

[0841] Examples 89 and 90. Synthesis of 1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of N-(2-methoxyethyl)-1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0842]

[0843] Conditions: a) 2-(Methylsulfonyl)ethan-1-amine hydrochloride, DIPEA, DMF, 60°C, 16 h; b) 10% Pd / C, MeOH, H2, RT, 16 h; c) Cyanogen bromide, THF, H2O, 50°C, 16 h; d) NaH, 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16 h; e) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h; f) 2-Methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0844] Step-a: Synthesis of ethyl 4-((2-(methylsulfonyl)ethyl)amino)-3-nitrobenzoate

[0845] The title compound was synthesized using the same procedure as compound 3a, using ethyl 4-chloro-3-nitrobenzoate and 2-(methylsulfonyl)ethan-1-amine hydrochloride as starting materials and heating to 60°C. (Yield: 89%); 1 H NMR (400MHz, DMSO-d6): δ8.69 (t, J=6.0Hz, 1H), 8.63 (d, J=2.0Hz, 1H), 8.02 (dd, J=2.0Hz, J=8.8Hz, 1H), 7.20 (d, J=9.2Hz, 1H), 4.30 (q, J=6.8Hz, 2H), 3.89 (q, J=5.6Hz, 2H), 3.52 (t, J=6.8Hz, 2H), 3.08 (s, 3H), 1.30 (t, J=6.8Hz, 3H); LC-MS: m / z317.0 (M+1) + .

[0846] Step-b: Synthesis of ethyl 3-amino-4-((2-(methylsulfonyl)ethyl)amino)benzoate

[0847] The title compound was synthesized using the same procedure as compound 1e using ethyl 4-((2-(methylsulfonyl)ethyl)amino)-3-nitrobenzoate as the starting material (yield: 86%); 1H NMR (400MHz, DMSO-d6): δ7.24-7.20 (m, 2H), 6.52 (d, J=8.4Hz, 1H), 5.45 (t, J=5.2Hz, 1H), 4.72 (s, 2H), 4.19 ( q, J=7.2Hz, 2H), 3.58 (q, J=6.4Hz, 2H), 3.38 (t, J=6.8Hz, 2H), 3.03 (s, 3H), 1.26 (t, J=6.8Hz, 3H); LC-MS: m / z 287.0(M+1) + .

[0848] Step-c: Synthesis of ethyl 2-amino-1-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazole-5-carboxylate

[0849] The title compound was synthesized using the same procedure as compound 1f using ethyl 3-amino-4-((2-(methylsulfonyl)ethyl)amino)benzoate as the starting material (yield: 86%); 1 H NMR (400MHz, DMSO-d6): δ7.71 (d, J=1.2Hz, 1H), 7.61 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.28 (d, J=8.4Hz, 1H), 6.75 (s, 2H), 4.47-4.40 (m, 2H), 4.30 (q, J=7.6Hz, 2H), 3.55 (t, J=6.8Hz, 2H), 3.03 (s, 3H), 1.31 (t, J=6.8Hz, 3H).

[0850] Step-d: Synthesis of ethyl 1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0851] The title compound was synthesized using the same procedure as compound 1g using ethyl 2-amino-1-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting materials (yield: 24%); 1H NMR (400MHz, DMSO-d6): δ13.4(bs,1H),8.25(d,J=1.6Hz,1H),7.89(dd,J=1.2Hz,J=8.0Hz,1H),7.63-7.61(m,2H),7.54(d,J=8.8Hz,1H),7.56 -7.51(m,1H),4.61(t,J=6.8Hz,2H),4.34(q,J=7.2Hz,2H),3.73(d),J=6.8Hz,2H),3.14(s,3H),1.35(t,J=7.6Hz,3H); LC-MS: m / z513.05(M+1) + .

[0852] Step-e: Synthesis of 1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0853] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 17%); 1 H NMR (400MHz, DMSO-d6): δ12.8(bs,1H),12.4(bs,1H),8.20(d,J=1.2Hz,1H),7.88(dd,J=1.2Hz,J=8.0Hz,1H),7.61-7.59( m,2H),7.54(d,J=8.4Hz,1H),7.22(d,J=8.8Hz,1H),4.61(t,J=6.8Hz,2H),3.72(t,J=6.8Hz,2H),3.14(s,3H); LC-MS: m / z 484.9(M+1) + .

[0854] Step-f: Synthesis of N-(2-methoxyethyl)-1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0855] The title compound was synthesized using the same procedure as compound 1i using 1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 32%); 1H NMR (400 MHz, DMSO-d6): δ 12.30 (bs, 1H), 8.48 (t, J = 5.2 Hz, 1H), 8.08 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.67-7.54 (m, 3H), 7.21 (d, J = 9.6 Hz, 1H), 4.60 (t, J = 6.8 Hz, 2H), 3.74 (t, J = 10.8 Hz, 2H), 3.48-3.44 (m, 4H), 3.28 (s, 3H), 3.14 (s, 3H); LC-MS: m / z 542.0 (M+1) + .

[0856] Example 91. Synthesis of 2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0857]

[0858] Conditions: a) SnCl22H2O, EtOH, reflux, 4 h; b) Potassium ethyl xanthate, EtOH, reflux, 16 h; c) SOCl2, catalytic DMF, reflux, 3 h; d) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; e) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h

[0859] Step-a: Synthesis of 2-amino-5-bromophenol

[0860] To a solution of 5-bromo-2-nitrophenol (4.0 g, 18.35 mmol) in ethanol (60 mL) at room temperature was added SnCl2.2H2O (20.6 g, 91.74 mmol), and the reaction mixture was refluxed for 4 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (20 mL) and basified with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with water (50 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (2.4 g, 70%). 1 H NMR (400MHz, DMSO-d6): δ9.44 (bs, 1H), 6.75 (d, J=2.4Hz, 1H), 6.67 (dd, J=2.0Hz, J=8.4Hz, 1H), 6.51 (d, J=8.4Hz, 1H), 4.65 (bs, 2H); LC-MS: m / z190.0 (M+1) + .

[0861] Step-b: Synthesis of 6-bromobenzo[d]oxazole-2-thiol

[0862] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-bromophenol as a starting material (yield: 98%); 1 H NMR (400MHz, DMSO-d6): δ 14.0 (bs, 1H), 7.84 (d, J=1.6Hz, 1H), 7.47 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.18 (d, J=8.4Hz, 1H); LC-MS: m / z 227.9 (M-1)-.

[0863] Step-c: Synthesis of 6-bromo-2-chlorobenzo[d]oxazole

[0864] To a solution of 6-bromobenzo[d]oxazole-2-thiol (2.89 g, 12.56 mmol) in thionyl chloride (20 mL) at room temperature was added N,N-dimethylformamide (0.2 mL) and the reaction mixture was refluxed for 3 h. The reaction mixture was concentrated, diluted with cold water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate solution (50 mL), brine solution (40 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound (2.8 g, 96%). 1 H NMR (400MHz, DMSO-d6): δ 8.14 (s, 1H), 7.72 (d, J=8.8Hz, 1H), 7.62 (dd, J=2.0Hz, J=8.8Hz, 1H).

[0865] Step-d: Synthesis of ethyl 2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0866] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 6-bromo-2-chlorobenzo[d]oxazole as starting materials (yield: 20%); 1H NMR (400MHz, DMSO-d6): δ11.56 (bs, 1H), 8.23 ​​(d, J=1.6Hz, 1H), 7.88 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.72 (d, J=1.6Hz, 1H), 7.54 (d, J=8.8Hz, 1H), 7.38-7.36 (m, 2H), 4.33 (q, J=7.2Hz, 2H), 3.64 (s, 3H), 1.35 (t, J=7.2Hz, 3H); LC-MS: m / z 416.9(M+1) + .

[0867] Step-e: Synthesis of 2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0868] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 75%); 1 H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (s, 1H), 7.87 (d, J=8.4Hz, 1H) , 7.71 (d, J=1.6Hz, 1H), 7.51 (d, J=8.8Hz, 1H), 7.42-7.35 (m, 2H), 3.64 (s, 3H); LC-MS: m / z 388.9(M+1) + .

[0869] Example 92. Synthesis of N-(2-hydroxyethyl)-2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0870]

[0871] Conditions: a) NaOMe, MeOH, 60°C, 40h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) Potassium ethyl xanthate, EtOH, reflux, 16h; d) SOCl2, catalytic DMF, reflux, 2h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; g) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0872] Step-a: Synthesis of 5-methoxy-2-nitrophenol

[0873] To a stirred suspension of sodium methoxide (0.86 g, 18.35 mmol) in methanol (50 mL) at room temperature was added a solution of 5-fluoro-2-nitrophenol (3.0 g, 19.1 mmol) in methanol (40 mL) via a syringe, and the reaction mixture was heated at 60 ° C for 40 h. The reaction mixture was cooled to room temperature, quenched with cold water (50 mL), acidified with 1N HCl and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using 3% ethyl acetate / hexane as eluent to give the title compound (2.0 g, 62%). 1 H NMR (400MHz, DMSO-d6): δ10.94 (s, 1H), 7.97 (d, J=9.6Hz, 1H), 6.63 (d, J=2.4Hz, 1H), 6.59 (dd, J=3.0Hz, J=9.2Hz, 1H), 3.83 (s, 3H); LC-MS: m / z 167.95(M-1) - .

[0874] Step-b: Synthesis of 2-amino-5-methoxyphenol

[0875] The title compound was synthesized using the same procedure as compound 1e using 5-methoxy-2-nitrophenol as the starting material (yield: 96%); 1 H NMR (400MHz, DMSO-d6): δ8.8 (bs, 1H), 6.49 (d, J = 8.4Hz, 1H), 6.30 (d, J = 2.1Hz, 1H), 6.18-6.14 (m, 1H), 3.58 (s, 3H); LC-MS: m / z 140.15 (M+1) + .

[0876] Step-c: Synthesis of 6-methoxybenzo[d]oxazole-2-thiol

[0877] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-methoxyphenol as a starting material (yield: 72%); 1 H NMR (400MHz, DMSO-d6): δ13.7 (s, 1H), 7.21 (d, J = 2.4Hz, 1H), 7.13 (d, J = 8.4Hz, 1H), 6.88 (dd, J = 2.0Hz, J = 8.4Hz, 1H), 3.77 (s, 3H); LC-MS: m / z 182.0(M+1)+ .

[0878] Step-d: Synthesis of 2-chloro-6-methoxybenzo[d]oxazole

[0879] The title compound was synthesized using the same procedure as in Example 32 step-d using 6-methoxybenzo[d]oxazole-2-thiol as the starting material and stirring for 2 h (yield: 91%); LC-MS: m / z 184.0 (M+1) + .

[0880] Step-e: Synthesis of ethyl 2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0881] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-methoxybenzo[d]oxazole as starting materials (yield: 18%); 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.21(d,J=1.4Hz,1H),7.87(dd,J=1.2Hz,J=8.4Hz,1H),7.50(d,J=8.0Hz,1H),7.36(d,J=8.4Hz,1H) ,7.13(d,J=2.0Hz,1H),6.83(dd,J=2.4Hz,J=8.4Hz,1H),4.33(q,J=6.8Hz,2H),3.82(s,3H),3.62(s,3H),1.35(t,J=7.2Hz,3H); LC-MS: m / z 367.0(M+1) + .

[0882] Step-f: Synthesis of 2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0883] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 79%); 1H NMR (400MHz, DMSO-d6): δ12.5(bs,2H),8.17(s,1H),7.85(dd,J=1.6Hz,J=8.4Hz,1H),7.47(d,J=8.4Hz,1H),7.3 7(d,J=8.8Hz,1H),7.12(d,J=2.0Hz,1H),6.82(dd,J=2.4Hz,J=8.8Hz,1H),3.79(s,3H),3.62(s,3H); LC-MS: m / z 339.0(M+1) + .

[0884] Step-g: Synthesis of N-(2-hydroxyethyl)-2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0885] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials (yield: 59%); 1 H NMR (400MHz, DMSO-d6): δ12.18(bs,1H),8.35(t,J=5.2Hz,1H),8.05(d,J=1.2 Hz,1H),7.75(dd,J=1.6Hz,J=8.4Hz,1H),7.45(d,J=8.4Hz,1H),7.35(d,J=8.4 Hz, 1H), 7.11 (d, J = 2.4Hz, 1H), 6.81 (dd, J = 2.4Hz, J = 8.8Hz, 1H), 4.72 (bs, 1H), 3.78 (s, 3H), 3.61 (s, 3H), 3.53 (t, J=6.0Hz, 2H), 3.35-3.30 (m, 2H); LC-MS: m / z 382.0(M+1) + .

[0886] Examples 93 and 94. Synthesis of 1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 1-((3-hydroxyoxetan-3-yl)methyl)-N-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0887]

[0888] Conditions: a) Nitromethane, TEA, RT, 16 h; b) 10% Pd / C, MeOH, H2, RT, 3 h; c) 3-(Aminomethyl)oxetan-3-ol, DIPEA, DMF, 60°C, 16 h; d) 10% Pd / C, MeOH, H2, RT, 16 h; e) Cyanogen bromide, THF, H2O, 50°C, 16 h; f) NaH, 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole, 1,4-dioxane, RT, 16 h; g) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h; h) 2-Methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[0889] Step-a: Synthesis of 3-(nitromethyl)oxetan-3-ol

[0890] To a solution of oxetan-3-one (10.0 g, 138.9 mmol) in nitromethane (25 mL) at 0° C. was added triethylamine (5 mL, 347.2 mmol), and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography using 40% ethyl acetate / hexane as eluent to give the title compound (14.0 g, 77%) as a light yellow liquid. 1 H NMR (400MHz, CDCl3): δ4.82 (s, 2H), 4.71 (d, J=8.0Hz, 2H), 4.61 (d, J=8.0Hz, 2H), 3.53 (s, 1H).

[0891] Step-b: Synthesis of 3-(aminomethyl)oxetan-3-ol

[0892] To a solution of 3-(nitromethyl)oxetan-3-ol (5.0 g, 37.6 g) in methanol (80 mL) was added a slurry of 10% Pd / C (2.0 g in 20 mL of methanol) under a nitrogen atmosphere. The reaction mixture was then stirred under a hydrogen balloon for 3 h. The reaction mixture was filtered through a bed of celite and concentrated in vacuo to afford the title compound (3.8 g, 98%); LC-MS: m / z 104.2 (M+1) + .

[0893] Step-c: Synthesis of ethyl 4-(((3-hydroxyoxetan-3-yl)methyl)amino)-3-nitrobenzoate

[0894] The title compound was synthesized using the same procedure as compound 3a, using ethyl 4-chloro-3-nitrobenzoate and 3-(aminomethyl)oxetan-3-ol as starting materials and heating to 60°C (yield: 54%); 1H NMR (400MHz, DMSO-d6): δ8.62(d,J=1.6Hz,1H),8.53(bs,1H),7.99(dd,J=2.0Hz,J=9.2Hz,1H),7.29(d,J=9.2Hz,1H),6.35(s,1 H), 4.51 (d, J = 6.8Hz, 2H), 4.44 (d, J = 6.8Hz, 2H), 4.29 (q, J = 7.2Hz, 2H), 3.75 (d, J = 5.2Hz, 2H), 1.31 (t, J = 6.8Hz, 3H); LC-MS: m / z 297.1(M+1) + .

[0895] Step-d: Synthesis of ethyl 3-amino-4-(((3-hydroxyoxetan-3-yl)methyl)amino)benzoate

[0896] The title compound was synthesized using the same procedure as compound 1e using ethyl 4-(((3-hydroxyoxetan-3-yl)methyl)amino)-3-nitrobenzoate as the starting material (yield: 95%); 1 H NMR (400MHz, DMSO-d6): δ7.23-7.20(m,2H),6.57(d,J=8.4Hz,1H),5.96(bs,1H),5.04(bs,1H),4.75(s ,2H),4.46-4.43(m,4H),4.19(q,J=7.2Hz,2H),3.40(d,J=5.6Hz,2H),1.26(t,J=6.8Hz,3H); LC-MS:m / z 267.1(M+1) + .

[0897] Step-e: Synthesis of ethyl 2-amino-1-((3-hydroxyoxetan-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate

[0898] The title compound was synthesized using the same procedure as compound 1f using ethyl 3-amino-4-(((3-hydroxyoxetan-3-yl)methyl)amino)benzoate as the starting material (yield: 70%); 1H NMR (400MHz, DMSO-d6): δ7.72(s,1H),7.59(dd,J=1.6Hz,J=8.0Hz,1H),7.35(d,J=8.0Hz,1H),6.56(s,2H),6.45(s,1 H), 4.55 (d, J = 6.4Hz, 2H), 4.43 (d, J = 6.0Hz, 2H), 4.34 (s, 2H), 4.28 (q, J = 6.8Hz, 2H), 1.32 (t, J = 5.2Hz, 3H); LC-MS: m / z 292.1(M+1) + .

[0899] Step-f: Synthesis of ethyl 1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0900] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-((3-hydroxyoxetan-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting materials (yield: 18%); 1 H NMR (400MHz, DMSO-d6): δ12.4(bs,1H),8.24(d,J=1.6Hz,1H),7.85(dd,J=1.6Hz,J=8.4Hz,1H),7.60-7.58(m,2H),7.53(d,J=8.4Hz,1H),7.23(dd,J= 1.2Hz,J=8.8Hz,1H),6.18(s,1H),4.79(d,J=6.8Hz,2H),4.50(bs,2H),4.4 6(d, J=6.8Hz, 2H), 4.33(q, J=6.8Hz, 2H), 1.35(t, J=7.6Hz, 3H); LC-MS: m / z 493.0(M+1) + .

[0901] Step-g: Synthesis of 1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0902] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 49%); 1H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (d, J=1.2Hz, 1H), 7.84 (dd, J=1.2Hz, J=8.0Hz, 1H), 7.60-7.52 ( m, 3H), 7.22 (dd, J=1.6Hz, J=8.4Hz, 1H), 6.18 (s, 1H), 4.79 (d, J=6.4Hz, 2H), 4.51 (s, 2H), 4.46 (d, J=6.4Hz, 2H); LC-MS: m / z 465.1(M+1) + .

[0903] Step-h: Synthesis of 1-((3-hydroxyoxetan-3-yl)methyl)-N-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0904] The title compound was synthesized using the same procedure as compound 1i, using 1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials. The crude product was purified by flash chromatography using 2% methanol / DCM as the eluent to give the title compound (yield: 28%). 1 H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.43 (t, J=5.2Hz, 1H), 8.07 (s, 1H), 7.73 (d, J=8.8Hz, 1H), 7.58 (s, 1H), 7.55-7.51 (m, 2H), 7.21 (d, J =8.4Hz, 1H), 6.17 (s, 1H), 4.79 (d, J = 6.8Hz, 2H), 4.50 (s, 2H), 4.46 (d, J = 6.4Hz, 2H), 3.49-3.43 (m, 4H), 3.28 (s, 3H); LC-MS: m / z522.0 (M+1) + .

[0905] Example 95. Synthesis of N-(2-hydroxyethyl)-1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0906]

[0907] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0908] The title compound was synthesized using the same procedure as in Example 6, step e, using 1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials. The crude product was purified by flash chromatography using 3% methanol / DCM as the eluent to give the title compound (yield: 15%). 1 H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.35 (t, J=5.6Hz, 1H), 8.07 (d, J=1.2Hz, 1 H), 7.73 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.58 (s, 1H), 7.58-7.51 (m, 2H), 7.22 (dd, J= 1.2Hz, J=10.0Hz, 1H), 6.17 (s, 1H), 4.80 (d, J=6.8Hz, 2H), 4.71 (t, J=5.2Hz, 1H), 4.51 (s, 2H), 4.46 (d, J=6.4Hz, 2H), 3.55-3.51 (m, 2H), 3.37-27 (m, 2H); LC-MS: m / z 508.45(M+1) + .

[0909] Examples 96 and 97. Synthesis of 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0910]

[0911] Conditions: a) Potassium ethyl xanthate, EtOH, reflux, 16 h; b) SOCl2, catalytic DMF, reflux, 3 h; c) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; d) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h; e) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16 h

[0912] Step-a: Synthesis of 6-chlorobenzo[d]oxazole-2-thiol

[0913] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-chlorophenol as a starting material (yield: 69%); 1H NMR (400MHz, DMSO-d6): δ14.0 (bs, 1H), 7.73 (d, J=2.0Hz, 1H), 7.35 (dd, J=1.6Hz, J=8.0Hz, 1H), 7.23 (d, J=8.8Hz, 1H); LC-MS: m / z 184.0 (M-1) - .

[0914] Step-b: Synthesis of 2,6-dichlorobenzo[d]oxazole

[0915] The title compound was synthesized using the same procedure as in Example 32 step-d using 6-chlorobenzo[d]oxazole-2-thiol as the starting material (yield: 69%); 1 H NMR (400MHz, DMSO-d6): δ 8.01 (d, J=1.6Hz, 1H), 7.77 (d, J=8.4Hz, 1H), 7.51 (dd, J=2.0Hz, J=8.4Hz, 1H).

[0916] Step-c: Synthesis of ethyl 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0917] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2,6-dichlorobenzo[d]oxazole as starting materials (yield: 24%); 1 H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.23 ​​(d, J = 1.6Hz, 1H), 7.88 (d, J = 8.0Hz, 1H), 7.60 (d, J = 2.0Hz, 1H), 7.53 (d, J = 8.4Hz, 1H ), 7.44 (d, J=8.0Hz, 1H), 7.25 (dd, J=2.0Hz, J=8.0Hz, 1H), 4.33 (q, J=7.2Hz, 2H), 3.64 (s, 3H), 1.35 (t, J=7.2Hz, 3H); LC-MS: m / z 369.0(M-1) - .

[0918] Step-d: Synthesis of 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0919] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 81%);1 H NMR (400MHz, DMSO-d6): δ 12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (d, J = 1.2Hz, 1H), 7.87 (dd, J = 1.6Hz, J = 8.4Hz, 1H), 7.59 (d , J=2.0Hz, 1H), 7.51 (d, J=8.4Hz, 1H), 7.45 (d, J=8.4Hz, 1H), 7.24 (dd, J=2.0Hz, J=8.4Hz, 1H), 3.64 (s, 3H); LC-MS: m / z 342.9(M+1) + .

[0920] Step-e: Synthesis of 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0921] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials (yield: 53%); 1 H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.37 (t, J=5.6Hz, 1H), 8.08 (s, 1H), 7.78 (d, J=8.4Hz, 1H), 7.58 (d, J=2.0Hz, 1H), 7.49 (d, J=8.8Hz, 1H), 7.44 (d, J=8.4Hz, 1H), 7.24 (dd, J=2.0Hz, J=8.4Hz, 1H), 4.72 (t, J=5.2Hz, 1H), 3.64(s, 3H), 3.55-3.51(m, 2H), 3.37-3.33(m, 2H); LC-MS: m / z386.1(M+1) + .

[0922] Examples 98 and 99. Synthesis of 1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0923]

[0924] Conditions: a) benzyl bromide, K2CO3, DMF, 0℃-RT, 16h; b) trifluoroethanol, NaH, THF, 0℃-RT, 3h; c) 10% Pd / C, MeOH, H2, RT, 16h; d) potassium ethyl xanthate, EtOH, reflux, 16h; e) SOCl2, catalytic DMF, reflux, 2h; f) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; g) LiOH.H2O, THF, EtOH, H2O, 60℃, 16h; h) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0℃-RT, 16h

[0925] Step-a: Synthesis of 2-(benzyloxy)-4-fluoro-1-nitrobenzene

[0926] To a stirred solution of 5-fluoro-2-nitrophenol (8.0 g, 50.9 mmol) in DMFA (80 mL) at 0 ° C., potassium carbonate (14.0 g, 101.8 mmol) and benzyl bromide (5.4 mL, 45.8 mmol) were added, and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2×200 mL). The combined organic layers were washed with water (2×200 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using 10% ethyl acetate / hexane as eluent to give the title compound (8.0 g, 64%). 1 H NMR (400MHz, DMSO-d6): δ 8.06-8.02 (m, 1H), 7.47-7.36 (m, 6H), 7.05-6.95 (m, 1H), 5.33 (s, 2H).

[0927] Step-b: Synthesis of 2-(benzyloxy)-1-nitro-4-(2,2,2-trifluoroethoxy)benzene

[0928] To a solution of trifluoroethanol (0.23 mL, 3.24 mmol) in THF (10 mL) at 0° C., sodium hydride (60% dispersion in mineral oil) (194 mg, 4.86 mmol) was added portionwise and stirred for 1 h. Subsequently, a solution of 2-(benzyloxy)-4-fluoro-1-nitrobenzene (400 mg, 1.62 mmol) was added to the reaction mixture and stirred at room temperature for 2 h. The reaction mixture was concentrated and diluted with cold water (20 mL). The precipitated solid was filtered and dried in vacuo to give the title compound (350 mg, 66%). 1HNMR (400MHz, DMSO-d6): δ8.01(d,J=9.2Hz,1H),7.48-7.33(m,5H),7.11(d,J=2 .8Hz, 1H), 6.82 (dd, J = 2.4Hz, J = 8.8Hz, 1H), 5.32 (s, 2H), 4.94 (q, J = 8.8Hz, 2H).

[0929] Step-c: Synthesis of 2-amino-5-(2,2,2-trifluoroethoxy)phenol

[0930] Under a nitrogen atmosphere, 10% Pd / C (50 mg) was added to a solution of 2-(benzyloxy)-1-nitro-4-(2,2,2-trifluoroethoxy)benzene (350 mg, 1.07 mmol) in methanol (10 mL). The reaction mixture was stirred under a hydrogen balloon for 16 h. The reaction mixture was filtered through a bed of celite and concentrated in vacuo to give the title compound (210 mg, 95%). 1 H NMR (400MHz, DMSO-d6): δ6.51 (d, J = 8.8Hz, 1H), 6.38 (d, J = 2.4Hz, 1H), 6.28 (dd, J = 2.8Hz, J = 8.8Hz, 1H), 4.48 (q, J = 8.8Hz, 2H); LC-MS: m / z 208.0 (M+1) + .

[0931] Step-d: Synthesis of 6-(2,2,2-trifluoroethoxy)benzo[d]oxazole-2-thiol

[0932] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-5-(2,2,2-trifluoroethoxy)phenol as a starting material (yield: 79%); 1 H NMR (400MHz, DMSO-d6): δ13.8 (bs, 1H), 7.38 (d, J = 2.4Hz, 1H), 7.18 (d, J = 8.8Hz, 1H), 7.01 (dd, J = 2.4Hz, J = 8.8Hz, 1H), 4.79 (q, J = 8.8Hz, 2H); LC-MS: m / z 250.0(M+1) + .

[0933] Step-e: Synthesis of 2-chloro-6-(2,2,2-trifluoroethoxy)benzo[d]oxazole

[0934] The title compound was synthesized using the same procedure as in Example 32, step d, using 6-(2,2,2-trifluoroethoxy)benzo[d]oxazole-2-thiol as the starting material and stirring for 2 h. (Yield: 87%). 1H NMR (400MHz, DMSO-d6): δ7.69 (d, J=8.8Hz, 1H), 7.60 (d, J=2.4Hz, 1H), 6.15 (dd, J=2.4Hz, J=8.8Hz, 1H), 4.85 (q, J=8.8Hz, 2H).

[0935] Step-f: Synthesis of ethyl 1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[0936] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-6-(2,2,2-trifluoroethoxy)benzo[d]oxazole as starting materials (yield: 21%); 1 H NMR (400MHz, DMSO-d6): δ12.3(bs,1H),8.22(d,J=1.6Hz,1H),7.88(dd,J=1.2Hz,J=8.0Hz,1H),7.51(d,J=8.4Hz,1H),7.39(d,J=8.4Hz,1H),7.2 9(d,J=2.4Hz,1H),6.94(dd,J=2.4Hz,J=8.4Hz,1H),4.77(q,J=8.8Hz,2H),4.33(q,J=7.2Hz,2H),3.63(s,3H),1.35(t,J=7.2Hz,3H); LC-MS: m / z 435.35(M+1) + .

[0937] Step-g: Synthesis of 1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid

[0938] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 62%); 1H NMR (400MHz, DMSO-d6): δ12.5 (bs, 2H), 8.18 (d, J=1.2Hz, 1H), 7.86 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.48 (d, J=8.8Hz, 1H), 7.4 0 (d, J=8.8Hz, 1H), 7.29 (d, J=2.4Hz, 1H), 6.93 (dd, J=2.4Hz, J=8.8Hz, 1H), 4.77 (q, J=9.2Hz, 2H), 3.62 (s, 3H); LC-MS: m / z 407.0(M+1) + .

[0939] Step-h: Synthesis of N-(2-methoxyethyl)-1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0940] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 70%); 1 H NMR (400MHz, DMSO-d6): δ12.2 (bs, 1H), 8.4 (t, J=5.6Hz, 1H), 8.06 (s, 1H), 7.75 (d, J=8.0Hz, 1H), 7.46 (d, J=8.0Hz, 1H), 7.39 (d, J=8.0Hz, 1H), 7.28 (d, J=1.6Hz, 1H), 6.93 (dd, J=2.4Hz, J=8.4Hz, 1H), 4.77 (q, J=8.8Hz, 2H), 3.62 (s, 3H), 3.48-3.43 (m, 4H), 3.28 (s, 3H); LC-S: m / z 464.0(M+1) + .

[0941] Example 100. Synthesis of N-(2-hydroxyethyl)-1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[0942]

[0943] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0944] The title compound was synthesized using the same procedure as in Example 6, step-e, using 1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials (yield: 63%); 1 H NMR (400MHz, DMSO-d6): δ12.5 (bs, 1H), 8.42 (t, J=5.2Hz, 1H), 8.07 (s, 1H), 7.81 (d, J=8.4Hz, 1H), 7.53 (d, J=8.4Hz, 1H), 7.40 (d, J=8.8Hz, 1H), 7. 32 (d, J=2.4Hz, 1H), 6.98 (dd, J=2.4Hz, J=8.8Hz, 1H), 4.80 (q, J=8.8Hz, 2H), 3.66 (s, 3H), 3.54 (t, J=6.4Hz, 2H), 3.36 (q, J=6.0Hz, 2H); LC-MS: m / z 450.0(M+1) + .

[0945] Examples 101 and 102. Synthesis of 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzoimidazole-5-carboxamide

[0946]

[0947] Conditions: a) KOH, water, 100°C, 30h; b) (2-bromoethoxy)(tert-butyl)dimethylsilane, K2CO3, DMF, 130°C, 4h; c) 10% Pd / C, MeOH, H2, RT, 16h; d) potassium ethylxanthate, EtOH, reflux, 16h; e) K2CO3, Mel, ACN, RT, 16h; f) m-CPBA, DCM, 0°C-RT, 4h; g) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; h) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; h) 2-methoxyethylamine, DPPA, DIPEA, DMF, 0°C-RT, 16h

[0948] Step-a: Synthesis of 3-(benzyloxy)-4-nitrophenol

[0949] To a stirred suspension of 2-(benzyloxy)-4-fluoro-1-nitrobenzene (4.0 g, 16.2 mmol) in water (70 mL) at room temperature was added potassium hydroxide (4.53 g, 80.9 mmol), and the reaction mixture was stirred at 100 ° C for 30 h. The reaction mixture was cooled to room temperature, diluted with water (50 mL), acidified with 1N HCl and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue that was purified by flash chromatography using 20% ​​ethyl acetate / hexane as eluent to give the title compound (1.5 g, 38%). 1 H NMR (400MHz, DMSO-d6): δ10.88 (s, 1H), 7.90 (d, J=8.8Hz, 1H), 7.49-7.47 (m, 2H), 7.43-7.40 (m, 2H), 7.35 (d, J=6.8Hz, 1H), 6.69 (d, J=2.4Hz, 1H), 6.49 (dd, J=2.4Hz, J=9.2Hz, 1H), 5.25 (s, 2H).

[0950] Step-b: Synthesis of (2-(3-(benzyloxy)-4-nitrophenoxy)ethoxy)(tert-butyl)dimethylsilane

[0951] To a stirred solution of 3-(benzyloxy)-4-nitrophenol (1.5 g, 6.1 mmol) in DMFA (15 mL) at room temperature in a sealed tube was added potassium carbonate (2.1 g, 15.3 mmol) and (2-bromoethoxy) (tert-butyl) dimethylsilane (1.75 g, 7.3 mmol) and heated at 130 ° C for 4 h. The reaction mixture was cooled to room temperature, diluted with water (50 mL) and extracted with ethyl acetate (2×50 mL). The combined organic layers were washed with water (2×500 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue that was purified by flash chromatography using 5% ethyl acetate / hexane as eluent to give the title compound (8.0 g, 64%). 1 H NMR (400MHz, DMSO-d6): δ7.96 (d, J=8.8Hz, 1H), 7.49-7.47 (m, 2H), 7.43-7.39 (m, 2H), 7.36-7.34 (m, 1H), 6.89 (d, J=2.4Hz, 1H), 6.67 (dd, J=2.4Hz, J=9.2Hz, 1H), 5.32 (s, 2H), 4.17 (t, J=4.4Hz, 2H), 3.92 (t, J=4.8Hz, 2H), 0.86 (s, 9H), 0.02 (s, 6H).

[0952] Step-c: Synthesis of 2-amino-5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenol

[0953] The title compound was synthesized using the same procedure as compound 1e using (2-(3-(benzyloxy)-4-nitrophenoxy)ethoxy)(tert-butyl)dimethylsilane as the starting material (yield: 87%); 1 H NMR (400MHz, DMSO-d6): δ6.47(d,J=8.0Hz,1H),6.30(d,J=2.8Hz,1H),6.15(dd, J=2.4Hz, J=8.4Hz, 1H), 3.84-3.80 (m, 4H), 0.87 (s, 9H), 0.02 (s, 6H); LC-MS: m / z 284.1(M+1) + .

[0954] Step-d: Synthesis of 6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazole-2-thiol

[0955] The title compound was synthesized using the same procedure as in Example 32, step c, using 2-amino-5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenol as the starting material (yield: 77%). The crude compound was used in the next step without any analytical data.

[0956] Step-e: Synthesis of 6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylthio)benzo[d]oxazole

[0957] The title compound was synthesized using the same procedure as compound 1b, using 6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazole-2-thiol as the starting material and stirring for 16 h. (Yield: 80%) 1 H NMR (400MHz, DMSO-d6): δ7.50(d,J=8.8Hz,1H),7.28(d,J=2.4Hz,1H),6.91(dd,J=2.8Hz,J=8.8Hz, 1H), 4.06 (t, J = 4.4Hz, 2H), 3.92 (t, J = 5.2Hz, 2H), 2.27 (s, 3H), 0.86 (s, 9H), 0.2 (s, 6H); LC-MS: m / z 340.0(M+1) + .

[0958] Step-f: Synthesis of 6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylsulfonyl)-benzo[d]oxazole

[0959] The title compound was synthesized using the same procedure as compound 1c, using 6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylthio)benzo[d]oxazole as the starting material and stirring for 4 h (yield: 100%); 1 H NMR (400MHz, DMSO-d6): δ7.90-7.89(m,1H),7.55(d,J=8.0Hz,1H),6.99-6.97(m,1H) ,4.10(t,J=4.8Hz,2H),3.95(t,J=5.2Hz,2H),3.62(s,3H),0.85(s,9H),0.2(s,6H).

[0960] Step-g: Synthesis of ethyl 2-((6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0961] The title compound was synthesized using the same procedure as compound 1g using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylsulfonyl)benzo[d]oxazole as starting materials (yield: 17%); 1 H NMR (400MHz, DMSO-d6): δ12.2(bs,1H),8.21(d,J=1.6Hz,1H),7.86(dd,J=1.6Hz,J =8.4Hz,1H),7.49(d,J=8.0Hz,1H),7.35(d,J=8.4Hz,1H),7.12(d,J=2.4Hz,1H),6 .81(dd,J=1.6Hz,J=8.0Hz,1H),4.32(q,J=7.6Hz,2H),4.06-4.04(m,2H),3.94-3. 92(m,2H),3.62(s,3H),1.35(t,J=6.8Hz,3H),0.88(s,9H),0.2(s,6H); LC-MS:m / z 511.1(M+1) + .

[0962] Step-h: Synthesis of 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0963] To a stirred solution of ethyl 2-((6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate (80 mg, 0.15 mmol) in a solvent mixture of THF (2 mL), ethanol (2 mL) and water (1 mL) was added lithium hydroxide monohydrate (32 mg, 0.78 mmol). The reaction mixture was heated at 60 °C with stirring for 16 h. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in water (20 mL) and acidified with 1N HCl. The resulting solid was filtered and dried under vacuum to give the title compound (50 mg, 87%); 1 H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.3 (bs, 1H), 8.16 (d, J=1.6Hz, 1H), 7.85 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.46 (d, J=8.4Hz, 1H), 7.36 (d, J=8. 4Hz, 1H), 7.12 (d, J=2.4Hz, 1H), 6.82 (dd, J=2.4Hz, J=8.4Hz, 1H), 4.85 (bs, 1H), 4.01 (t, J=4.8Hz, 2H), 3.75-3.73 (m, 2H), 3.66 (s, 3H); LC-MS: m / z 369.0(M+1) + .

[0964] Step-i: Synthesis of 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0965] The title compound was synthesized using the same procedure as for compound 1i, using 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials. The crude product was purified by flash chromatography using 4% methanol / DCM as the eluent (yield: 17%). 1H NMR (400MHz, DMSO-d6): δ12.2 (bs, 1H), 8.43 (t, J=5.2Hz, 1H), 8.05 (d, J=1.2Hz, 1H) , 7.75 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.45 (d, J=8.8Hz, 1H), 7.35 (d, J=8.4Hz, 1H), 7.1 2 (d, J=2.4Hz, 1H), 6.82 (dd, J=2.8Hz, J=8.8Hz, 1H), 4.11 (t, J=4.4Hz, 2H), 3.66 (t, J=4.4Hz, 2H), 3.61 (s, 3H), 3.49-3.41 (m, 4H), 3.28 (bs, 1H), 3.24 (s, 3H); LC-MS: m / z 426.4(M+1) + .

[0966] Example 103. Synthesis of 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0967]

[0968] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0969] The title compound was synthesized using the same procedure as in Example 6, step e, using 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials. The crude product was purified by flash chromatography using 6% methanol / DCM as eluent to give the title compound (yield: 18%). 1 H NMR (400MHz, DMSO-d6): δ12.05 (bs, 1H), 8.35 (t, J=5.2Hz, 1H), 8.05 (s, 1H), 7.75 (d, J= 8.0Hz, 1H), 7.45 (d, J=8.4Hz, 1H), 7.35 (d, J=8.4Hz, 1H), 7.11 (d, J=2.4Hz, 1H), 6.82 (d d, J=2.8Hz, J=8.8Hz, 1H), 4.85 (bs, 1H), 4.72 (t, J=4.8Hz, 1H), 4.01 (t, J=4.8Hz, 2H), 3 .72 (q, J=4.4Hz, 2H), 3.61 (s, 3H), 3.53 (q, J=5.6Hz, 2H), 3.37-3.33 (m, 2H); LC-MS: m / z 412.0(M+1)+ .

[0970] Example 104. Synthesis of 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0971]

[0972] Conditions: a) 2-(2-aminoethoxy)ethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0973] The title compound was synthesized using the same procedure as in Example 6, step e, using 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials. The crude product was purified by flash chromatography using 10% methanol / DCM as the eluent to give the title compound (yield: 18%). 1 H NMR (400MHz, DMSO-d6): δ12.05 (bs, 1H), 8.41 (bs, 1H), 8.04 (s, 1H), 7.74 (d, J = 8.4Hz, 1H), 7.45 (d, J = 8.4Hz, 1H), 7.35 (d, J = 8.8Hz, 1H), 7.11 (s , 1H), 6.82 (d, J=6.8Hz, 1H), 4.61 (bs, 2H), 4.01 (t, J=4.4Hz, 2H), 3.72 (t, J=4.8Hz, 2H), 3.66 (s, 3H), 3.57-3.43 (m, 8H); LC-MS: m / z456.3 (M+1) + .

[0974] Example 105. Synthesis of N-(2-aminoethyl)-2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide hydrochloride

[0975]

[0976] Conditions: a) tert-butyl (2-aminoethyl)carbamate, HBTU, DIPEA, DMF, 0°C-RT, 16h; b) HCl, 1,4-dioxane, 0°C-RT, 3h

[0977] Step-a: Synthesis of tert-butyl (2-(2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethyl)carbamate

[0978] To a stirred solution of 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (100 mg, 0.27 mmol) in DMFA (2 mL) at 0° C. was added N-ethyldiisopropylamine (0.09 mL, 0.54 mmol) and HBTU (102 mg, 0.27 mmol). The reaction mixture was stirred for 30 min before tert-butyl (2-aminoethyl)carbamate (48 mg, 0.30 mmol) was added and stirring was continued at room temperature for 16 h. Once the reaction was complete, the reaction mixture was diluted with water (15 mL) and stirred for 15 min. The resulting solid was filtered and dried under vacuum to give the crude product, which was purified by flash chromatography using 3% methanol in DCM as eluent to give the title compound (70 mg, 50%). 1 H NMR (400MHz, DMSO-d6): δ12.20 (bs, 1H), 8.39 (bs, 1H), 8.05 (s, 1H), 7.73 (d, J=8.4Hz , 1H), 7.45 (d, J=8.4Hz, 1H), 7.35 (d, J=8.0Hz, 1H), 7.11 (d, J=2.0Hz, 1H), 6.91 (bs, 1 H), 6.82 (dd, J = 2.0 Hz, J = 8.4 Hz, 1H), 4.85 (bs, 1H), 4.01 (t, J = 4.8 Hz, 2H), 3.72 (bs, 2H), 3.61 (s, 3H), 3.30 (2H, combined with DMSO water peak), 3.12 (d, J = 6.0 Hz, 2H), 1.38 (s, 9H); LC-MS: m / z 511.3 (M+1) + .

[0979] Step-b: Synthesis of N-(2-aminoethyl)-2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide hydrochloride

[0980] To a stirred solution of tert-butyl (2-(2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamido)ethyl)carbamate (70 mg, 0.14 mmol) in 1,4-dioxane (3 mL) at 0°C was added 4M HCl in 1,4-dioxane (1 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure, and the residue was triturated with diethyl ether and the solvent was decanted. The resulting solid was dried in vacuo to give the title compound (35 mg, 57%); 1 HNMR (400MHz, DMSO-d6): δ12.5 (bs, 1H), 8.78 (s, 1H), 8.12-8.07 (m, 4H), 7.90 (d, J = 8.0Hz, 1H), 7.56 (d, J = 8.4Hz, 1H), 7.36 (d, J = 8.4Hz, 1H), 7. 18 (s, 1H), 6.88 (d, J=8.0Hz, 1H), 4.02 (bs, 2H), 3.73 (bs, 2H), 3.66 (s, 3H), 3.56 (q, J=5.2Hz, 2H), 3.02 (q, J=5.6Hz, 2H); LC-MS: m / z411.2 (M+1) + .

[0981] Example 106. Synthesis of N-(2-((4,5-dihydro-1H-imidazol-2-yl)amino)ethyl)-2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0982]

[0983] Condition: a)N 1 -(4,5-dihydro-1H-imidazol-2-yl)ethane-1,2-diamine, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0984] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and N1-(4,5-dihydro-1H-imidazol-2-yl)ethane-1,2-diamine as starting materials (yield: 58%); 1H NMR (400 MHz, DMSO-d6): δ 8.73 (bs, 1H), 8.49 (s, 1H), 8.05 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 2.0 Hz, 1H), 6.79 (dd, J = 1.6 Hz, J = 8.0 Hz, 1H), 4.86 (bs, 1H), 4.00 (t, J = 4.8 Hz, 2H), 3.72 (bs, 2H), 3.60-3.55 (m, 7H), 3.43 (bs, 2H), 3.30 (2H, combined with DMSO water peak); LC-MS: m / z 479.2(M+1) + .

[0985] Examples 107 and 108. Synthesis of 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[0986]

[0987] Conditions: a) HNO3 (65-70%), AcOH, 0°C-RT, 2h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) Potassium ethyl xanthate, EtOH, reflux, 16h; d) SOCl2, catalytic DMF, reflux, 2h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; g) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[0988] Step-a: Synthesis of 4-fluoro-2-nitro-5-(trifluoromethyl)phenol

[0989] To a solution of 4-fluoro-3-(trifluoromethyl)phenol (1 g, 5.6 mmol) in acetic acid (20 mL) was added dropwise acetic acid (5 mL) containing 60% aqueous nitric acid solution (3 mL) at 10-15 ° C. The reaction mixture was stirred at room temperature for 2 h. Subsequently, the mixture was poured into ice water (50 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with water (2×50 mL), brine solution (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude product, which was purified by flash chromatography using 5% EtOAc / hexane as eluent to give the title compound (700 mg, 22%). 1 H NMR (400MHz, DMSO-d6): δ11.71 (bs, 1H), 8.14 (d, J=10.4Hz, 1H), 7.44 (d, J=5.6Hz, 1H); LC-MS: m / z 224.0 (M-1) - .

[0990] Step-b: Synthesis of 2-amino-4-fluoro-5-(trifluoromethyl)phenol

[0991] The title compound was synthesized using the same procedure as compound 1e using 4-fluoro-2-nitro-5-(trifluoromethyl)phenol as the starting material (yield: 82%); 1 H NMR (400MHz, DMSO-d6): δ9.54 (s, 1H), 6.78 (d, J=7.2Hz, 1H), 6.48 (d, J=13.2Hz, 1H), 5.5 (bs, 2H).

[0992] Step-c: Synthesis of 5-fluoro-6-(trifluoromethyl)benzo[d]oxazole-2-thiol

[0993] The title compound was synthesized using the same procedure as in Example 32 step-c using 2-amino-4-fluoro-5-(trifluoromethyl)phenol as a starting material (yield: 82%); 1 H NMR (400MHz, DMSO-d6): δ14.4 (bs, 1H), 8.10 (d, J = 5.6Hz, 1H), 7.43 (d, J = 9.6Hz, 1H); LC-MS: m / z 236.0 (M-1) - .

[0994] Step-d: Synthesis of 2-chloro-5-fluoro-6-(trifluoromethyl)benzo[d]oxazole

[0995] The title compound was synthesized using the same procedure as in Example 32 step-d using 5-fluoro-6-(trifluoromethyl)benzo[d]oxazole-2-thiol as a starting material and stirring for 2 h (yield: 99%);1 H NMR (400MHz, DMSO-d6): δ7.74 (d, J = 6.0 Hz, 1H), 7.30 (d, J = 10.0 Hz, 1H).

[0996] Step-e: Synthesis of ethyl 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate

[0997] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-5-fluoro-6-(trifluoromethyl)benzo[d]oxazole as starting materials (yield: 52%); 1 H NMR (400MHz, DMSO-d6): δ12.43(bs,1H),8.22(d,J=1.6Hz,1H),7.88(dd,J=1.6Hz,J=8.4Hz,1H),7.83(d,J=6.0Hz,1H ),7.75(d,J=8.4Hz,1H),7.41(d,J=11.2Hz,1H),4.33(q,J=7.2Hz,2H),3.66(s,3H),1.35(t,J=7.2Hz,3H); LC-MS: m / z 423.0(M+1) + .

[0998] Step-f: Synthesis of 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid

[0999] The title compound was synthesized using the same procedure as compound 1h using ethyl 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 86%); 1 HNMR (400MHz, DMSO-d6): δ12.4(bs,2H),8.20(s,1H),7.89(d,J=8.4Hz,1H),7.84(d, J=6.4Hz, 1H), 7.55 (d, J=8.8Hz, 1H), 7.44 (d, J=11.2Hz, 1H), 3.67 (s, 3H); LC-MS: m / z 395.1(M+1) + .

[1000] Step-g: Synthesis of 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide

[1001] The title compound was synthesized using the same procedure as in Example 6, step-e, using 2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials (yield: 72%); 1 HNMR (400MHz, DMSO-d6): δ12.35(bs,1H),8.40(bs,1H),8.09(s,1H),7.84-7.79(m,2H),7.54(d,J=8.4Hz,1 H),7.44(d,J=11.6Hz,1H),4.50(bs,1H),3.67(s,3H),3.54(t,J=6.4Hz,2H),3.38-3.33(m,2H); LC-MS:m / z 438.0(M+1) + .

[1002] Example 109. Synthesis of N-(2-methoxyethyl)-1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxamide

[1003]

[1004] Conditions: a) 10% Pd / C, MeOH, H2, RT, 16 h; b) thiophosgene, THF, RT, 16 h; c) SOCl2, catalytic DMF, reflux, 2 h; d) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; e) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h; f) 2-methoxyethan-1-amine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[1005] Step-a: Synthesis of 3-aminopyridin-2-ol

[1006] The title compound was synthesized using the same procedure as compound 1e using 3-nitropyridin-2-ol as the starting material (yield: 85%); 1 H NMR (400MHz, DMSO-d6): δ11.3 (bs, 1H), 6.59 (dd, J=2.0Hz, J=6.8Hz, 1H), 6.43 (dd, J =2.4Hz, J=6.8Hz, 1H), 5.98 (t, J=6.0Hz, 1H), 4.97 (bs, 2H); LC-MS: m / z111.25 (M+1) + .

[1007] Step-b: Synthesis of oxazolo[5,4-b]pyridine-2-thiol

[1008] To a solution of 3-aminopyridine-2-ol (500 mg, 4.5 mmol) in THF (15 mL) at room temperature was slowly added thiophosgene (0.41 mL, 5.4 mmol) over a 15 min period and stirred at room temperature for 16 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (9 mL) and concentrated. The aqueous layer was basified with 10 N sodium hydroxide solution (5 mL) and extracted with ethyl acetate (2 × 30 mL), and the aqueous layer was acidified with 1 N HCl and extracted with ethyl acetate (2 × 100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue which was purified by flash chromatography using 2% methanol / DCM as eluent to give the title compound (200 mg, 29%); LC-MS: m / z 153.15 (M+1) + .

[1009] Step-c: Synthesis of 2-chlorooxazolo[5,4-b]pyridine

[1010] To a solution of oxazolo[5,4-b]pyridine-2-thiol (200 mg, 1.31 mmol) in thionyl chloride (5 mL) at room temperature was added N,N-dimethylformamide (1 drop), and the reaction mixture was refluxed for 2 h. The reaction mixture was concentrated under reduced pressure, and the crude compound (220 mg) was used in the next step without any further purification; 1 H NMR (400MHz, DMSO-d6): δ8.40 (dd, J=1.6Hz, J=4.8Hz, 1H), 8.26 (dd, J=1.2Hz, J=7.6Hz, 1H), 7.56-7.53 (m, 1H); LC-MS: m / z 155.1 (M+1) + .

[1011] Step-d: Synthesis of ethyl 1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylate

[1012] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chlorooxazolo[5,4-b]pyridine as starting materials (yield: 20%); 1H NMR (400MHz, DMSO-d6): δ8.24 (s, 1H), 8.02 (d, J=5.2Hz, 1H), 7.89 (dd, J=1.6Hz, J=8.8Hz, 1H), 7.79 (d, J=7.2Hz, 1 H), 7.56 (d, J=8.4Hz, 1H), 7.29-7.26 (m, 1H), 4.33 (q, J=7.2Hz, 2H), 3.67 (s, 3H), 1.35 (t, J=6.8Hz, 3H); LC-MS: m / z 338.15(M+1) + .

[1013] Step-e: Synthesis of 1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylic acid

[1014] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 54%); 1 H NMR (400MHz, DMSO-d6): δ12.8 (bs, 1H), 12.4 (bs, 1H), 8.20 (s, 1H), 8.01 (d, J=5.2Hz, 1H), 7.89 (d, J=8.0Hz , 1H), 7.79 (d, J=7.2Hz, 1H), 7.54 (d, J=8.0Hz, 1H), 7.28-7.25 (m, 1H), 3.67 (s, 3H); LC-MS: m / z310.1 (M+1) + .

[1015] Step-f: Synthesis of N-(2-methoxyethyl)-1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxamide

[1016] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 38%); 1HNMR (400MHz, DMSO-d6): δ12.38 (bs, 1H), 8.47 (s, 1H), 8.09 (s, 1H), 8.0 (d, J=3.6Hz, 1H), 7.79-7.77 (m, 2 H), 7.52 (d, J=8.4Hz, 1H), 7.27-7.24 (m, 1H), 3.66 (s, 3H), 3.48-3.44 (m, 4H), 3.28 (s, 3H); LC-MS: m / z 367.2(M+1) + .

[1017] Example 110. Synthesis of N-(2-hydroxyethyl)-1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxamide

[1018]

[1019] Conditions: a) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[1020] The title compound was synthesized using the same procedure as in Example 6, step-e, using 1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting materials (yield: 51%); 1 H NMR (400MHz, DMSO-d6): δ12.3 (bs, 1H), 8.38 (bs, 1H), 8.09 (s, 1H), 8.01 (d, J=4.4Hz, 1H), 7.80-7.76 (m, 2H), 7.52 ( d, J=8.4Hz, 1H), 7.25 (t, J=6.8Hz, 1H), 4.72 (bs, 1H), 3.66 (s, 3H), 3.53 (bs, 2H), 3.35 (q, J=6.0Hz, 2H); LC-MS: m / z 353.0(M+1) + .

[1021] Examples 111 and 112. Synthesis of 1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylic acid and N-(2-methoxyethyl)-1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxamide

[1022]

[1023] Conditions: a) CS2, EtOH, reflux, 12 h; b) SOCl2, catalytic DMF, reflux, 2 h; c) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16 h; d) LiOH.H2O, THF, EtOH, H2O, 60°C, 16 h; e) 2-methoxyethan-1-amine, DPPA, DIPEA, DMF, 0°C-RT, 16 h

[1024] Step-a: Synthesis of oxazolo[4,5-b]pyridine-2-thiol

[1025] To a solution of 2-aminopyridin-3-ol (2.2 g, 20 mmol) in ethanol (40 mL) at room temperature was added potassium hydroxide (1.68 g, 30 mmol) and carbon disulfide (15 mL). The reaction mixture was refluxed for 12 h, then cooled to room temperature, diluted with water (75 mL) and neutralized with glacial acetic acid. The precipitated solid was filtered and dried in vacuo to give the title compound (1.8 g, 59%). 1 H NMR (400MHz, DMSO-d6): δ14.5 (s, 1H), 8.23 ​​(dd, J=1.2Hz, J=5.2Hz, 1H), 7.88 (dd, J=1.6Hz, J=8.4Hz, 1H), 7.29-7.26 (m, 1H); LC-MS: m / z 153.1 (M+1) + .

[1026] Step-b: Synthesis of 2-chlorooxazolo[4,5-b]pyridine

[1027] The title compound was synthesized using the same procedure as in Example 32, step d, using oxazolo[4,5-b]pyridine-2-thiol as the starting material and heating for 2 h. (Yield: 100%); 1 H NMR (400MHz, DMSO-d6): δ8.01 (dd, J=1.6Hz, J=5.6Hz, 1H), 7.61 (dd, J=1.2Hz, J=8.0Hz, 1H), 7.10-7.06 (m, 1H); LC-MS: m / z 155.01 (M+1) + .

[1028] Step-c: Synthesis of ethyl 1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylate

[1029] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chlorooxazolo[4,5-b]pyridine as starting materials (yield: 32%); 1 H NMR (400MHz, DMSO-d6): δ7.98 (s, 1H), 7.94 (d, J = 4.4Hz, 1H), 7.62 (d, J = 9.2Hz, 1H), 7.36 (d, J = 7.2Hz, 1H) , 7.21-7.18 (m, 1H), 6.77-6.74 (m, 1H), 4.32-4.26 (m, 2H), 3.57 (s, 3H), 1.38 (t, J=6.8Hz, 3H); LC-MS: m / z 338.15(M+1) + .

[1030] Step-d: Synthesis of 1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylic acid

[1031] The title compound was synthesized using the same procedure as compound 1h using ethyl 1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylate as the starting material (yield: 73%); 1 H NMR (400MHz, DMSO-d6): δ12.83 (bs, 1H), 12.44 (bs, 1H), 8.26-8.23 (m, 2H), 7.89 (d, J=8.4Hz, 1H), 7 .78 (d, J=7.6Hz, 1H), 7.75 (d, J=8.4Hz, 1H), 7.12-7.09 (m, 1H), 3.72 (s, 3H); LC-MS: m / z310.15 (M+1) + .

[1032] Step-e: Synthesis of N-(2-methoxyethyl)-1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxamide

[1033] The title compound was synthesized using the same procedure as compound 1i using 1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting materials (yield: 53%); 1HNMR (400MHz, DMSO-d6): δ12.4(bs, 1H), 8.48(bs, 1H), 8.23(d, J=4.4Hz, 1H), 8.13(s, 1H), 7.79-7.75(s, 2 H), 7.53 (d, J=8.4Hz, 1H), 7.11-7.08 (m, 1H), 3.67 (s, 3H), 3.48-3.44 (m, 4H), 3.29 (s, 3H); LC-MS: m / z 367.2(M+1) + .

[1034] Example 113. Synthesis of N-(2-hydroxyethyl)-1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide

[1035]

[1036] Conditions: a) ethyl (E)-5,5,5-trifluoro-4-oxopent-2-enoate, NaOEt, EtOH, 90°C, 2h; b) 10% Pd / C, MeOH, H2, RT, 16h; c) thiophosgene, THF, RT, 16h; d) SOCl2, catalytic DMF, reflux, 3h; e) NaH, ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate, 1,4-dioxane, RT, 16h; f) LiOH.H2O, THF, EtOH, H2O, 60°C, 16h; g) 2-aminoethan-1-ol, HBTU, DIPEA, DMF, 0°C-RT, 16h

[1037] Step-a: Synthesis of 3-nitro-6-(trifluoromethyl)pyridin-2-ol

[1038] To a solution of 2-nitroacetamide (5.0 g, 47.8 mmol) in ethanol (25 mL) at room temperature was added (E)-5,5,5-trifluoro-4-oxopent-2-enoic acid ethyl ester (11.24 g, 57.3 mmol) and ethanol containing 25% sodium ethoxide (25.9 mL, 95.3 mmol). The reaction mixture was stirred at 90 ° C for 2 h. The reaction mixture was cooled to room temperature, diluted with water (50 mL), acidified with 1N HCl and extracted with EtOAc (2×150 mL). The combined organic layers were washed with brine solution (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue which was purified by flash chromatography using 50% EtOAc / hexane as eluent to give the title compound (1.5 g). 1H NMR (400MHz, DMSO-d6): δ 8.58 (d, J=8.4Hz, 1H), 7.84 (bs, 1H), 7.51 (d, J=7.6Hz, 1H).

[1039] Step-b: Synthesis of 3-amino-6-(trifluoromethyl)pyridin-2-ol

[1040] The title compound was synthesized using the same procedure as compound 1e using 3-nitro-6-(trifluoromethyl)pyridin-2-ol as the starting material (yield: 82%); 1 H NMR (400MHz, DMSO-d6): δ11.7(bs,1H),6.88(bs,1H),6.69(bs,1H),5.60(s,2H); LC-MS: m / z 179.1(M+1) + .

[1041] Step-c: Synthesis of 5-(trifluoromethyl)oxazolo[5,4-b]pyridine-2-thiol

[1042] The title compound was synthesized using the same procedure as in Example 109 step-b using 3-amino-6-(trifluoromethyl)pyridin-2-ol as a starting material (yield: 65%); 1 H NMR (400MHz, DMSO-d6): δ7.81-7.75 (m, 2H); LC-MS: m / z219.0 (M-1).

[1043] Step-d: Synthesis of 2-chloro-5-(trifluoromethyl)oxazolo[5,4-b]pyridine

[1044] The title compound was synthesized using the same procedure as in Example 32, step-d, using 5-(trifluoromethyl)oxazolo[5,4-b]pyridine-2-thiol as a starting material (yield: 74%). The crude compound was used in the next step without further purification.

[1045] Step-e: Synthesis of ethyl 1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate

[1046] The title compound was synthesized using the same procedure as in Example 32 step-e using ethyl 2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and 2-chloro-5-(trifluoromethyl)oxazolo[5,4-b]pyridine as starting materials (yield: 43%); 1H NMR (400MHz, DMSO-d6): δ12...

Claims

1. A compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof: in: Ring A is pyridyl or phenyl; X is -O-; R is: (1) optionally with -(C1-C4)alkoxy, -NR a R a or-SO2R a substituted-(C1-C4)alkyl; or (2) -(CH2) optionally substituted by one or more groups selected from the following i 3-6 membered monocyclic heterocyclic group: halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy and -NR a R a ; Each R1 is independently halogen, -(CH2) k COOH, -(CH2) optionally substituted by halogen k CO(C1-C4)alkyl, -(CH2) p C(=O)NR a R3, -C(=NOH)CF3, -CH(CF3)OH or -CH(CF3)NR a R3; Each R2 is independently halogen; CN; -(C1-C4)alkyl optionally substituted by halogen; -(C1-C4)alkoxy optionally substituted by halogen, hydroxy, methoxy or ethoxy; -C(=O)(C1-C4)alkyl; 3-4 membered monocyclic cycloalkyl; -O(CH2) i 3-7 membered monocyclic heterocyclic group, 3-7 membered monocyclic heterocyclic group; or 5-6 membered heteroaryl, wherein the heterocyclic group or heteroaryl in the group represented by R2 or represented by R2 is optionally substituted by halogen, hydroxyl or -(C1-C4)alkoxy; Each R3 is independently H, (C1-C4) alkyl, (C1-C4) alkoxy, -(CH2) p1 3-7 membered monocyclic heterocyclic group, -(CH2) p1 NH3-7-membered monocyclic heterocyclic group, 5-6-membered heteroaryl, -O(CH2) p2 NR a C(=O)(C1-C4)alkyl, -(CH2) p2 O(CH2) p2 O(C=O)(C1-C4)alkyl or (CH2) p2 NR a C(=O)(C1-C4)alkyl, wherein the alkyl, alkoxy, heteroaryl or heterocyclic group represented by R3 or in the group represented by R3 is optionally substituted by one or more groups selected from the group consisting of halo, -CN, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)alkoxy, -(C1-C4)hydroxyalkyl, -(C1-C4)haloalkoxy, -(C1-C4)carboxyalkoxy, -S(O)2(C1-C4)alkyl, -(C1-C4)hydroxyalkoxy and -NR a R a ; Each R a are independently -H or -(C1-C4)alkyl; i is 0 or 1; k is 0, 1, 2, 3, or 4; m is 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, 3, or 4; p1 is 0, 1, 2, 3, or 4; and p2 is 2, 3, or 4.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is represented by structural formula (II):

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is represented by structural formula (II-B):

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R is -(C1-C4)alkyl optionally substituted with methoxy or -SO2CH3; -(CH2)tetrahydrofuranyl; -(CH2)oxetanyl optionally substituted with hydroxy; pyrrolidinyl; piperidinyl; or tetrahydropyranyl; wherein the pyrrolidinyl or piperidinyl is optionally substituted with -(C1-C4)alkyl.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is -COOH, -C(=O)CF3, -CH(CF3)(NH2), -C(=NOH)CF3 or -C(=O)NHR3.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is (C1-C4) alkyl, (C1-C4) alkoxy, (CH2) p1 3-6 membered monocyclic heterocyclic group or (CH2) p2 NHC(=O)(C1-C4)alkyl, wherein the alkyl, alkoxy or heterocyclic group represented by R3 or in the group represented by R3 is optionally substituted by one or more groups selected from the group consisting of halogen, -OH, -(C1-C4)alkyl, -(C1-C4)haloalkyl, -(C1-C4)hydroxyalkyl, -(C1-C4)alkoxy, -(C1-C4)haloalkoxy, -S(O)2(C1-C4)alkyl, -(C1-C4)hydroxyalkoxy and -NR a R a .

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0 or R2 is halogen; CN; -(C1-C4)alkyl optionally substituted by halo; -(C1-C4)alkoxy optionally substituted by halo, hydroxy, methoxy or ethoxy; -C(=O)(C1-C4)alkyl; cyclopropyl; O-tetrahydropyranyl; N-pyrrolidinyl; or thiazolyl.

8. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is represented by structural formula (III-B): Where n is 0 or 1.

9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is -COOH or -C(=O)NHR3, R3 is -(C1-C4)alkyl, -hydroxy(C1-C4)alkyl, -methoxy(C1-C4)alkyl, amino(C1-C4)alkyl, -(C1-C4)hydroxyalkoxy(C1-C4)alkyl or -(CH2) p2 NHC(=O)(dimethylamino(C1-C4)alkyl).

10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 0 or R2 is halo, -(C1-C4)haloalkyl, -(C1-C4)haloalkoxy, -(C1-C4)alkoxy optionally substituted with methoxy, or -N-pyrrolidinyl.

11. The compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein n is 0 or R2 is F, CF3, OCHF2, OCF3, OCH2CH2OCH3 or -N-pyrrolidinyl.

12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 0, R1 is -C(=O)NH(C1-C4)alkyl optionally substituted by -OH, NH2, oxetanyl or -(C1-C4)hydroxyalkoxy; or -C(=O)NH(CH2) p2 NHC(═O)(dimethylamino(C1-C4)alkyl); or R2 is F, R1 is -C(=O)NH(methoxy(C1-C4)alkyl); or R2 is -N-pyrrolidinyl, R1 is -C(=O)NH((C1-C4)hydroxyalkoxy(C1-C4)alkyl), or R2 is CF3, OCHF2 or OCF3, R1 is -COOH; or R2 is OCH2CH2OCH3, R1 is -C(=O)NH((C1-C4)hydroxyalkoxy(C1-C4)alkyl), -C(=O)NH(hydroxy(C1-C4)alkyl), -C(=O)NH(methoxy(C1-C4)alkyl) or -C(=O)NH(hydroxy(C1-C4)alkoxy).

13. The compound according to claim 8 or a pharmaceutically acceptable salt thereof, wherein R1 is -C(═O)NH(C1-C4)alkyl optionally substituted by -OH, NH2, -(C1-C4)-alkoxy or -(C1-C4)hydroxyalkoxy, and n is 0 or R2 is OCH2CH2OCH3.

14. The compound according to claim 13 or a pharmaceutically acceptable salt thereof, wherein n is 0.

15. The compound according to claim 14 or a pharmaceutically acceptable salt thereof, wherein R1 is -C(=O)NH(C1-C4)alkyl substituted by -(C1-C4)hydroxyalkoxy.

16. A compound, wherein the compound is: 2-(Benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 13 or a pharmaceutically acceptable salt thereof, wherein R1 is -C(=O)NH(C1-C4)alkyl substituted by -(C1-C4)alkoxy, and R2 is OCH2CH2OCH3.

18. A compound, wherein the compound is: 2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is 20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.

21. Use of a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating sickle cell disease.